Action,ActionId,AuthorityGroup,Company,CompanyId,CompanyOwnershipRelationship,Country,CountryId,Drug,DrugId,DrugRelationship,EntityType,HighestPatStatus,HighestPatStatusForCnty,HighestPatStatusId,HighestPatStatusIdForCnty,Indication,IndicationId,LatestChange,ParentCompany,ParentCompanyId,Patent,PatentId,Status,StatusDate,StatusId,StatusSortCode,TherapyArea,TherapyAreaId
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Academia Sinica,28429,US-07691575,PA3471716,Extension,2025-11-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Academia Sinica,28429,US-07691575,PA3471716,Extension,2025-11-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Academia Sinica,28429,US-07691575,PA3471716,Granted,2010-04-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Academia Sinica,28429,US-07691575,PA3471716,Granted,2010-04-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Academia Sinica,28429,US-07691575,PA3471716,First Publication,2007-03-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Academia Sinica,28429,US-07691575,PA3471716,First Publication,2007-03-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Academia Sinica,28429,US-07691575,PA3471716,First Priority,2005-08-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Academia Sinica,28429,US-07691575,PA3471716,First Priority,2005-08-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Academia Sinica,28429,US-07691575,PA3471716,Extension,2025-11-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Academia Sinica,28429,US-07691575,PA3471716,Extension,2025-11-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Academia Sinica,28429,US-07691575,PA3471716,Granted,2010-04-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Academia Sinica,28429,US-07691575,PA3471716,Granted,2010-04-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Academia Sinica,28429,US-07691575,PA3471716,First Publication,2007-03-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Academia Sinica,28429,US-07691575,PA3471716,First Publication,2007-03-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Academia Sinica,28429,US-07691575,PA3471716,First Priority,2005-08-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Academia Sinica,28429,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Academia Sinica,28429,US-07691575,PA3471716,First Priority,2005-08-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,Sanofi SA,1009547,WO-09207577,IN1509870,First Publication,1992-05-14 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Sanofi SA,1009547,WO-09207577,IN1509870,First Publication,1992-05-14 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sanofi SA,1009547,WO-09207577,IN1509870,First Publication,1992-05-14 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,Sanofi SA,1009547,WO-09207577,IN1509870,First Priority,1990-10-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Sanofi SA,1009547,WO-09207577,IN1509870,First Priority,1990-10-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sanofi SA,1009547,WO-09207577,IN1509870,First Priority,1990-10-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Germany,DE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,UK,GB,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Liechtenstein,LI,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Denmark,DK,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Switzerland,CH,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Luxembourg,LU,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Netherlands,NL,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,France,FR,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Austria,AT,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Italy,IT,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Sweden,SE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Belgium,BE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Assumed Expiry,2010-06-06 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,European Patent,EP,null,null,null,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,Granted,1991-10-23 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,European Patent,EP,null,null,null,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,First Publication,1991-10-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,France,FR,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00452598,IN1576286,First Priority,1990-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Luxembourg,LU,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,UK,GB,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Germany,DE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Italy,IT,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Austria,AT,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Sweden,SE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Belgium,BE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Denmark,DK,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Netherlands,NL,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Liechtenstein,LI,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,Switzerland,CH,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,France,FR,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Assumed Expiry,2010-10-16 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,European Patent,EP,null,null,null,null,Assumed Expiry,Granted,EXP,GRT,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,Granted,1991-05-08 00:00:00,GRT,3,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,European Patent,EP,null,null,null,null,Assumed Expiry,Granted,EXP,GRT,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,First Publication,1991-05-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Roussel Uclaf SA,26119,Owner,France,FR,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Leukemia,199,null,Sanofi SA,1009547,EP-00426521,IN1573351,First Priority,1989-10-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,"melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma), Delcath/NCI",72209,Delivery device,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07022097,PA2916777,Extension,2023-06-24 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,"melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma), Delcath/NCI",72209,Delivery device,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07022097,PA2916777,Granted,2006-04-04 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,"melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma), Delcath/NCI",72209,Delivery device,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07022097,PA2916777,First Publication,2004-11-11 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,"melphalan (percutaneous hepatic perfusion, hepatocellular carcinoma/cholangiocarcinoma/metastatic ocular melanoma), Delcath/NCI",72209,Delivery device,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07022097,PA2916777,First Priority,2003-05-09 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07435592,PA2917599,Extension,2025-04-26 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07435592,PA2917599,Granted,2008-10-14 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07435592,PA2917599,First Publication,2004-11-18 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07435592,PA2917599,First Priority,2003-05-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,NeXstar Pharmaceuticals Inc,15906,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Unidentified indication,1005,null,Gilead Sciences Inc,16450,WO-08905151,IN1501324,First Publication,1989-06-15 00:00:00,PUB,2,Unidentified indication,1005
IL-2 receptor agonist,221,null,NeXstar Pharmaceuticals Inc,15906,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Unidentified indication,1005,null,Gilead Sciences Inc,16450,WO-08905151,IN1501324,First Priority,1987-12-04 00:00:00,PRI,1,Unidentified indication,1005
IL-2 receptor agonist,221,null,Movecare Ltd,1009528,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Movecare Ltd,1009528,WO-2004069272,PA2907050,First Publication,2004-08-19 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Movecare Ltd,1009528,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Movecare Ltd,1009528,WO-2004069272,PA2907050,First Publication,2004-08-19 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Movecare Ltd,1009528,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Movecare Ltd,1009528,WO-2004069272,PA2907050,First Publication,2004-08-19 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Movecare Ltd,1009528,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Movecare Ltd,1009528,WO-2004069272,PA2907050,First Priority,2003-02-05 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Movecare Ltd,1009528,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Movecare Ltd,1009528,WO-2004069272,PA2907050,First Priority,2003-02-05 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Movecare Ltd,1009528,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Movecare Ltd,1009528,WO-2004069272,PA2907050,First Priority,2003-02-05 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Individual,21144,US-20050118292,PA2991153,First Publication,2005-06-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Individual,21144,US-20050118292,PA2991153,First Priority,2003-12-01 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,National Jewish Health,18461,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,National Jewish Health,18461,WO-00180889,PA145127,First Publication,2001-11-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,National Jewish Health,18461,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vaccination,384,null,National Jewish Health,18461,WO-00180889,PA145127,First Publication,2001-11-01 00:00:00,PUB,2,Prophylaxis,706
IL-2 receptor agonist,221,null,National Jewish Health,18461,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immunization,413,null,National Jewish Health,18461,WO-00180889,PA145127,First Publication,2001-11-01 00:00:00,PUB,2,Prophylaxis,706
IL-2 receptor agonist,221,null,National Jewish Health,18461,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,National Jewish Health,18461,WO-00180889,PA145127,First Publication,2001-11-01 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,National Jewish Health,18461,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,National Jewish Health,18461,WO-00180889,PA145127,First Priority,2000-04-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,National Jewish Health,18461,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Vaccination,384,null,National Jewish Health,18461,WO-00180889,PA145127,First Priority,2000-04-26 00:00:00,PRI,1,Prophylaxis,706
IL-2 receptor agonist,221,null,National Jewish Health,18461,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immunization,413,null,National Jewish Health,18461,WO-00180889,PA145127,First Priority,2000-04-26 00:00:00,PRI,1,Prophylaxis,706
IL-2 receptor agonist,221,null,National Jewish Health,18461,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,National Jewish Health,18461,WO-00180889,PA145127,First Priority,2000-04-26 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07282479,PA2915972,Extension,2024-07-14 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07282479,PA2915972,Granted,2007-10-16 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07282479,PA2915972,First Publication,2004-11-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-07282479,PA2915972,First Priority,2003-03-31 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bayer Corp,14486,Owner,World,WO,AIC-284,28450,Formulation,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Bayer AG,14455,WO-00200243,PA148016,First Publication,2002-01-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Bayer Corp,14486,Owner,World,WO,AIC-284,28450,Formulation,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Bayer AG,14455,WO-00200243,PA148016,First Publication,2002-01-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bayer Corp,14486,Owner,US,US,AIC-284,28450,Formulation,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Bayer AG,14455,WO-00200243,PA148016,First Priority,2000-06-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bayer Corp,14486,Owner,US,US,AIC-284,28450,Formulation,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Bayer AG,14455,WO-00200243,PA148016,First Priority,2000-06-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,TKB Associates Ltd Partnership,23389,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,TKB Associates Ltd Partnership,23389,WO-09613275,IN2195008,First Publication,1996-05-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,TKB Associates Ltd Partnership,23389,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,TKB Associates Ltd Partnership,23389,WO-09613275,IN2195008,First Priority,1994-10-31 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Protherics Salt Lake City Inc,25065,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Precancer,1060,null,BTG plc,15266,WO-02102309,PA172070,First Publication,2002-12-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Protherics Salt Lake City Inc,25065,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Precancer,1060,null,BTG plc,15266,WO-02102309,PA172070,First Priority,2002-06-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Southern California,20673,WO-03015697,PA200949,First Publication,2003-02-27 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,University of Southern California,20673,WO-03015697,PA200949,First Publication,2003-02-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,University of Southern California,20673,WO-03015697,PA200949,First Publication,2003-02-27 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Southern California,20673,WO-03015697,PA200949,First Publication,2003-02-27 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,University of Southern California,20673,WO-03015697,PA200949,First Publication,2003-02-27 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,University of Southern California,20673,WO-03015697,PA200949,First Publication,2003-02-27 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,University of Southern California,20673,WO-03015697,PA200949,First Publication,2003-02-27 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Southern California,20673,WO-03015697,PA200949,First Priority,2001-08-13 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,University of Southern California,20673,WO-03015697,PA200949,First Priority,2001-08-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,University of Southern California,20673,WO-03015697,PA200949,First Priority,2001-08-13 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Southern California,20673,WO-03015697,PA200949,First Priority,2001-08-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,University of Southern California,20673,WO-03015697,PA200949,First Priority,2001-08-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,University of Southern California,20673,WO-03015697,PA200949,First Priority,2001-08-13 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,"vasopermeation enhancement agents (solid tumor), Peregrine",12900,New use,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,University of Southern California,20673,WO-03015697,PA200949,First Priority,2001-08-13 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Greenville Health System,28934,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Greenville Health System,28934,WO-03017944,PA201500,First Publication,2003-03-06 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Greenville Health System,28934,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Greenville Health System,28934,WO-03017944,PA201500,First Priority,2001-08-27 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Penta Biotech Inc,1024584,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Penta Biotech Inc,1024584,US-20080286315,PA3713190,First Publication,2008-11-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Penta Biotech Inc,1024584,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Penta Biotech Inc,1024584,US-20080286315,PA3713190,First Priority,2007-01-31 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Corixa Corp,15542,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vaccination,384,null,GlaxoSmithKline plc,28355,WO-03037275,PA206792,First Publication,2003-05-08 00:00:00,PUB,2,Prophylaxis,706
IL-2 receptor agonist,221,null,Corixa Corp,15542,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Vaccination,384,null,GlaxoSmithKline plc,28355,WO-03037275,PA206792,First Priority,2001-10-31 00:00:00,PRI,1,Prophylaxis,706
IL-2 receptor agonist,221,null,Immunex Corp,14131,Owner,US,US,interleukin-2,DOC1000491,Process,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Immune disorder,185,null,Amgen Inc,14109,US-04401756,IN1030018,Assumed Expiry,2001-04-14 00:00:00,EXP,5,Immune disorder,185
IL-2 receptor agonist,221,null,Immunex Corp,14131,Owner,US,US,interleukin-2,DOC1000491,Process,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Immune disorder,185,null,Amgen Inc,14109,US-04401756,IN1030018,Granted,1983-08-30 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Immunex Corp,14131,Owner,US,US,interleukin-2,DOC1000491,Process,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Immune disorder,185,null,Amgen Inc,14109,US-04401756,IN1030018,First Publication,1983-08-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Immunex Corp,14131,Owner,US,US,interleukin-2,DOC1000491,Process,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Immune disorder,185,null,Amgen Inc,14109,US-04401756,IN1030018,First Priority,1981-04-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Immunex Corp,14131,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Immune disorder,185,null,Amgen Inc,14109,US-04407945,IN1030475,Assumed Expiry,2001-04-29 00:00:00,EXP,5,Immune disorder,185
IL-2 receptor agonist,221,null,Immunex Corp,14131,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Immune disorder,185,null,Amgen Inc,14109,US-04407945,IN1030475,Granted,1983-10-04 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Immunex Corp,14131,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Immune disorder,185,null,Amgen Inc,14109,US-04407945,IN1030475,First Publication,1983-10-04 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Immunex Corp,14131,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Immune disorder,185,null,Amgen Inc,14109,US-04407945,IN1030475,First Priority,1981-04-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Publication,2003-05-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Publication,2003-05-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Publication,2003-05-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Publication,2003-05-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Publication,2003-05-01 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Priority,2001-09-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Priority,2001-09-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Priority,2001-09-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Priority,2001-09-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Medcell Biologics Inc,30888,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Medcell Biologics Inc,30888,WO-03034820,PA206406,First Priority,2001-09-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Zeneca Group plc,16955,Owner,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,AstraZeneca plc,14190,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,US-05258407,IN2152996,Assumed Expiry,2011-12-31 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Sanofi SA,1009547,US-05258407,IN2152996,Assumed Expiry,2011-12-31 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Autoimmune disease,36,null,Sanofi SA,1009547,US-05258407,IN2152996,Assumed Expiry,2011-12-31 00:00:00,EXP,5,Immune disorder,185
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,US-05258407,IN2152996,Granted,1993-11-02 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Sanofi SA,1009547,US-05258407,IN2152996,Granted,1993-11-02 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Autoimmune disease,36,null,Sanofi SA,1009547,US-05258407,IN2152996,Granted,1993-11-02 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,US-05258407,IN2152996,First Publication,1993-11-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Sanofi SA,1009547,US-05258407,IN2152996,First Publication,1993-11-02 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Autoimmune disease,36,null,Sanofi SA,1009547,US-05258407,IN2152996,First Publication,1993-11-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,US-05258407,IN2152996,First Priority,1991-12-31 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Sanofi SA,1009547,US-05258407,IN2152996,First Priority,1991-12-31 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Sterling-Winthrop Inc,21681,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Autoimmune disease,36,null,Sanofi SA,1009547,US-05258407,IN2152996,First Priority,1991-12-31 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fordham University,24709,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Fordham University,24709,WO-09918801,IN2553108,First Publication,1999-04-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fordham University,24709,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Fordham University,24709,WO-09918801,IN2553108,First Publication,1999-04-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fordham University,24709,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Fordham University,24709,WO-09918801,IN2553108,First Publication,1999-04-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fordham University,24709,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Fordham University,24709,WO-09918801,IN2553108,First Publication,1999-04-22 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Fordham University,24709,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Fordham University,24709,WO-09918801,IN2553108,First Priority,1997-10-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fordham University,24709,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Fordham University,24709,WO-09918801,IN2553108,First Priority,1997-10-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fordham University,24709,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Fordham University,24709,WO-09918801,IN2553108,First Priority,1997-10-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fordham University,24709,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Fordham University,24709,WO-09918801,IN2553108,First Priority,1997-10-16 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,European Molecular Biology Laboratory,27641,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,European Molecular Biology Laboratory,27641,WO-00212337,PA149941,First Publication,2002-02-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,European Molecular Biology Laboratory,27641,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,European Molecular Biology Laboratory,27641,WO-00212337,PA149941,First Publication,2002-02-14 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,European Molecular Biology Laboratory,27641,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,European Molecular Biology Laboratory,27641,WO-00212337,PA149941,First Priority,2000-08-09 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,European Molecular Biology Laboratory,27641,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,European Molecular Biology Laboratory,27641,WO-00212337,PA149941,First Priority,2000-08-09 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,HIV infection,158,null,Individual,21144,US-07501494,PA2903726,Extension,2024-09-20 00:00:00,EXT,4,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,HIV infection,158,null,Individual,21144,US-07501494,PA2903726,Granted,2009-03-10 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,HIV infection,158,null,Individual,21144,US-07501494,PA2903726,First Publication,2004-07-15 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,HIV infection,158,null,Individual,21144,US-07501494,PA2903726,First Priority,2003-01-15 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Individual,21144,US-20050142234,PA2998533,First Publication,2005-06-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Individual,21144,US-20050142234,PA2998533,First Priority,2003-12-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,HIV infection,158,null,University of Arizona,20527,US-05911990,IN2693527,Assumed Expiry,2016-08-13 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Acquired immune deficiency syndrome,4,null,University of Arizona,20527,US-05911990,IN2693527,Assumed Expiry,2016-08-13 00:00:00,EXP,5,Immune disorder,185
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,HIV infection,158,null,University of Arizona,20527,US-05911990,IN2693527,Granted,1999-06-15 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Acquired immune deficiency syndrome,4,null,University of Arizona,20527,US-05911990,IN2693527,Granted,1999-06-15 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,HIV infection,158,null,University of Arizona,20527,US-05911990,IN2693527,First Publication,1999-06-15 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Acquired immune deficiency syndrome,4,null,University of Arizona,20527,US-05911990,IN2693527,First Publication,1999-06-15 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,HIV infection,158,null,University of Arizona,20527,US-05911990,IN2693527,First Priority,1996-08-13 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Acquired immune deficiency syndrome,4,null,University of Arizona,20527,US-05911990,IN2693527,First Priority,1996-08-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,The Liposome Company Inc,17877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Unidentified indication,1005,null,Perrigo Co plc,1091305,WO-08905151,IN1501324,First Publication,1989-06-15 00:00:00,PUB,2,Unidentified indication,1005
IL-2 receptor agonist,221,null,The Liposome Company Inc,17877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Unidentified indication,1005,null,Perrigo Co plc,1091305,WO-08905151,IN1501324,First Priority,1987-12-04 00:00:00,PRI,1,Unidentified indication,1005
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Harvard Medical School,24839,WO-09902711,IN2720183,First Publication,1999-01-21 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Harvard Medical School,24839,WO-09902711,IN2720183,First Publication,1999-01-21 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Harvard Medical School,24839,WO-09902711,IN2720183,First Priority,1997-07-10 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Harvard Medical School,24839,WO-09902711,IN2720183,First Priority,1997-07-10 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Sanofi (pre-1999),26495,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Publication,1990-05-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi (pre-1999),26495,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Publication,1990-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Sanofi (pre-1999),26495,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Publication,1990-05-03 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Sanofi (pre-1999),26495,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Publication,1990-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Sanofi (pre-1999),26495,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Priority,1988-10-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi (pre-1999),26495,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Priority,1988-10-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Sanofi (pre-1999),26495,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Priority,1988-10-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Sanofi (pre-1999),26495,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Priority,1988-10-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,E I DuPont de Nemours & Co,15825,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,DowDuPont Inc,1155603,WO-09010070,IN1504058,First Publication,1990-09-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,E I DuPont de Nemours & Co,15825,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,DowDuPont Inc,1155603,WO-09010070,IN1504058,First Priority,1989-02-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,"L19-IL-2 fusion protein, Philogen",45599,General interest,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Philogen SpA,29032,WO-2009001219,PA3729539,First Publication,2008-12-31 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,"L19-IL-2 fusion protein, Philogen",45599,General interest,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Philogen SpA,29032,WO-2009001219,PA3729539,First Priority,2007-06-28 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Massachusetts,20615,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,University of Massachusetts,20615,WO-2004093820,PA2915375,First Publication,2004-11-04 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,University of Massachusetts,20615,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,University of Massachusetts,20615,WO-2004093820,PA2915375,First Publication,2004-11-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Massachusetts,20615,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Massachusetts,20615,WO-2004093820,PA2915375,First Priority,2003-04-23 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Massachusetts,20615,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,University of Massachusetts,20615,WO-2004093820,PA2915375,First Priority,2003-04-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Sweden,SE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Sweden,SE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Sweden,SE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Sweden,SE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Germany,DE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Germany,DE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Germany,DE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Germany,DE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Denmark,DK,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Denmark,DK,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Denmark,DK,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Denmark,DK,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Switzerland,CH,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Switzerland,CH,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Switzerland,CH,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Switzerland,CH,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Greece,GR,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Greece,GR,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Greece,GR,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Greece,GR,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Italy,IT,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Italy,IT,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Italy,IT,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Italy,IT,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,UK,GB,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,UK,GB,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,UK,GB,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,UK,GB,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Liechtenstein,LI,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Liechtenstein,LI,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Liechtenstein,LI,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Liechtenstein,LI,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Austria,AT,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Austria,AT,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Austria,AT,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Austria,AT,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Spain,ES,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Spain,ES,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Spain,ES,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Spain,ES,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Luxembourg,LU,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Luxembourg,LU,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Luxembourg,LU,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Luxembourg,LU,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,France,FR,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,France,FR,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,France,FR,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,France,FR,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Belgium,BE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Belgium,BE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Belgium,BE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Belgium,BE,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Netherlands,NL,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Netherlands,NL,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Netherlands,NL,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Netherlands,NL,doxifluridine,6065,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Assumed Expiry,2011-11-28 00:00:00,EXP,5,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,European Patent,EP,doxifluridine,6065,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Granted,1992-06-03 00:00:00,GRT,3,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,European Patent,EP,doxifluridine,6065,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Granted,1992-06-03 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,European Patent,EP,doxifluridine,6065,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Granted,1992-06-03 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,European Patent,EP,doxifluridine,6065,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,Granted,1992-06-03 00:00:00,GRT,3,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,European Patent,EP,doxifluridine,6065,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,First Publication,1992-06-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,European Patent,EP,doxifluridine,6065,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,First Publication,1992-06-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,European Patent,EP,doxifluridine,6065,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,First Publication,1992-06-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,European Patent,EP,doxifluridine,6065,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,First Publication,1992-06-03 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Japan,JP,doxifluridine,6065,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Lymphoma,203,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,First Priority,1990-11-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Japan,JP,doxifluridine,6065,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Melanoma,205,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,First Priority,1990-11-29 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Japan,JP,doxifluridine,6065,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,First Priority,1990-11-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Takeda Pharmaceutical Co Ltd,20300,Owner,Japan,JP,doxifluridine,6065,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Prostate tumor,276,null,Takeda Pharmaceutical Co Ltd,20300,EP-00488718,IN1580317,First Priority,1990-11-29 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Publication,2003-10-23 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Publication,2003-10-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Publication,2003-10-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Publication,2003-10-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Publication,2003-10-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vascular disease,742,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Publication,2003-10-23 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Priority,2002-04-09 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Priority,2002-04-09 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Priority,2002-04-09 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Priority,2002-04-09 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Priority,2002-04-09 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Beth Israel Deaconess Medical Center,24877,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Vascular disease,742,null,Harvard Medical School,24839,WO-03087320,PA2876500,First Priority,2002-04-09 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Nicotine dependence,235,null,Individual,21144,WO-2005021766,PA2952338,First Publication,2005-03-10 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2005021766,PA2952338,First Publication,2005-03-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Nicotine dependence,235,null,Individual,21144,WO-2005021766,PA2952338,First Priority,2003-09-02 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Individual,21144,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2005021766,PA2952338,First Priority,2003-09-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,US Government,20516,WO-2004021995,PA2890866,First Publication,2004-03-18 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,WO-2004021995,PA2890866,First Publication,2004-03-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,US Government,20516,WO-2004021995,PA2890866,First Publication,2004-03-18 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,US Government,20516,WO-2004021995,PA2890866,First Priority,2002-09-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,US Government,20516,WO-2004021995,PA2890866,First Priority,2002-09-06 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,US Government,20516,WO-2004021995,PA2890866,First Priority,2002-09-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2009053109,PA4786873,First Publication,2009-04-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Individual,21144,WO-2009053109,PA4786873,First Publication,2009-04-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2009053109,PA4786873,First Priority,2007-10-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Individual,21144,WO-2009053109,PA4786873,First Priority,2007-10-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,interleukin-2,DOC1000491,General interest,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,WO-2004034789,PA2894903,First Publication,2004-04-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,interleukin-2,DOC1000491,General interest,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,US Government,20516,WO-2004034789,PA2894903,First Publication,2004-04-29 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,interleukin-2,DOC1000491,General interest,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,US Government,20516,WO-2004034789,PA2894903,First Publication,2004-04-29 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,interleukin-2,DOC1000491,General interest,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,US Government,20516,WO-2004034789,PA2894903,First Publication,2004-04-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,interleukin-2,DOC1000491,General interest,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,WO-2004034789,PA2894903,First Priority,2002-10-15 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,interleukin-2,DOC1000491,General interest,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,US Government,20516,WO-2004034789,PA2894903,First Priority,2002-10-15 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,interleukin-2,DOC1000491,General interest,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,US Government,20516,WO-2004034789,PA2894903,First Priority,2002-10-15 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,interleukin-2,DOC1000491,General interest,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,US Government,20516,WO-2004034789,PA2894903,First Priority,2002-10-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Publication,1990-05-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Publication,1990-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Publication,1990-05-03 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Publication,1990-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Priority,1988-10-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Priority,1988-10-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Priority,1988-10-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Sanofi SA,1009547,WO-09004406,IN1503179,First Priority,1988-10-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Sepsis,114,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Biliary cancer,1516,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Arthritis,28,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Dementia,90,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Individual,21144,WO-2005112912,PA3063784,First Publication,2005-12-01 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Sepsis,114,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Biliary cancer,1516,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Arthritis,28,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Dementia,90,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Sepsis,114,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Biliary cancer,1516,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Arthritis,28,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Dementia,90,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Individual,21144,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Individual,21144,WO-2005112912,PA3063784,First Priority,2004-04-24 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone disease,45,null,Individual,21144,US-20060040878,PA3097755,First Publication,2006-02-23 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone disease,45,null,Individual,21144,US-20060040878,PA3097755,First Priority,2004-08-20 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Netherlands,NL,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Liechtenstein,LI,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Italy,IT,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Greece,GR,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Austria,AT,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Switzerland,CH,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Germany,DE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Luxembourg,LU,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,UK,GB,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Spain,ES,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,France,FR,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Belgium,BE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,Sweden,SE,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Assumed Expiry,2009-10-23 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,European Patent,EP,null,null,null,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,Granted,1990-05-02 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,European Patent,EP,null,null,null,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,First Publication,1990-05-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Sanofi SA,1009547,Owner,France,FR,null,null,null,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Sanofi SA,1009547,EP-00366532,IN1566202,First Priority,1988-10-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Cleveland Clinic Foundation,22123,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,University of Pennsylvania,20658,WO-2006124412,PA3350473,First Publication,2006-11-23 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,University of Pennsylvania,20658,WO-2006124412,PA3350473,First Publication,2006-11-23 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,University of Pennsylvania,20658,WO-2006124412,PA3350473,First Priority,2005-05-11 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,University of Pennsylvania,20658,WO-2006124412,PA3350473,First Priority,2005-05-11 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Duke University,20567,WO-2004031357,PA2893219,First Publication,2004-04-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Duke University,20567,WO-2004031357,PA2893219,First Priority,2002-10-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,denileukin diftitox,7237,New use,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,Individual,21144,US-20060269514,PA3392812,First Publication,2006-11-30 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,denileukin diftitox,7237,New use,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,Individual,21144,US-20060269514,PA3392812,First Priority,2005-05-27 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Avaris AB,1003172,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Avaris AB,1003172,WO-2006004518,PA3075022,First Publication,2006-01-12 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Avaris AB,1003172,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Avaris AB,1003172,WO-2006004518,PA3075022,First Publication,2006-01-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Avaris AB,1003172,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Avaris AB,1003172,WO-2006004518,PA3075022,First Priority,2004-07-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Avaris AB,1003172,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Avaris AB,1003172,WO-2006004518,PA3075022,First Priority,2004-07-02 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,TTC Co Ltd,1005064,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,TTC Co Ltd,1005064,US-07282479,PA2915972,Extension,2024-07-14 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,TTC Co Ltd,1005064,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,TTC Co Ltd,1005064,US-07282479,PA2915972,Granted,2007-10-16 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,TTC Co Ltd,1005064,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,TTC Co Ltd,1005064,US-07282479,PA2915972,First Publication,2004-11-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,TTC Co Ltd,1005064,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,TTC Co Ltd,1005064,US-07282479,PA2915972,First Priority,2003-03-31 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Carcinoma,54,null,Botanic Oil Innovations Inc,1017656,US-20050244375,PA3057638,First Publication,2005-11-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Carcinoma,54,null,Botanic Oil Innovations Inc,1017656,US-20050244375,PA3057638,First Priority,2004-04-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV-1 infection,159,null,Individual,21144,WO-2007004231,PA3444044,First Publication,2007-01-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV-1 infection,159,null,Individual,21144,WO-2007004231,PA3444044,First Priority,2005-07-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Louisville,21246,WO-2007067683,PA3510001,First Publication,2007-06-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,University of Louisville,21246,WO-2007067683,PA3510001,First Publication,2007-06-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,University of Louisville,21246,WO-2007067683,PA3510001,First Publication,2007-06-14 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,University of Louisville,21246,WO-2007067683,PA3510001,First Publication,2007-06-14 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Louisville,21246,WO-2007067683,PA3510001,First Priority,2005-12-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,University of Louisville,21246,WO-2007067683,PA3510001,First Priority,2005-12-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,University of Louisville,21246,WO-2007067683,PA3510001,First Priority,2005-12-08 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,University of Louisville,21246,WO-2007067683,PA3510001,First Priority,2005-12-08 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Responsif GmbH,1005807,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Responsif GmbH,1005807,WO-2004064855,PA2905357,First Publication,2004-08-05 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Responsif GmbH,1005807,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Responsif GmbH,1005807,WO-2004064855,PA2905357,First Publication,2004-08-05 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Responsif GmbH,1005807,Owner,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Responsif GmbH,1005807,WO-2004064855,PA2905357,First Priority,2003-01-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Responsif GmbH,1005807,Owner,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Responsif GmbH,1005807,WO-2004064855,PA2905357,First Priority,2003-01-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Publication,1995-01-05 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Publication,1995-01-05 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Publication,1995-01-05 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Publication,1995-01-05 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Publication,1995-01-05 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Septic shock,816,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Publication,1995-01-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Publication,1995-01-05 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Priority,1993-06-22 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Priority,1993-06-22 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Priority,1993-06-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Priority,1993-06-22 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Priority,1993-06-22 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Septic shock,816,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Priority,1993-06-22 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Peptech (UK) Ltd,24752,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Teva Pharmaceutical Industries Ltd,20348,WO-09500538,IN2715754,First Priority,1993-06-22 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,SD-208,39180-X1,Component of Combination,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Individual,21144,WO-2015140150,PA8349414,First Publication,2015-09-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,European Patent,EP,SD-208,39180-X1,Component of Combination,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Individual,21144,WO-2015140150,PA8349414,First Priority,2014-03-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Weizmann Institute of Science,15489,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Neurodegenerative disease,233,null,Weizmann Institute of Science,15489,EP-00501445,IN1581745,First Publication,1992-09-02 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Weizmann Institute of Science,15489,Owner,Israel,IL,null,null,null,null,First Publication,First Priority,PUB,PRI,Neurodegenerative disease,233,null,Weizmann Institute of Science,15489,EP-00501445,IN1581745,First Priority,1991-02-27 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Individual,21144,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Individual,21144,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Owner,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,France,FR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Sweden,SE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Belgium,BE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Germany,DE,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Liechtenstein,LI,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Denmark,DK,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Italy,IT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Spain,ES,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Austria,AT,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Greece,GR,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Switzerland,CH,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Luxembourg,LU,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,somatropin,4433,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,Netherlands,NL,calcitonin,2712,Formulation,null,Assumed Expiry,Assumed Expiry,EXP,EXP,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Assumed Expiry,2011-07-16 00:00:00,EXP,5,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,Granted,2003-10-08 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,somatropin,4433,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,European Patent,EP,calcitonin,2712,Formulation,null,Assumed Expiry,Granted,EXP,GRT,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Publication,1992-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,granulocyte colony-stimulating factor,1002881-D,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,interleukin-2,DOC1000491,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,somatropin,4433,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Neoplasm,230,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Osteoporosis,246,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Imperial Chemical Industries Plc,17015,Third Party,UK,GB,calcitonin,2712,Formulation,null,Assumed Expiry,First Priority,EXP,PRI,Viral infection,344,null,Akzo Nobel NV,13802,EP-00473268,IN1578655,First Priority,1990-07-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Bone tumor,1012,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Basal cell carcinoma,1764,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Bone metastases,1829,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,ingenol mebutate,32757,New use,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Bone tumor,1012,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Basal cell carcinoma,1764,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Bone metastases,1829,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,World,WO,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Publication,2006-06-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Bone tumor,1012,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Basal cell carcinoma,1764,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Bone metastases,1829,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,ingenol mebutate,32757,New use,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Bone tumor,1012,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Basal cell carcinoma,1764,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Bone metastases,1829,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Peplin Research Pty Ltd,26343,Owner,Australia,AU,"ingenol mebutate (injectable), Peplin Biotech",49899,New use,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,LEO Pharma A/S,17774,WO-2006063382,PA3206803,First Priority,2004-12-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Individual,21144,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Individual,21144,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,sunitinib,12973,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Individual,21144,US-20100166701,PA5634974,First Publication,2010-07-01 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,sunitinib,12973,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,US-20100166701,PA5634974,First Publication,2010-07-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,sunitinib,12973,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Individual,21144,US-20100166701,PA5634974,First Priority,2008-03-06 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,sunitinib,12973,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,US-20100166701,PA5634974,First Priority,2008-03-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,World,WO,Multikine,7401,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,CEL-SCI Corp,15339,WO-2006122178,PA3333093,First Publication,2006-11-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,US,US,Multikine,7401,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,CEL-SCI Corp,15339,WO-2006122178,PA3333093,First Priority,2005-05-10 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,S-Cell Biosciences Inc,1013069,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergic rhinitis,1107,null,S-Cell Biosciences Inc,1013069,WO-2008101037,PA3674708,First Publication,2008-08-21 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,S-Cell Biosciences Inc,1013069,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Upper respiratory tract inflammation,1491,null,S-Cell Biosciences Inc,1013069,WO-2008101037,PA3674708,First Publication,2008-08-21 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,S-Cell Biosciences Inc,1013069,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,S-Cell Biosciences Inc,1013069,WO-2008101037,PA3674708,First Publication,2008-08-21 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,S-Cell Biosciences Inc,1013069,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergic rhinitis,1107,null,S-Cell Biosciences Inc,1013069,WO-2008101037,PA3674708,First Priority,2007-02-14 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,S-Cell Biosciences Inc,1013069,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Upper respiratory tract inflammation,1491,null,S-Cell Biosciences Inc,1013069,WO-2008101037,PA3674708,First Priority,2007-02-14 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,S-Cell Biosciences Inc,1013069,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,S-Cell Biosciences Inc,1013069,WO-2008101037,PA3674708,First Priority,2007-02-14 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Inflammatory disease,188,null,Individual,21144,US-08053231,PA3695844,Extension,2029-06-12 00:00:00,EXT,4,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Rheumatoid arthritis,291,null,Individual,21144,US-08053231,PA3695844,Extension,2029-06-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Ulcerative colitis,337,null,Individual,21144,US-08053231,PA3695844,Extension,2029-06-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Autoimmune disease,36,null,Individual,21144,US-08053231,PA3695844,Extension,2029-06-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Inflammatory disease,188,null,Individual,21144,US-08053231,PA3695844,Granted,2011-11-08 00:00:00,GRT,3,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Rheumatoid arthritis,291,null,Individual,21144,US-08053231,PA3695844,Granted,2011-11-08 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Ulcerative colitis,337,null,Individual,21144,US-08053231,PA3695844,Granted,2011-11-08 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Autoimmune disease,36,null,Individual,21144,US-08053231,PA3695844,Granted,2011-11-08 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Inflammatory disease,188,null,Individual,21144,US-08053231,PA3695844,First Publication,2008-10-09 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Rheumatoid arthritis,291,null,Individual,21144,US-08053231,PA3695844,First Publication,2008-10-09 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Ulcerative colitis,337,null,Individual,21144,US-08053231,PA3695844,First Publication,2008-10-09 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Autoimmune disease,36,null,Individual,21144,US-08053231,PA3695844,First Publication,2008-10-09 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Inflammatory disease,188,null,Individual,21144,US-08053231,PA3695844,First Priority,2007-04-03 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Rheumatoid arthritis,291,null,Individual,21144,US-08053231,PA3695844,First Priority,2007-04-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Ulcerative colitis,337,null,Individual,21144,US-08053231,PA3695844,First Priority,2007-04-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Autoimmune disease,36,null,Individual,21144,US-08053231,PA3695844,First Priority,2007-04-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,oxaliplatin,3792,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,oxaliplatin,3792,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,oxaliplatin,3792,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,LOR-2040,21259,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,LOR-2040,21259,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,LOR-2040,21259,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,capecitabine,12205,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,capecitabine,12205,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,World,WO,capecitabine,12205,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Publication,2005-07-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,oxaliplatin,3792,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,oxaliplatin,3792,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,oxaliplatin,3792,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,LOR-2040,21259,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,LOR-2040,21259,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,LOR-2040,21259,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,capecitabine,12205,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,capecitabine,12205,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Aptose Biosciences Inc,17215,Owner,US,US,capecitabine,12205,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Aptose Biosciences Inc,17215,WO-2005065719,PA3002671,First Priority,2004-01-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,All India Institute of Medical Sciences,26112,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV-1 infection,159,null,All India Institute of Medical Sciences,26112,WO-2007004231,PA3444044,First Publication,2007-01-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,All India Institute of Medical Sciences,26112,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV-1 infection,159,null,All India Institute of Medical Sciences,26112,WO-2007004231,PA3444044,First Priority,2005-07-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Merck KGaA,18101,WO-03066102,PA2868222,First Publication,2003-08-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Merck KGaA,18101,WO-03066102,PA2868222,First Publication,2003-08-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Merck KGaA,18101,WO-03066102,PA2868222,First Priority,2002-02-06 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Merck KGaA,18101,WO-03066102,PA2868222,First Priority,2002-02-06 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Idera Pharmaceuticals Inc,17006,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Idera Pharmaceuticals Inc,17006,WO-2005009355,PA2943006,First Publication,2005-02-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Idera Pharmaceuticals Inc,17006,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Idera Pharmaceuticals Inc,17006,WO-2005009355,PA2943006,First Publication,2005-02-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Idera Pharmaceuticals Inc,17006,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Idera Pharmaceuticals Inc,17006,WO-2005009355,PA2943006,First Publication,2005-02-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Idera Pharmaceuticals Inc,17006,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Idera Pharmaceuticals Inc,17006,WO-2005009355,PA2943006,First Priority,2003-07-15 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Idera Pharmaceuticals Inc,17006,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Idera Pharmaceuticals Inc,17006,WO-2005009355,PA2943006,First Priority,2003-07-15 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Idera Pharmaceuticals Inc,17006,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Idera Pharmaceuticals Inc,17006,WO-2005009355,PA2943006,First Priority,2003-07-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Publication,2000-10-12 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Publication,2000-10-12 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Publication,2000-10-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bacterial infection,40,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Publication,2000-10-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Publication,2000-10-12 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Priority,1999-04-02 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Priority,1999-04-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Priority,1999-04-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bacterial infection,40,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Priority,1999-04-02 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Harvard Medical School,24839,WO-00059515,IN2749373,First Priority,1999-04-02 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Semmelweis University,25632,Third Party,World,WO,Multikine,7401,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Semmelweis University,25632,WO-2006122178,PA3333093,First Publication,2006-11-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Semmelweis University,25632,Third Party,US,US,Multikine,7401,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Semmelweis University,25632,WO-2006122178,PA3333093,First Priority,2005-05-10 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoid leukemia,1255,null,Novartis AG,23137,WO-2005044294,PA2986461,First Publication,2005-05-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,Novartis AG,23137,WO-2005044294,PA2986461,First Publication,2005-05-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,Novartis AG,23137,WO-2005044294,PA2986461,First Publication,2005-05-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,Novartis AG,23137,WO-2005044294,PA2986461,First Publication,2005-05-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,Novartis AG,23137,WO-2005044294,PA2986461,First Publication,2005-05-19 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Carcinoma,54,null,Novartis AG,23137,WO-2005044294,PA2986461,First Publication,2005-05-19 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Novartis AG,23137,WO-2005044294,PA2986461,First Publication,2005-05-19 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lymphoid leukemia,1255,null,Novartis AG,23137,WO-2005044294,PA2986461,First Priority,2003-11-04 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,Novartis AG,23137,WO-2005044294,PA2986461,First Priority,2003-11-04 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,Novartis AG,23137,WO-2005044294,PA2986461,First Priority,2003-11-04 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,Novartis AG,23137,WO-2005044294,PA2986461,First Priority,2003-11-04 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,Novartis AG,23137,WO-2005044294,PA2986461,First Priority,2003-11-04 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Carcinoma,54,null,Novartis AG,23137,WO-2005044294,PA2986461,First Priority,2003-11-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Novartis AG,23137,WO-2005044294,PA2986461,First Priority,2003-11-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Korea Advanced Institute of Science and Technology,25540,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Growth disorder,140,null,Korea Advanced Institute of Science and Technology,25540,WO-2006126750,PA3388360,First Publication,2006-11-30 00:00:00,PUB,2,Growth disorder,140
IL-2 receptor agonist,221,null,Korea Advanced Institute of Science and Technology,25540,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Korea Advanced Institute of Science and Technology,25540,WO-2006126750,PA3388360,First Publication,2006-11-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Korea Advanced Institute of Science and Technology,25540,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Growth disorder,140,null,Korea Advanced Institute of Science and Technology,25540,WO-2006126750,PA3388360,First Priority,2005-05-23 00:00:00,PRI,1,Growth disorder,140
IL-2 receptor agonist,221,null,Korea Advanced Institute of Science and Technology,25540,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Korea Advanced Institute of Science and Technology,25540,WO-2006126750,PA3388360,First Priority,2005-05-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,World,WO,mercaptamine,70175,New use,null,First Publication,First Publication,PUB,PUB,Acute stress disorder,1936,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Publication,2005-07-28 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,World,WO,mercaptamine,70175,New use,null,First Publication,First Publication,PUB,PUB,Hashimotos disease,1977,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Publication,2005-07-28 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,World,WO,mercaptamine,70175,New use,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Publication,2005-07-28 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,World,WO,mercaptamine,70175,New use,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Publication,2005-07-28 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,World,WO,mercaptamine,70175,New use,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Publication,2005-07-28 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,US,US,mercaptamine,70175,New use,null,First Publication,First Priority,PUB,PRI,Acute stress disorder,1936,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Priority,2004-01-13 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,US,US,mercaptamine,70175,New use,null,First Publication,First Priority,PUB,PRI,Hashimotos disease,1977,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Priority,2004-01-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,US,US,mercaptamine,70175,New use,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Priority,2004-01-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,US,US,mercaptamine,70175,New use,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Priority,2004-01-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Omega Bio-Pharma (IP2) Ltd,1004036,Owner,US,US,mercaptamine,70175,New use,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Omega Bio-Pharma (IP2) Ltd,1004036,WO-2005067899,PA3004494,First Priority,2004-01-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Flamel Technologies SA,16192,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Avadel Pharmaceuticals plc,1128249,WO-2008025425,PA3610876,First Publication,2008-03-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Flamel Technologies SA,16192,Owner,World,WO,insulin human,CP149712,Formulation,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Avadel Pharmaceuticals plc,1128249,WO-2008025425,PA3610876,First Publication,2008-03-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Flamel Technologies SA,16192,Owner,France,FR,interleukin-2,DOC1000491,Formulation,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Avadel Pharmaceuticals plc,1128249,WO-2008025425,PA3610876,First Priority,2006-07-28 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Flamel Technologies SA,16192,Owner,France,FR,insulin human,CP149712,Formulation,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Avadel Pharmaceuticals plc,1128249,WO-2008025425,PA3610876,First Priority,2006-07-28 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Merck KGaA,18101,WO-2005021592,PA2952594,First Publication,2005-03-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Merck KGaA,18101,WO-2005021592,PA2952594,First Publication,2005-03-10 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck KGaA,18101,WO-2005021592,PA2952594,First Publication,2005-03-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Merck KGaA,18101,WO-2005021592,PA2952594,First Priority,2003-08-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Merck KGaA,18101,WO-2005021592,PA2952594,First Priority,2003-08-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck KGaA,18101,WO-2005021592,PA2952594,First Priority,2003-08-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Fungal infection,124,null,University of California,20547,WO-2007016185,PA3462955,First Publication,2007-02-08 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prion infection,1300,null,University of California,20547,WO-2007016185,PA3462955,First Publication,2007-02-08 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycoplasma infection,222,null,University of California,20547,WO-2007016185,PA3462955,First Publication,2007-02-08 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Parasitic infection,252,null,University of California,20547,WO-2007016185,PA3462955,First Publication,2007-02-08 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,University of California,20547,WO-2007016185,PA3462955,First Publication,2007-02-08 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of California,20547,WO-2007016185,PA3462955,First Publication,2007-02-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bacterial infection,40,null,University of California,20547,WO-2007016185,PA3462955,First Publication,2007-02-08 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of California,20547,WO-2007016185,PA3462955,First Publication,2007-02-08 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Fungal infection,124,null,University of California,20547,WO-2007016185,PA3462955,First Priority,2005-07-29 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prion infection,1300,null,University of California,20547,WO-2007016185,PA3462955,First Priority,2005-07-29 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Mycoplasma infection,222,null,University of California,20547,WO-2007016185,PA3462955,First Priority,2005-07-29 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Parasitic infection,252,null,University of California,20547,WO-2007016185,PA3462955,First Priority,2005-07-29 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,University of California,20547,WO-2007016185,PA3462955,First Priority,2005-07-29 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of California,20547,WO-2007016185,PA3462955,First Priority,2005-07-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bacterial infection,40,null,University of California,20547,WO-2007016185,PA3462955,First Priority,2005-07-29 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of California,20547,WO-2007016185,PA3462955,First Priority,2005-07-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,US Government,20516,WO-2008051220,PA3631562,First Publication,2008-05-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,US Government,20516,WO-2008051220,PA3631562,First Publication,2008-05-02 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,US Government,20516,WO-2008051220,PA3631562,First Publication,2008-05-02 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,WO-2008051220,PA3631562,First Publication,2008-05-02 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,US Government,20516,WO-2008051220,PA3631562,First Publication,2008-05-02 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,US Government,20516,WO-2008051220,PA3631562,First Publication,2008-05-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,US Government,20516,WO-2008051220,PA3631562,First Priority,2006-10-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,US Government,20516,WO-2008051220,PA3631562,First Priority,2006-10-24 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,US Government,20516,WO-2008051220,PA3631562,First Priority,2006-10-24 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,WO-2008051220,PA3631562,First Priority,2006-10-24 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,US Government,20516,WO-2008051220,PA3631562,First Priority,2006-10-24 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,US Government,20516,WO-2008051220,PA3631562,First Priority,2006-10-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Hepatitis virus infection,155,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,Extension,2021-09-13 00:00:00,EXT,4,Inflammatory disease,188
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Sarcoma,194,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,Extension,2021-09-13 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Melanoma,205,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,Extension,2021-09-13 00:00:00,EXT,4,Dermatological disease,95
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,Extension,2021-09-13 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Hepatitis virus infection,155,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,Granted,2010-05-18 00:00:00,GRT,3,Inflammatory disease,188
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Sarcoma,194,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,Granted,2010-05-18 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Melanoma,205,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,Granted,2010-05-18 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,Granted,2010-05-18 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Hepatitis virus infection,155,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,First Publication,2007-11-22 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Sarcoma,194,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,First Publication,2007-11-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Melanoma,205,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,First Publication,2007-11-22 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,First Publication,2007-11-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Hepatitis virus infection,155,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,First Priority,2001-07-13 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Sarcoma,194,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,First Priority,2001-07-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Melanoma,205,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,First Priority,2001-07-13 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,CMS Peptides Patent Holding Co Ltd,1030678,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,China Medical System Holdings Ltd,1037068,US-07718768,PA3572052,First Priority,2001-07-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Henry Ford Health System,22802,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Nervous system tumor,232,null,Henry Ford Health System,22802,WO-2005006947,PA2941027,First Publication,2005-01-27 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Henry Ford Health System,22802,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Henry Ford Health System,22802,WO-2005006947,PA2941027,First Publication,2005-01-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Henry Ford Health System,22802,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Henry Ford Health System,22802,WO-2005006947,PA2941027,First Publication,2005-01-27 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Henry Ford Health System,22802,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Nervous system tumor,232,null,Henry Ford Health System,22802,WO-2005006947,PA2941027,First Priority,2003-07-03 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Henry Ford Health System,22802,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Henry Ford Health System,22802,WO-2005006947,PA2941027,First Priority,2003-07-03 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Henry Ford Health System,22802,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Henry Ford Health System,22802,WO-2005006947,PA2941027,First Priority,2003-07-03 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diarrhea,102,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Headache,148,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Fever,1833,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Temperature disorder,1023
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pain,20,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Nausea,226,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Skin rash,3020,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diarrhea,102,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Headache,148,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Fever,1833,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Temperature disorder,1023
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Nausea,226,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin rash,3020,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Microparticle Proteomics Lls,1039677,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Microparticle Proteomics Lls,1039677,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Emory University,20573,US-20080311140,PA3724264,First Publication,2008-12-18 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Emory University,20573,US-20080311140,PA3724264,First Priority,2007-05-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thrombosis,1076,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hormone deficiency,364,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vascular disease,742,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Thrombosis,1076,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal disease,286,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Hormone deficiency,364,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Vascular disease,742,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,XL-Protein GmbH,1050061,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Kyowa Hakko Kogyo Co Ltd,17724,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Kirin Holdings Co Ltd,1037687,WO-2005053742,PA2993700,First Publication,2005-06-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Kyowa Hakko Kogyo Co Ltd,17724,Owner,Japan,JP,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Kirin Holdings Co Ltd,1037687,WO-2005053742,PA2993700,First Priority,2003-12-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,World,WO,Multikine,7401,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,CEL-SCI Corp,15339,WO-2005120550,PA3069061,First Publication,2005-12-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,World,WO,Multikine,7401,Formulation,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,CEL-SCI Corp,15339,WO-2005120550,PA3069061,First Publication,2005-12-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,US,US,Multikine,7401,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,CEL-SCI Corp,15339,WO-2005120550,PA3069061,First Priority,2004-06-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,US,US,Multikine,7401,Formulation,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,CEL-SCI Corp,15339,WO-2005120550,PA3069061,First Priority,2004-06-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Novartis AG,23137,WO-2005062929,PA3000811,First Publication,2005-07-14 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis Vaccines & Diagnostics Srl,1002977,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Novartis AG,23137,WO-2005062929,PA3000811,First Priority,2003-12-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2011103882,PA6555344,First Publication,2011-09-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2011103882,PA6555344,First Priority,2010-02-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,World,WO,Multikine,7401,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,CEL-SCI Corp,15339,WO-2006004633,PA3075064,First Publication,2006-01-12 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,US,US,Multikine,7401,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,CEL-SCI Corp,15339,WO-2006004633,PA3075064,First Priority,2004-06-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Unidentified indication,1005,null,Neose Technologies Inc,24203,WO-2005067601,PA3004666,First Publication,2005-07-28 00:00:00,PUB,2,Unidentified indication,1005
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Unidentified indication,1005,null,Neose Technologies Inc,24203,WO-2005067601,PA3004666,First Priority,2004-01-09 00:00:00,PRI,1,Unidentified indication,1005
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergic rhinitis,1107,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Fungal infection,124,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prion infection,1300,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatitis virus infection,155,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Protozoal infection,278,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Wound healing,347,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bacterial infection,40,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Publication,2005-08-04 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergic rhinitis,1107,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Fungal infection,124,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Prion infection,1300,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatitis virus infection,155,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Protozoal infection,278,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Wound healing,347,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Bacterial infection,40,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MNLpharma Ltd,1003444,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Summit Therapeutics plc,1017551,WO-2005070418,PA3006122,First Priority,2004-01-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Amicus Therapeutics Inc,1003633,Owner,World,WO,migalastat hydrochloride,CP165604,Formulation,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,Amicus Therapeutics Inc,1003633,WO-2007137072,PA3573816,First Publication,2007-11-29 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Amicus Therapeutics Inc,1003633,Owner,World,WO,migalastat hydrochloride,CP165604,Formulation,null,First Publication,First Publication,PUB,PUB,Fabry disease,774,null,Amicus Therapeutics Inc,1003633,WO-2007137072,PA3573816,First Publication,2007-11-29 00:00:00,PUB,2,Ocular disease,239
IL-2 receptor agonist,221,null,Amicus Therapeutics Inc,1003633,Owner,World,WO,migalastat,47398,General interest,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,Amicus Therapeutics Inc,1003633,WO-2007137072,PA3573816,First Publication,2007-11-29 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Amicus Therapeutics Inc,1003633,Owner,World,WO,migalastat,47398,General interest,null,First Publication,First Publication,PUB,PUB,Fabry disease,774,null,Amicus Therapeutics Inc,1003633,WO-2007137072,PA3573816,First Publication,2007-11-29 00:00:00,PUB,2,Ocular disease,239
IL-2 receptor agonist,221,null,Amicus Therapeutics Inc,1003633,Owner,US,US,migalastat hydrochloride,CP165604,Formulation,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,Amicus Therapeutics Inc,1003633,WO-2007137072,PA3573816,First Priority,2006-05-16 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Amicus Therapeutics Inc,1003633,Owner,US,US,migalastat hydrochloride,CP165604,Formulation,null,First Publication,First Priority,PUB,PRI,Fabry disease,774,null,Amicus Therapeutics Inc,1003633,WO-2007137072,PA3573816,First Priority,2006-05-16 00:00:00,PRI,1,Ocular disease,239
IL-2 receptor agonist,221,null,Amicus Therapeutics Inc,1003633,Owner,US,US,migalastat,47398,General interest,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,Amicus Therapeutics Inc,1003633,WO-2007137072,PA3573816,First Priority,2006-05-16 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Amicus Therapeutics Inc,1003633,Owner,US,US,migalastat,47398,General interest,null,First Publication,First Priority,PUB,PRI,Fabry disease,774,null,Amicus Therapeutics Inc,1003633,WO-2007137072,PA3573816,First Priority,2006-05-16 00:00:00,PRI,1,Ocular disease,239
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,alemtuzumab,2716,Component of Combination,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,Novartis AG,23137,WO-2005016380,PA2948568,First Publication,2005-02-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,alemtuzumab,2716,Component of Combination,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,Novartis AG,23137,WO-2005016380,PA2948568,First Priority,2003-07-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Proscan Rx Pharma,1009372,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Proscan Rx Pharma,1009372,WO-2005100404,PA3055109,First Publication,2005-10-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Proscan Rx Pharma,1009372,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Proscan Rx Pharma,1009372,WO-2005100404,PA3055109,First Publication,2005-10-27 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Proscan Rx Pharma,1009372,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Proscan Rx Pharma,1009372,WO-2005100404,PA3055109,First Priority,2004-04-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Proscan Rx Pharma,1009372,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Proscan Rx Pharma,1009372,WO-2005100404,PA3055109,First Priority,2004-04-19 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infertility,1079,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Growth disorder,140,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Growth disorder,140
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neutropenia,1991,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ischemia,637,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Blood clotting disorder,75,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Publication,2005-12-22 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infertility,1079,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Growth disorder,140,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Growth disorder,140
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neutropenia,1991,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Blood clotting disorder,75,null,Neose Technologies Inc,24203,WO-2005121331,PA3069149,First Priority,2004-06-03 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infertility,1079,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Growth disorder,140,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Growth disorder,140
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neutropenia,1991,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ischemia,637,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Blood clotting disorder,75,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Publication,2005-12-22 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infertility,1079,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Growth disorder,140,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Growth disorder,140
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neutropenia,1991,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Neose Technologies Inc,24203,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Blood clotting disorder,75,null,Neose Technologies Inc,24203,WO-2005121332,PA3069150,First Priority,2004-06-03 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Cleveland Clinic Foundation,22123,WO-2007149381,PA3583796,First Publication,2007-12-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,sodium stibogluconate,CP154657,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Cleveland Clinic Foundation,22123,WO-2007149381,PA3583796,First Publication,2007-12-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,"sodium stibogluconate (cancer), VioQuest",53174,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Cleveland Clinic Foundation,22123,WO-2007149381,PA3583796,First Publication,2007-12-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interferon alfa,14232,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Cleveland Clinic Foundation,22123,WO-2007149381,PA3583796,First Publication,2007-12-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Cleveland Clinic Foundation,22123,WO-2007149381,PA3583796,First Priority,2006-06-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,sodium stibogluconate,CP154657,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Cleveland Clinic Foundation,22123,WO-2007149381,PA3583796,First Priority,2006-06-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,"sodium stibogluconate (cancer), VioQuest",53174,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Cleveland Clinic Foundation,22123,WO-2007149381,PA3583796,First Priority,2006-06-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interferon alfa,14232,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Cleveland Clinic Foundation,22123,WO-2007149381,PA3583796,First Priority,2006-06-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Karolinska Institutet,21110,WO-2006004518,PA3075022,First Publication,2006-01-12 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Karolinska Institutet,21110,WO-2006004518,PA3075022,First Publication,2006-01-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Karolinska Institutet,21110,WO-2006004518,PA3075022,First Priority,2004-07-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Karolinska Institutet,21110,WO-2006004518,PA3075022,First Priority,2004-07-02 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Publication,2006-08-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Publication,2006-08-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Publication,2006-08-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Publication,2006-08-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Publication,2006-08-10 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,University of New South Wales,25163,WO-2006081620,PA3221829,First Priority,2005-02-02 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,University of New South Wales,25163,WO-2006081619,PA3221830,First Publication,2006-08-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,University of New South Wales,25163,WO-2006081619,PA3221830,First Publication,2006-08-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of New South Wales,25163,WO-2006081619,PA3221830,First Publication,2006-08-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,University of New South Wales,25163,WO-2006081619,PA3221830,First Publication,2006-08-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,University of New South Wales,25163,WO-2006081619,PA3221830,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,University of New South Wales,25163,WO-2006081619,PA3221830,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of New South Wales,25163,WO-2006081619,PA3221830,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of New South Wales,25163,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,University of New South Wales,25163,WO-2006081619,PA3221830,First Priority,2005-02-02 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis,154,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis virus infection,155,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,"sodium stibogluconate (cancer), VioQuest",53174,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,"sodium stibogluconate (cancer), VioQuest",53174,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis,154,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,"sodium stibogluconate (cancer), VioQuest",53174,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis virus infection,155,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interferon alfa,14232,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interferon alfa,14232,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis,154,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,World,WO,interferon alfa,14232,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis virus infection,155,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Publication,2007-12-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis,154,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis virus infection,155,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,"sodium stibogluconate (cancer), VioQuest",53174,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,"sodium stibogluconate (cancer), VioQuest",53174,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis,154,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,"sodium stibogluconate (cancer), VioQuest",53174,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis virus infection,155,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interferon alfa,14232,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interferon alfa,14232,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis,154,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,interferon alfa,14232,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis virus infection,155,null,Cleveland Clinic Foundation,22123,WO-2007149382,PA3584104,First Priority,2006-06-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Parasitic infection,252,null,University of Zurich,25713,WO-2006032525,PA3167042,First Publication,2006-03-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,University of Zurich,25713,WO-2006032525,PA3167042,First Publication,2006-03-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bacterial infection,40,null,University of Zurich,25713,WO-2006032525,PA3167042,First Publication,2006-03-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Zurich,25713,WO-2006032525,PA3167042,First Publication,2006-03-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Nerve tumor,763,null,University of Zurich,25713,WO-2006032525,PA3167042,First Publication,2006-03-30 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Parasitic infection,252,null,University of Zurich,25713,WO-2006032525,PA3167042,First Priority,2004-09-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,University of Zurich,25713,WO-2006032525,PA3167042,First Priority,2004-09-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Bacterial infection,40,null,University of Zurich,25713,WO-2006032525,PA3167042,First Priority,2004-09-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Zurich,25713,WO-2006032525,PA3167042,First Priority,2004-09-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Nerve tumor,763,null,University of Zurich,25713,WO-2006032525,PA3167042,First Priority,2004-09-24 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Johns Hopkins University,20596,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Johns Hopkins University,20596,WO-2006074430,PA3213150,First Publication,2006-07-13 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Johns Hopkins University,20596,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Johns Hopkins University,20596,WO-2006074430,PA3213150,First Priority,2005-01-07 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,World,WO,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Publication,2006-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,VioQuest Pharmaceuticals Inc,1009439,Owner,US,US,sodium stibogluconate,CP154657,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,VioQuest Pharmaceuticals Inc,1009439,WO-2006053162,PA3196916,First Priority,2004-11-11 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Endonovo Therapeutics Inc,1096155,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Endonovo Therapeutics Inc,1096155,WO-2007102812,PA3544800,First Publication,2007-09-13 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Endonovo Therapeutics Inc,1096155,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Endonovo Therapeutics Inc,1096155,WO-2007102812,PA3544800,First Priority,2006-03-07 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological disease,142,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Publication,2006-10-11 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Publication,2006-10-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung disease,283,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Publication,2006-10-11 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Publication,2006-10-11 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cystic fibrosis,88,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Publication,2006-10-11 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological disease,142,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Priority,2005-04-08 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Priority,2005-04-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung disease,283,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Priority,2005-04-08 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Priority,2005-04-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cystic fibrosis,88,null,Max Delbruck Centrum Fur Molekulare Medizin,17961,EP-01710316,PA3240037,First Priority,2005-04-08 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Individual,21144,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Medifocus Inc,1077407,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Medifocus Inc,1077407,WO-2004031357,PA2893219,First Publication,2004-04-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Medifocus Inc,1077407,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Medifocus Inc,1077407,WO-2004031357,PA2893219,First Priority,2002-10-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,MediGene Ltd,28195,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,MediGene AG,24224,WO-2006103429,PA3237977,First Publication,2006-10-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MediGene Ltd,28195,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,MediGene AG,24224,WO-2006103429,PA3237977,First Publication,2006-10-05 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,MediGene Ltd,28195,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,MediGene AG,24224,WO-2006103429,PA3237977,First Priority,2005-04-01 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MediGene Ltd,28195,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,MediGene AG,24224,WO-2006103429,PA3237977,First Priority,2005-04-01 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fortovia Therapeutics Inc,25179,Owner,World,WO,talabostat,34323,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Barings LLC,1172186,WO-2007058957,PA3502185,First Publication,2007-05-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Fortovia Therapeutics Inc,25179,Owner,World,WO,talabostat,34323,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Barings LLC,1172186,WO-2007058957,PA3502185,First Publication,2007-05-24 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Fortovia Therapeutics Inc,25179,Owner,World,WO,talabostat,34323,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Barings LLC,1172186,WO-2007058957,PA3502185,First Publication,2007-05-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Fortovia Therapeutics Inc,25179,Owner,US,US,talabostat,34323,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Barings LLC,1172186,WO-2007058957,PA3502185,First Priority,2005-11-10 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Fortovia Therapeutics Inc,25179,Owner,US,US,talabostat,34323,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Barings LLC,1172186,WO-2007058957,PA3502185,First Priority,2005-11-10 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Fortovia Therapeutics Inc,25179,Owner,US,US,talabostat,34323,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Barings LLC,1172186,WO-2007058957,PA3502185,First Priority,2005-11-10 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Emphysema,111,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Alpha-1 antitrypsin deficiency,1298,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Rare disease,9099
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,HIV infection,158,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Pulmonary hypertension,1867,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung disease,283,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Connective tissue disease,570,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Vascular disease,742,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung tumor,755,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Degeneration,817,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Degeneration,817
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Cystic fibrosis,88,null,MediciNova Inc,28088,US-07427396,PA3077939,Granted,2008-09-23 00:00:00,GRT,3,Rare disease,9099
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Emphysema,111,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Alpha-1 antitrypsin deficiency,1298,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,HIV infection,158,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Pulmonary hypertension,1867,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung disease,283,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Connective tissue disease,570,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Vascular disease,742,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung tumor,755,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Degeneration,817,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Cystic fibrosis,88,null,MediciNova Inc,28088,US-07427396,PA3077939,First Publication,2006-01-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Emphysema,111,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Alpha-1 antitrypsin deficiency,1298,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,HIV infection,158,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Pulmonary hypertension,1867,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung disease,283,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Connective tissue disease,570,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Vascular disease,742,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung tumor,755,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Degeneration,817,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Avigen Inc,14343,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Cystic fibrosis,88,null,MediciNova Inc,28088,US-07427396,PA3077939,First Priority,2004-06-03 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thrombosis,1076,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hormone deficiency,364,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Thrombosis,1076,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal disease,286,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Hormone deficiency,364,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,International Biotechnology Center Generium LLC,1065293,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Pharmstandard OJSC,1047078,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck KGaA,18101,WO-2008003473,PA3590135,First Publication,2008-01-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,daclizumab,2546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck KGaA,18101,WO-2008003473,PA3590135,First Publication,2008-01-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,basiliximab,11141,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck KGaA,18101,WO-2008003473,PA3590135,First Publication,2008-01-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck KGaA,18101,WO-2008003473,PA3590135,First Priority,2006-07-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,daclizumab,2546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck KGaA,18101,WO-2008003473,PA3590135,First Priority,2006-07-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,basiliximab,11141,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck KGaA,18101,WO-2008003473,PA3590135,First Priority,2006-07-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,trastuzumab,6386,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,trastuzumab,6386,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,trastuzumab,6386,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,trastuzumab,6386,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,cetuximab,10388,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,cetuximab,10388,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,cetuximab,10388,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,cetuximab,10388,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Publication,2011-01-06 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,trastuzumab,6386,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,trastuzumab,6386,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,trastuzumab,6386,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,trastuzumab,6386,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,cetuximab,10388,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,cetuximab,10388,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,cetuximab,10388,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,cetuximab,10388,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Philogen SpA,29032,WO-2011001276,PA6307974,First Priority,2009-06-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Carcinoma,54,null,Novartis AG,23137,WO-2005086798,PA3033993,First Publication,2005-09-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Carcinoma,54,null,Novartis AG,23137,WO-2005086798,PA3033993,First Priority,2004-03-05 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Vasogen Ireland Ltd,16822,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,IntelliPharmaCeutics International Inc,1016256,WO-2004024171,PA2891350,First Publication,2004-03-25 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Vasogen Ireland Ltd,16822,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,IntelliPharmaCeutics International Inc,1016256,WO-2004024171,PA2891350,First Priority,2002-09-16 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Corcept Therapeutics Inc,28807,Owner,World,WO,"mifepristone (Cushing's syndrome/cancer), Corcept Therapeutics",43078,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Corcept Therapeutics Inc,28807,WO-2007131041,PA3568677,First Publication,2007-11-15 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Corcept Therapeutics Inc,28807,Owner,World,WO,"mifepristone (Cushing's syndrome/cancer), Corcept Therapeutics",43078,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Corcept Therapeutics Inc,28807,WO-2007131041,PA3568677,First Publication,2007-11-15 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Corcept Therapeutics Inc,28807,Owner,World,WO,"mifepristone (Cushing's syndrome/cancer), Corcept Therapeutics",43078,Component of Combination,null,First Publication,First Publication,PUB,PUB,Depression,93,null,Corcept Therapeutics Inc,28807,WO-2007131041,PA3568677,First Publication,2007-11-15 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Corcept Therapeutics Inc,28807,Owner,US,US,"mifepristone (Cushing's syndrome/cancer), Corcept Therapeutics",43078,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Corcept Therapeutics Inc,28807,WO-2007131041,PA3568677,First Priority,2006-05-02 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Corcept Therapeutics Inc,28807,Owner,US,US,"mifepristone (Cushing's syndrome/cancer), Corcept Therapeutics",43078,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Corcept Therapeutics Inc,28807,WO-2007131041,PA3568677,First Priority,2006-05-02 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Corcept Therapeutics Inc,28807,Owner,US,US,"mifepristone (Cushing's syndrome/cancer), Corcept Therapeutics",43078,Component of Combination,null,First Publication,First Priority,PUB,PRI,Depression,93,null,Corcept Therapeutics Inc,28807,WO-2007131041,PA3568677,First Priority,2006-05-02 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Renal cell carcinoma,1766,null,Novartis AG,23137,GB-02415904,PA3075252,Granted,2006-01-11 00:00:00,GRT,3,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Novartis AG,23137,GB-02415904,PA3075252,Granted,2006-01-11 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Cancer,651,null,Novartis AG,23137,GB-02415904,PA3075252,Granted,2006-01-11 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Renal cell carcinoma,1766,null,Novartis AG,23137,GB-02415904,PA3075252,First Publication,2005-03-16 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Novartis AG,23137,GB-02415904,PA3075252,First Publication,2005-03-16 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Cancer,651,null,Novartis AG,23137,GB-02415904,PA3075252,First Publication,2005-03-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Renal cell carcinoma,1766,null,Novartis AG,23137,GB-02415904,PA3075252,First Priority,2005-02-07 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Novartis AG,23137,GB-02415904,PA3075252,First Priority,2005-02-07 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,UK,GB,null,null,null,null,Granted,Granted,GRT,GRT,Cancer,651,null,Novartis AG,23137,GB-02415904,PA3075252,First Priority,2005-02-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2007071389,PA3515253,First Publication,2007-06-28 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071389,PA3515253,First Publication,2007-06-28 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2007071389,PA3515253,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071389,PA3515253,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2007071389,PA3515253,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071389,PA3515253,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071409,PA3515786,First Publication,2007-06-28 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Sinorda Biomedicine Ltd,1093165,WO-2007071409,PA3515786,First Publication,2007-06-28 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071409,PA3515786,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Sinorda Biomedicine Ltd,1093165,WO-2007071409,PA3515786,First Priority,2005-12-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071409,PA3515786,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Sinorda Biomedicine Ltd,1093165,WO-2007071409,PA3515786,First Priority,2005-12-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,GlaxoSmithKline plc,28355,WO-2007062831,PA3507532,First Publication,2007-06-07 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,GlaxoSmithKline plc,28355,WO-2007062831,PA3507532,First Publication,2007-06-07 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,GlaxoSmithKline plc,28355,WO-2007062831,PA3507532,First Publication,2007-06-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,GlaxoSmithKline plc,28355,WO-2007062831,PA3507532,First Publication,2007-06-07 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,GlaxoSmithKline plc,28355,WO-2007062831,PA3507532,First Priority,2005-11-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,GlaxoSmithKline plc,28355,WO-2007062831,PA3507532,First Priority,2005-11-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,GlaxoSmithKline plc,28355,WO-2007062831,PA3507532,First Priority,2005-11-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,GlaxoSmithKline plc,28355,WO-2007062831,PA3507532,First Priority,2005-11-30 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,GlaxoSmithKline plc,28355,WO-2007062832,PA3507653,First Publication,2007-06-07 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,GlaxoSmithKline plc,28355,WO-2007062832,PA3507653,First Publication,2007-06-07 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,GlaxoSmithKline plc,28355,WO-2007062832,PA3507653,First Publication,2007-06-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,GlaxoSmithKline plc,28355,WO-2007062832,PA3507653,First Publication,2007-06-07 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,GlaxoSmithKline plc,28355,WO-2007062832,PA3507653,First Priority,2005-11-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,GlaxoSmithKline plc,28355,WO-2007062832,PA3507653,First Priority,2005-11-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,GlaxoSmithKline plc,28355,WO-2007062832,PA3507653,First Priority,2005-11-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,GlaxoSmithKline plc,28355,WO-2007062832,PA3507653,First Priority,2005-11-30 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Publication,2007-06-28 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Publication,2007-06-28 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Publication,2007-06-28 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Priority,2005-12-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Sinorda Biomedicine Ltd,1093165,WO-2007071388,PA3515822,First Priority,2005-12-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,Sinorda Biomedicine Ltd,1093165,WO-2007071410,PA3515846,First Publication,2007-06-28 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071410,PA3515846,First Publication,2007-06-28 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,Sinorda Biomedicine Ltd,1093165,WO-2007071410,PA3515846,First Priority,2005-12-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071410,PA3515846,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,Sinorda Biomedicine Ltd,1093165,WO-2007071410,PA3515846,First Priority,2005-12-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2007071410,PA3515846,First Priority,2005-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Protherics Salt Lake City Inc,25065,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BTG plc,15266,WO-2007109303,PA3549543,First Publication,2007-09-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Protherics Salt Lake City Inc,25065,Owner,US,US,interleukin-2,DOC1000491,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,BTG plc,15266,WO-2007109303,PA3549543,First Priority,2006-03-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,US,US,Multikine,7401,General interest,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,CEL-SCI Corp,15339,US-20080131396,PA3645106,First Publication,2008-06-05 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,US,US,Multikine,7401,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,CEL-SCI Corp,15339,US-20080131396,PA3645106,First Publication,2008-06-05 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,US,US,Multikine,7401,General interest,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,CEL-SCI Corp,15339,US-20080131396,PA3645106,First Priority,2006-12-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CEL-SCI Corp,15339,Owner,US,US,Multikine,7401,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,CEL-SCI Corp,15339,US-20080131396,PA3645106,First Priority,2006-12-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Gaucher disease,132,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hypercholesterolemia,174,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ataxia telangiectasia,1840,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Tay Sachs disease,2000,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Retinitis pigmentosa,2004,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Ocular disease,239
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Blooms syndrome,2016,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Duchenne dystrophy,2020,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Growth disorder,140
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Retinoblastoma,289,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Sickle cell anemia,303,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thalassemia,322,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hemophilia,439,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ischemia,637,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cystic fibrosis,88,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Gaucher disease,132,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hypercholesterolemia,174,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ataxia telangiectasia,1840,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Tay Sachs disease,2000,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Retinitis pigmentosa,2004,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Ocular disease,239
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Blooms syndrome,2016,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Duchenne dystrophy,2020,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Growth disorder,140
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Retinoblastoma,289,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Sickle cell anemia,303,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Thalassemia,322,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hemophilia,439,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Poetic Genetics LLC,1017776,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cystic fibrosis,88,null,Poetic Genetics LLC,1017776,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,MannKind Corp,19058,Owner,World,WO,MKC-1106-PP,41921,General interest,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,MannKind Corp,19058,WO-2008100598,PA3674486,First Publication,2008-08-21 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MannKind Corp,19058,Owner,World,WO,MKC-1106-PP,41921,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,MannKind Corp,19058,WO-2008100598,PA3674486,First Publication,2008-08-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,MannKind Corp,19058,Owner,World,WO,MKC-1106-PP,41921,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,MannKind Corp,19058,WO-2008100598,PA3674486,First Publication,2008-08-21 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MannKind Corp,19058,Owner,US,US,MKC-1106-PP,41921,General interest,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,MannKind Corp,19058,WO-2008100598,PA3674486,First Priority,2007-02-15 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MannKind Corp,19058,Owner,US,US,MKC-1106-PP,41921,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,MannKind Corp,19058,WO-2008100598,PA3674486,First Priority,2007-02-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,MannKind Corp,19058,Owner,US,US,MKC-1106-PP,41921,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,MannKind Corp,19058,WO-2008100598,PA3674486,First Priority,2007-02-15 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Publication,2008-12-24 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Publication,2008-12-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Publication,2008-12-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Priority,2007-06-21 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Priority,2007-06-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Priority,2007-06-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Priority,2007-06-21 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Priority,2007-06-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Angelica Therapeutics Inc,1036112,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Angelica Therapeutics Inc,1036112,WO-2008157776,PA3726542,First Priority,2007-06-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuromuscular disease,234,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Enzyme deficiency,2367,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inborn error of metabolism,636,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neurological disease,677,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Rice University,21247,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Blood clotting disorder,75,null,Rice University,21247,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuromuscular disease,234,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Enzyme deficiency,2367,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inborn error of metabolism,636,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neurological disease,677,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Rice University,21247,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Blood clotting disorder,75,null,Rice University,21247,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuromuscular disease,234,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Enzyme deficiency,2367,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inborn error of metabolism,636,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neurological disease,677,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Blood clotting disorder,75,null,University of Texas System,21864,WO-2008131445,PA3703724,First Publication,2008-10-30 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuromuscular disease,234,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Enzyme deficiency,2367,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inborn error of metabolism,636,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neurological disease,677,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Texas System,21864,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Blood clotting disorder,75,null,University of Texas System,21864,WO-2008131445,PA3703724,First Priority,2007-04-23 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Inflammatory disease,188,null,Hokkaido University,22822,US-08053231,PA3695844,Extension,2029-06-12 00:00:00,EXT,4,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Rheumatoid arthritis,291,null,Hokkaido University,22822,US-08053231,PA3695844,Extension,2029-06-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Ulcerative colitis,337,null,Hokkaido University,22822,US-08053231,PA3695844,Extension,2029-06-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Autoimmune disease,36,null,Hokkaido University,22822,US-08053231,PA3695844,Extension,2029-06-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Inflammatory disease,188,null,Hokkaido University,22822,US-08053231,PA3695844,Granted,2011-11-08 00:00:00,GRT,3,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Rheumatoid arthritis,291,null,Hokkaido University,22822,US-08053231,PA3695844,Granted,2011-11-08 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Ulcerative colitis,337,null,Hokkaido University,22822,US-08053231,PA3695844,Granted,2011-11-08 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Autoimmune disease,36,null,Hokkaido University,22822,US-08053231,PA3695844,Granted,2011-11-08 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Inflammatory disease,188,null,Hokkaido University,22822,US-08053231,PA3695844,First Publication,2008-10-09 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Rheumatoid arthritis,291,null,Hokkaido University,22822,US-08053231,PA3695844,First Publication,2008-10-09 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Ulcerative colitis,337,null,Hokkaido University,22822,US-08053231,PA3695844,First Publication,2008-10-09 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Autoimmune disease,36,null,Hokkaido University,22822,US-08053231,PA3695844,First Publication,2008-10-09 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Inflammatory disease,188,null,Hokkaido University,22822,US-08053231,PA3695844,First Priority,2007-04-03 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Rheumatoid arthritis,291,null,Hokkaido University,22822,US-08053231,PA3695844,First Priority,2007-04-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Ulcerative colitis,337,null,Hokkaido University,22822,US-08053231,PA3695844,First Priority,2007-04-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Hokkaido University,22822,Third Party,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Autoimmune disease,36,null,Hokkaido University,22822,US-08053231,PA3695844,First Priority,2007-04-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Baylor College of Medicine,20534,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Baylor College of Medicine,20534,US-20080311140,PA3724264,First Publication,2008-12-18 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Baylor College of Medicine,20534,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Baylor College of Medicine,20534,US-20080311140,PA3724264,First Priority,2007-05-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thrombosis,1076,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hormone deficiency,364,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vascular disease,742,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Thrombosis,1076,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal disease,286,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Hormone deficiency,364,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Vascular disease,742,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Easton Pharmaceuticals Inc,1062762,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Southern California,20673,WO-2009026278,PA3752974,First Publication,2009-02-26 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,University of Southern California,20673,WO-2009026278,PA3752974,First Publication,2009-02-26 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,University of Southern California,20673,WO-2009026278,PA3752974,First Publication,2009-02-26 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Southern California,20673,WO-2009026278,PA3752974,First Priority,2007-08-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,University of Southern California,20673,WO-2009026278,PA3752974,First Priority,2007-08-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,University of Southern California,20673,WO-2009026278,PA3752974,First Priority,2007-08-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Stiftung Tierrztliche Hochschule Hannover,1023156,Owner,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Stiftung Tierrztliche Hochschule Hannover,1023156,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,aldesleukin,6306,Formulation,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Novartis AG,23137,WO-2006081510,PA3219080,First Publication,2006-08-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,aldesleukin,6306,Formulation,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Novartis AG,23137,WO-2006081510,PA3219080,First Publication,2006-08-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,aldesleukin,6306,Formulation,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Novartis AG,23137,WO-2006081510,PA3219080,First Priority,2005-01-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,aldesleukin,6306,Formulation,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Novartis AG,23137,WO-2006081510,PA3219080,First Priority,2005-01-27 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,sorafenib,29831,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Novartis AG,23137,WO-2006089150,PA3225439,First Publication,2006-08-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,sorafenib,29831,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Novartis AG,23137,WO-2006089150,PA3225439,First Publication,2006-08-24 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,sorafenib,29831,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Novartis AG,23137,WO-2006089150,PA3225439,First Publication,2006-08-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,sorafenib,29831,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Novartis AG,23137,WO-2006089150,PA3225439,First Publication,2006-08-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Novartis AG,23137,WO-2006089150,PA3225439,First Publication,2006-08-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Novartis AG,23137,WO-2006089150,PA3225439,First Publication,2006-08-24 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Novartis AG,23137,WO-2006089150,PA3225439,First Publication,2006-08-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Novartis AG,23137,WO-2006089150,PA3225439,First Publication,2006-08-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,sorafenib,29831,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Novartis AG,23137,WO-2006089150,PA3225439,First Priority,2005-02-18 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,sorafenib,29831,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Novartis AG,23137,WO-2006089150,PA3225439,First Priority,2005-02-18 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,sorafenib,29831,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Novartis AG,23137,WO-2006089150,PA3225439,First Priority,2005-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,sorafenib,29831,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Novartis AG,23137,WO-2006089150,PA3225439,First Priority,2005-02-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Novartis AG,23137,WO-2006089150,PA3225439,First Priority,2005-02-18 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Novartis AG,23137,WO-2006089150,PA3225439,First Priority,2005-02-18 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Novartis AG,23137,WO-2006089150,PA3225439,First Priority,2005-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Chiron Corp,15385,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Novartis AG,23137,WO-2006089150,PA3225439,First Priority,2005-02-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Karolinska University Hospital,26093,Third Party,World,WO,alemtuzumab,2716,Component of Combination,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,Karolinska Institutet,21110,WO-2005016380,PA2948568,First Publication,2005-02-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Karolinska University Hospital,26093,Third Party,US,US,alemtuzumab,2716,Component of Combination,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,Karolinska Institutet,21110,WO-2005016380,PA2948568,First Priority,2003-07-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Publication,PUB,PUB,Glioma,1108,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Publication,2010-07-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Publication,2010-07-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Publication,2010-07-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,temozolomide,4529,Component of Combination,null,First Publication,First Publication,PUB,PUB,Glioma,1108,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Publication,2010-07-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,temozolomide,4529,Component of Combination,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Publication,2010-07-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,temozolomide,4529,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Publication,2010-07-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Priority,PUB,PRI,Glioma,1108,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Priority,2008-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Priority,2008-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,"F-16-IL-2 fusion protein (cancer), Philogen",62159,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Priority,2008-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,temozolomide,4529,Component of Combination,null,First Publication,First Priority,PUB,PRI,Glioma,1108,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Priority,2008-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,temozolomide,4529,Component of Combination,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Priority,2008-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,temozolomide,4529,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Philogen SpA,29032,WO-2010078916,PA5647422,First Priority,2008-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,sunitinib,12973,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Philogen SpA,29032,WO-2010078945,PA5647434,First Publication,2010-07-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,sunitinib,12973,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Philogen SpA,29032,WO-2010078945,PA5647434,First Publication,2010-07-15 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,sunitinib,12973,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Philogen SpA,29032,WO-2010078945,PA5647434,First Priority,2009-01-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,US,US,sunitinib,12973,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Philogen SpA,29032,WO-2010078945,PA5647434,First Priority,2009-01-07 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,migalastat hydrochloride,CP165604,Formulation,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,US Government,20516,WO-2007137072,PA3573816,First Publication,2007-11-29 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,migalastat hydrochloride,CP165604,Formulation,null,First Publication,First Publication,PUB,PUB,Fabry disease,774,null,US Government,20516,WO-2007137072,PA3573816,First Publication,2007-11-29 00:00:00,PUB,2,Ocular disease,239
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,migalastat,47398,General interest,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,US Government,20516,WO-2007137072,PA3573816,First Publication,2007-11-29 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,migalastat,47398,General interest,null,First Publication,First Publication,PUB,PUB,Fabry disease,774,null,US Government,20516,WO-2007137072,PA3573816,First Publication,2007-11-29 00:00:00,PUB,2,Ocular disease,239
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,migalastat hydrochloride,CP165604,Formulation,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,US Government,20516,WO-2007137072,PA3573816,First Priority,2006-05-16 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,migalastat hydrochloride,CP165604,Formulation,null,First Publication,First Priority,PUB,PRI,Fabry disease,774,null,US Government,20516,WO-2007137072,PA3573816,First Priority,2006-05-16 00:00:00,PRI,1,Ocular disease,239
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,migalastat,47398,General interest,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,US Government,20516,WO-2007137072,PA3573816,First Priority,2006-05-16 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,migalastat,47398,General interest,null,First Publication,First Priority,PUB,PRI,Fabry disease,774,null,US Government,20516,WO-2007137072,PA3573816,First Priority,2006-05-16 00:00:00,PRI,1,Ocular disease,239
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Head and neck tumor,623,null,Individual,21144,US-06896879,PA2936295,Extension,2023-09-02 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-06896879,PA2936295,Extension,2023-09-02 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Head and neck tumor,623,null,Individual,21144,US-06896879,PA2936295,Granted,2005-05-24 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-06896879,PA2936295,Granted,2005-05-24 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Head and neck tumor,623,null,Individual,21144,US-06896879,PA2936295,First Publication,2005-01-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-06896879,PA2936295,First Publication,2005-01-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Head and neck tumor,623,null,Individual,21144,US-06896879,PA2936295,First Priority,2003-07-03 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,Individual,21144,US-06896879,PA2936295,First Priority,2003-07-03 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Individual,21144,US-07691575,PA3471716,Extension,2025-11-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Individual,21144,US-07691575,PA3471716,Extension,2025-11-12 00:00:00,EXT,4,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Individual,21144,US-07691575,PA3471716,Granted,2010-04-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Individual,21144,US-07691575,PA3471716,Granted,2010-04-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Individual,21144,US-07691575,PA3471716,First Publication,2007-03-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Individual,21144,US-07691575,PA3471716,First Publication,2007-03-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune disorder,185,null,Individual,21144,US-07691575,PA3471716,First Priority,2005-08-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Immune deficiency,504,null,Individual,21144,US-07691575,PA3471716,First Priority,2005-08-29 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,Cedars-Sinai Medical Center,15328,WO-2011056685,PA6439711,First Publication,2011-05-12 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Heart injury,3111,null,Cedars-Sinai Medical Center,15328,WO-2011056685,PA6439711,First Publication,2011-05-12 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,Cedars-Sinai Medical Center,15328,WO-2011056685,PA6439711,First Publication,2011-05-12 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Cedars-Sinai Medical Center,15328,WO-2011056685,PA6439711,First Publication,2011-05-12 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,Cedars-Sinai Medical Center,15328,WO-2011056685,PA6439711,First Priority,2009-10-27 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Heart injury,3111,null,Cedars-Sinai Medical Center,15328,WO-2011056685,PA6439711,First Priority,2009-10-27 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,Cedars-Sinai Medical Center,15328,WO-2011056685,PA6439711,First Priority,2009-10-27 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Cedars-Sinai Medical Center,15328,WO-2011056685,PA6439711,First Priority,2009-10-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,World,WO,zoledronic acid,2765,General interest,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,University of Maryland,20611,WO-2010141093,PA6276939,First Publication,2010-12-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,World,WO,zoledronic acid,2765,General interest,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Maryland,20611,WO-2010141093,PA6276939,First Publication,2010-12-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,World,WO,zoledronic acid,2765,General interest,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,University of Maryland,20611,WO-2010141093,PA6276939,First Publication,2010-12-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,World,WO,zoledronic acid,2765,General interest,null,First Publication,First Publication,PUB,PUB,Squamous cell carcinoma,307,null,University of Maryland,20611,WO-2010141093,PA6276939,First Publication,2010-12-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,World,WO,zoledronic acid,2765,General interest,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,University of Maryland,20611,WO-2010141093,PA6276939,First Publication,2010-12-09 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,US,US,zoledronic acid,2765,General interest,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,University of Maryland,20611,WO-2010141093,PA6276939,First Priority,2009-06-04 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,US,US,zoledronic acid,2765,General interest,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Maryland,20611,WO-2010141093,PA6276939,First Priority,2009-06-04 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,US,US,zoledronic acid,2765,General interest,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,University of Maryland,20611,WO-2010141093,PA6276939,First Priority,2009-06-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,US,US,zoledronic acid,2765,General interest,null,First Publication,First Priority,PUB,PRI,Squamous cell carcinoma,307,null,University of Maryland,20611,WO-2010141093,PA6276939,First Priority,2009-06-04 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Maryland,20611,Owner,US,US,zoledronic acid,2765,General interest,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Maryland,20611,WO-2010141093,PA6276939,First Priority,2009-06-04 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Chemotherapeutisches Forschungsinstitut,21074,Owner,World,WO,maC46/M87o,62695,Product,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Georg-Speyer-Haus Chem Inst,20232,WO-2009087110,PA5320390,First Publication,2009-07-16 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Chemotherapeutisches Forschungsinstitut,21074,Owner,European Patent,EP,maC46/M87o,62695,Product,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Georg-Speyer-Haus Chem Inst,20232,WO-2009087110,PA5320390,First Priority,2008-01-09 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,OncBioMune Pharmaceuticals Inc,1064053,Owner,World,WO,"prostatac vaccine, OncBioMune",81309,Formulation,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,OncBioMune Pharmaceuticals Inc,1064053,WO-2012096870,PA7012384,First Publication,2012-07-19 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,OncBioMune Pharmaceuticals Inc,1064053,Owner,US,US,"prostatac vaccine, OncBioMune",81309,Formulation,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,OncBioMune Pharmaceuticals Inc,1064053,WO-2012096870,PA7012384,First Priority,2011-01-13 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Fortovia Therapeutics Inc,25179,Owner,World,WO,talabostat,34323,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Barings LLC,1172186,WO-2008033368,PA3616710,First Publication,2008-03-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Fortovia Therapeutics Inc,25179,Owner,US,US,talabostat,34323,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Barings LLC,1172186,WO-2008033368,PA3616710,First Priority,2006-09-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergic rhinitis,1107,null,Universite Laval,20602,US-20090297545,PA5450629,First Publication,2009-12-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Universite Laval,20602,US-20090297545,PA5450629,First Publication,2009-12-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Escherichia coli infection,120,null,Universite Laval,20602,US-20090297545,PA5450629,First Publication,2009-12-03 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Influenza virus infection,191,null,Universite Laval,20602,US-20090297545,PA5450629,First Publication,2009-12-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Arthritis,28,null,Universite Laval,20602,US-20090297545,PA5450629,First Publication,2009-12-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Streptococcus pneumoniae infection,313,null,Universite Laval,20602,US-20090297545,PA5450629,First Publication,2009-12-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Atherosclerosis,33,null,Universite Laval,20602,US-20090297545,PA5450629,First Publication,2009-12-03 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Clostridium difficile infection,995,null,Universite Laval,20602,US-20090297545,PA5450629,First Publication,2009-12-03 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergic rhinitis,1107,null,Universite Laval,20602,US-20090297545,PA5450629,First Priority,2008-05-27 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Universite Laval,20602,US-20090297545,PA5450629,First Priority,2008-05-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Escherichia coli infection,120,null,Universite Laval,20602,US-20090297545,PA5450629,First Priority,2008-05-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Influenza virus infection,191,null,Universite Laval,20602,US-20090297545,PA5450629,First Priority,2008-05-27 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Arthritis,28,null,Universite Laval,20602,US-20090297545,PA5450629,First Priority,2008-05-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Streptococcus pneumoniae infection,313,null,Universite Laval,20602,US-20090297545,PA5450629,First Priority,2008-05-27 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Atherosclerosis,33,null,Universite Laval,20602,US-20090297545,PA5450629,First Priority,2008-05-27 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,Universite Laval,20602,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Clostridium difficile infection,995,null,Universite Laval,20602,US-20090297545,PA5450629,First Priority,2008-05-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Scripps Research Institute,21102,WO-2008054612,PA3634445,First Publication,2008-05-08 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Scripps Research Institute,21102,WO-2008054612,PA3634445,First Publication,2008-05-08 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Scripps Research Institute,21102,WO-2008054612,PA3634445,First Priority,2006-10-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Scripps Research Institute,21102,WO-2008054612,PA3634445,First Priority,2006-10-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Publication,2010-04-29 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Publication,2010-04-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lewis lung carcinoma,2786,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Publication,2010-04-29 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Publication,2010-04-29 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Publication,2010-04-29 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,World,WO,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Publication,2010-04-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Priority,2008-10-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Priority,2008-10-21 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lewis lung carcinoma,2786,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Priority,2008-10-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Priority,2008-10-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Priority,2008-10-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,E Merck Patent GmbH,21290,Owner,US,US,NHS-IL2-LT,57922,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Merck KGaA,18101,WO-2010046097,PA5579560,First Priority,2008-10-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Cancer,651,null,Individual,21144,US-08470562,PA5404180,Granted,2013-06-25 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Individual,21144,US-08470562,PA5404180,Granted,2013-06-25 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Cancer,651,null,Individual,21144,US-08470562,PA5404180,First Publication,2009-10-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Individual,21144,US-08470562,PA5404180,First Publication,2009-10-15 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Cancer,651,null,Individual,21144,US-08470562,PA5404180,First Priority,2008-04-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Individual,21144,US-08470562,PA5404180,First Priority,2008-04-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,University of Miami,20622,WO-2010060026,PA5603139,First Publication,2010-05-27 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,University of Miami,20622,WO-2010060026,PA5603139,First Priority,2008-11-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Immune System Key Ltd,1020782,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Immune System Key Ltd,1020782,WO-2007122622,PA3562435,First Publication,2007-11-01 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Immune System Key Ltd,1020782,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Immune System Key Ltd,1020782,WO-2007122622,PA3562435,First Publication,2007-11-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Immune System Key Ltd,1020782,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Immune System Key Ltd,1020782,WO-2007122622,PA3562435,First Priority,2006-04-24 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Immune System Key Ltd,1020782,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Immune System Key Ltd,1020782,WO-2007122622,PA3562435,First Priority,2006-04-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute lymphoblastic leukemia,1728,null,Individual,21144,US-20120141505,PA6880196,First Publication,2012-06-07 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Individual,21144,US-20120141505,PA6880196,First Publication,2012-06-07 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute lymphoblastic leukemia,1728,null,Individual,21144,US-20120141505,PA6880196,First Priority,2010-11-01 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Individual,21144,US-20120141505,PA6880196,First Priority,2010-11-01 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,McGill University,20617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,McGill University,20617,WO-2009152610,PA5462552,First Publication,2009-12-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,McGill University,20617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioma,1108,null,McGill University,20617,WO-2009152610,PA5462552,First Publication,2009-12-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,McGill University,20617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,McGill University,20617,WO-2009152610,PA5462552,First Publication,2009-12-23 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,McGill University,20617,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,McGill University,20617,WO-2009152610,PA5462552,First Publication,2009-12-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,McGill University,20617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,McGill University,20617,WO-2009152610,PA5462552,First Priority,2008-06-20 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,McGill University,20617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioma,1108,null,McGill University,20617,WO-2009152610,PA5462552,First Priority,2008-06-20 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,McGill University,20617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,McGill University,20617,WO-2009152610,PA5462552,First Priority,2008-06-20 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,McGill University,20617,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,McGill University,20617,WO-2009152610,PA5462552,First Priority,2008-06-20 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,denileukin diftitox,7237,New use,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,University of Louisville,21246,WO-2008157785,PA3726389,First Publication,2008-12-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,denileukin diftitox,7237,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Louisville,21246,WO-2008157785,PA3726389,First Publication,2008-12-24 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,denileukin diftitox,7237,New use,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,University of Louisville,21246,WO-2008157785,PA3726389,First Publication,2008-12-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,denileukin diftitox,7237,New use,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,University of Louisville,21246,WO-2008157785,PA3726389,First Priority,2007-06-20 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,denileukin diftitox,7237,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Louisville,21246,WO-2008157785,PA3726389,First Priority,2007-06-20 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,denileukin diftitox,7237,New use,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Louisville,21246,WO-2008157785,PA3726389,First Priority,2007-06-20 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Novo Nordisk A/S,18614,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Novo Nordisk A/S,18614,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,IPH-2101,56589,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Publication,2006-07-13 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,Denmark,DK,IPH-2101,56589,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Innate Pharma SA,28788,WO-2006072625,PA3213656,First Priority,2005-01-06 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,World,WO,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Publication,2009-04-30 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Third Party,Germany,DE,"interferon beta-1a follow-on biologic (intramuscular), CinnaGen",80044,Formulation,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Fraunhofer-Gesellschaft,16217,WO-2009052942,PA4786711,First Priority,2007-10-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Charite Universitaetsmedizin Berlin,30065,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Humboldt University of Berlin,22239,WO-2009053109,PA4786873,First Publication,2009-04-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Charite Universitaetsmedizin Berlin,30065,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Humboldt University of Berlin,22239,WO-2009053109,PA4786873,First Publication,2009-04-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Charite Universitaetsmedizin Berlin,30065,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Humboldt University of Berlin,22239,WO-2009053109,PA4786873,First Priority,2007-10-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Charite Universitaetsmedizin Berlin,30065,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Humboldt University of Berlin,22239,WO-2009053109,PA4786873,First Priority,2007-10-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,VSV-GP,97827,New use,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Individual,21144,WO-2010040526,PA5561469,First Publication,2010-04-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,VSV-GP,97827,New use,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Individual,21144,WO-2010040526,PA5561469,First Publication,2010-04-15 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Individual,21144,Owner,Germany,DE,VSV-GP,97827,New use,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Individual,21144,WO-2010040526,PA5561469,First Priority,2008-10-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,Germany,DE,VSV-GP,97827,New use,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Individual,21144,WO-2010040526,PA5561469,First Priority,2008-10-08 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Aarhus Universitets Forskningsfond,25165,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Aarhus Universitets Forskningsfond,25165,WO-2010022740,PA5524884,First Publication,2010-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Aarhus Universitets Forskningsfond,25165,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Aarhus Universitets Forskningsfond,25165,WO-2010022740,PA5524884,First Publication,2010-03-04 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Aarhus Universitets Forskningsfond,25165,Owner,Denmark,DK,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Aarhus Universitets Forskningsfond,25165,WO-2010022740,PA5524884,First Priority,2008-08-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Aarhus Universitets Forskningsfond,25165,Owner,Denmark,DK,null,null,null,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,Aarhus Universitets Forskningsfond,25165,WO-2010022740,PA5524884,First Priority,2008-08-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Region Midtjylland,1033527,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Region Midtjylland,1033527,WO-2010022740,PA5524884,First Publication,2010-03-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Region Midtjylland,1033527,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Region Midtjylland,1033527,WO-2010022740,PA5524884,First Publication,2010-03-04 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Region Midtjylland,1033527,Owner,Denmark,DK,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Region Midtjylland,1033527,WO-2010022740,PA5524884,First Priority,2008-08-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Region Midtjylland,1033527,Owner,Denmark,DK,null,null,null,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,Region Midtjylland,1033527,WO-2010022740,PA5524884,First Priority,2008-08-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Chemotherapeutisches Forschungsinstitut,21074,Third Party,World,WO,VSV-GP,97827,New use,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Georg-Speyer-Haus Chem Inst,20232,WO-2010040526,PA5561469,First Publication,2010-04-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Chemotherapeutisches Forschungsinstitut,21074,Third Party,World,WO,VSV-GP,97827,New use,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Georg-Speyer-Haus Chem Inst,20232,WO-2010040526,PA5561469,First Publication,2010-04-15 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Chemotherapeutisches Forschungsinstitut,21074,Third Party,Germany,DE,VSV-GP,97827,New use,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Georg-Speyer-Haus Chem Inst,20232,WO-2010040526,PA5561469,First Priority,2008-10-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Chemotherapeutisches Forschungsinstitut,21074,Third Party,Germany,DE,VSV-GP,97827,New use,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Georg-Speyer-Haus Chem Inst,20232,WO-2010040526,PA5561469,First Priority,2008-10-08 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Washington University in St Louis,26113,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Washington University in St Louis,26113,WO-2009114816,PA5378523,First Publication,2009-09-17 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Washington University in St Louis,26113,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Washington University in St Louis,26113,WO-2009114816,PA5378523,First Publication,2009-09-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Washington University in St Louis,26113,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Washington University in St Louis,26113,WO-2009114816,PA5378523,First Priority,2008-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Washington University in St Louis,26113,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Washington University in St Louis,26113,WO-2009114816,PA5378523,First Priority,2008-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Korea University,1039203,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Korea University,1039203,WO-2009114816,PA5378523,First Publication,2009-09-17 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Korea University,1039203,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Korea University,1039203,WO-2009114816,PA5378523,First Publication,2009-09-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Korea University,1039203,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Korea University,1039203,WO-2009114816,PA5378523,First Priority,2008-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Korea University,1039203,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Korea University,1039203,WO-2009114816,PA5378523,First Priority,2008-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Influenza virus infection,191,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Parasitic infection,252,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neisseria meningitidis infection,389,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hypersensitivity,505,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,University of Oxford,22182,WO-2009118523,PA5394186,First Publication,2009-10-01 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Influenza virus infection,191,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Parasitic infection,252,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Neisseria meningitidis infection,389,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Hypersensitivity,505,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,University of Oxford,22182,WO-2009118523,PA5394186,First Priority,2008-03-25 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,University of Southern California,20673,WO-2009126877,PA5403011,First Publication,2009-10-15 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Southern California,20673,WO-2009126877,PA5403011,First Publication,2009-10-15 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,University of Southern California,20673,WO-2009126877,PA5403011,First Priority,2008-04-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Southern California,20673,WO-2009126877,PA5403011,First Priority,2008-04-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Scleroderma,1105,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Gastritis,128,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Glomerulonephritis,135,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Guillain Barre syndrome,141,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Hepatitis,154,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Hashimotos disease,1977,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,World,WO,AIC-284,28450,New use,null,First Publication,First Publication,PUB,PUB,Myasthenia gravis,848,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Publication,2009-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Scleroderma,1105,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Gastritis,128,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Glomerulonephritis,135,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Guillain Barre syndrome,141,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Hepatitis,154,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Hashimotos disease,1977,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,AiCuris Anti-infective Cures GmbH,1020319,Owner,Germany,DE,AIC-284,28450,New use,null,First Publication,First Priority,PUB,PRI,Myasthenia gravis,848,null,Santo Holding AG,1020318,WO-2009135615,PA5430701,First Priority,2008-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Third Party,World,WO,ICT-121,60746,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Cedars-Sinai Medical Center,15328,WO-2010129895,PA6248487,First Publication,2010-11-11 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Cedars-Sinai Medical Center,15328,Third Party,US,US,ICT-121,60746,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Cedars-Sinai Medical Center,15328,WO-2010129895,PA6248487,First Priority,2009-05-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Herlev Hospital Region Hovedstaden,1048858,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Koebenhavns Universitet,24588,WO-2009143843,PA5448159,First Publication,2009-12-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Herlev Hospital Region Hovedstaden,1048858,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Koebenhavns Universitet,24588,WO-2009143843,PA5448159,First Publication,2009-12-03 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Herlev Hospital Region Hovedstaden,1048858,Owner,Denmark,DK,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Koebenhavns Universitet,24588,WO-2009143843,PA5448159,First Priority,2008-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Herlev Hospital Region Hovedstaden,1048858,Owner,Denmark,DK,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Koebenhavns Universitet,24588,WO-2009143843,PA5448159,First Priority,2008-04-17 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brutons disease,2401,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immunoglobulin A deficiency,2510,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immunoglobulin G deficiency,2511,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Common variable immunodeficiency,2640,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Brutons disease,2401,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immunoglobulin A deficiency,2510,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immunoglobulin G deficiency,2511,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Common variable immunodeficiency,2640,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Leipzig,DOL1000146,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,University of Leipzig,DOL1000146,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Publication,2010-01-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,Component of Combination,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Publication,2010-01-21 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Publication,2010-01-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,SentoClone,68037,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Publication,2010-01-21 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,bevacizumab,8047,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Publication,2010-01-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,bevacizumab,8047,Component of Combination,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Publication,2010-01-21 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,bevacizumab,8047,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Publication,2010-01-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,World,WO,bevacizumab,8047,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Publication,2010-01-21 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,SentoClone,68037,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,bevacizumab,8047,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,bevacizumab,8047,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,bevacizumab,8047,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,US,US,bevacizumab,8047,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,SentoClone,68037,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,bevacizumab,8047,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,bevacizumab,8047,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,bevacizumab,8047,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SentoClone International AB,1033247,Owner,Denmark,DK,bevacizumab,8047,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Sinorda Biomedicine Ltd,1093165,WO-2010006808,PA5486910,First Priority,2008-07-18 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,12D7,67714,Product,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,University of Zurich,25713,WO-2010003529,PA5479665,First Publication,2010-01-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,12D7,67714,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Zurich,25713,WO-2010003529,PA5479665,First Publication,2010-01-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,12D7,67714,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Zurich,25713,WO-2010003529,PA5479665,First Publication,2010-01-14 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,World,WO,12D7,67714,Product,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,University of Zurich,25713,WO-2010003529,PA5479665,First Publication,2010-01-14 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,12D7,67714,Product,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,University of Zurich,25713,WO-2010003529,PA5479665,First Priority,2008-06-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,12D7,67714,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Zurich,25713,WO-2010003529,PA5479665,First Priority,2008-06-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,12D7,67714,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Zurich,25713,WO-2010003529,PA5479665,First Priority,2008-06-16 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Zurich,25713,Owner,European Patent,EP,12D7,67714,Product,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,University of Zurich,25713,WO-2010003529,PA5479665,First Priority,2008-06-16 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Aduro BioTech Inc,1039923,Owner,World,WO,ANZ-521,57286,Product,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Aduro BioTech Inc,1039923,WO-2010011870,PA5495394,First Publication,2010-01-28 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Aduro BioTech Inc,1039923,Owner,World,WO,ANZ-100,54704,General interest,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Aduro BioTech Inc,1039923,WO-2010011870,PA5495394,First Publication,2010-01-28 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Aduro BioTech Inc,1039923,Owner,World,WO,CRS-207,51139,General interest,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Aduro BioTech Inc,1039923,WO-2010011870,PA5495394,First Publication,2010-01-28 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Aduro BioTech Inc,1039923,Owner,US,US,ANZ-521,57286,Product,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Aduro BioTech Inc,1039923,WO-2010011870,PA5495394,First Priority,2008-07-24 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Aduro BioTech Inc,1039923,Owner,US,US,ANZ-100,54704,General interest,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Aduro BioTech Inc,1039923,WO-2010011870,PA5495394,First Priority,2008-07-24 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Aduro BioTech Inc,1039923,Owner,US,US,CRS-207,51139,General interest,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Aduro BioTech Inc,1039923,WO-2010011870,PA5495394,First Priority,2008-07-24 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Entamoeba histolytica infection,115,null,State University of New York,26880,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Haemophilus influenzae infection,145,null,State University of New York,26880,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,State University of New York,26880,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neisseria gonorrhoeae infection,227,null,State University of New York,26880,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Streptococcus pneumoniae infection,313,null,State University of New York,26880,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Streptococcus mutans infection,3227,null,State University of New York,26880,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Entamoeba histolytica infection,115,null,State University of New York,26880,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Haemophilus influenzae infection,145,null,State University of New York,26880,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,State University of New York,26880,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neisseria gonorrhoeae infection,227,null,State University of New York,26880,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Streptococcus pneumoniae infection,313,null,State University of New York,26880,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,State University of New York,26880,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Streptococcus mutans infection,3227,null,State University of New York,26880,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Sydney West Area Health Service,1016884,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Sydney West Area Health Service,1016884,WO-2010099576,PA5710348,First Publication,2010-09-10 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Sydney West Area Health Service,1016884,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Sydney West Area Health Service,1016884,WO-2010099576,PA5710348,First Publication,2010-09-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Sydney West Area Health Service,1016884,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sydney West Area Health Service,1016884,WO-2010099576,PA5710348,First Publication,2010-09-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Sydney West Area Health Service,1016884,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Sydney West Area Health Service,1016884,WO-2010099576,PA5710348,First Priority,2009-03-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Sydney West Area Health Service,1016884,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,Sydney West Area Health Service,1016884,WO-2010099576,PA5710348,First Priority,2009-03-04 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Sydney West Area Health Service,1016884,Owner,Australia,AU,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sydney West Area Health Service,1016884,WO-2010099576,PA5710348,First Priority,2009-03-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Appendicitis,26,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Bronchitis,50,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Ischemia,637,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Toxicity,735,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Injury,748,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Appendicitis,26,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Bronchitis,50,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Toxicity,735,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Injury,748,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Appendicitis,26,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Bronchitis,50,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Toxicity,735,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Injury,748,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Appendicitis,26,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Bronchitis,50,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Toxicity,735,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Araim Pharmaceuticals Inc,1048899,Owner,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Injury,748,null,Araim Pharmaceuticals Inc,1048899,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,U.S. Department of Health and Human Services,1042246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,US Government,20516,WO-2011047324,PA6416800,First Publication,2011-04-21 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,U.S. Department of Health and Human Services,1042246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,US Government,20516,WO-2011047324,PA6416800,First Priority,2009-10-16 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteosarcoma,1772,null,Provenance Biopharmaceuticals Corp,1046272,WO-2010117448,PA5986385,First Publication,2010-10-14 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Provenance Biopharmaceuticals Corp,1046272,WO-2010117448,PA5986385,First Publication,2010-10-14 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Provenance Biopharmaceuticals Corp,1046272,WO-2010117448,PA5986385,First Publication,2010-10-14 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteosarcoma,1772,null,Provenance Biopharmaceuticals Corp,1046272,WO-2010117448,PA5986385,First Priority,2009-04-05 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Provenance Biopharmaceuticals Corp,1046272,WO-2010117448,PA5986385,First Priority,2009-04-05 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Provenance Biopharmaceuticals Corp,1046272,WO-2010117448,PA5986385,First Priority,2009-04-05 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brutons disease,2401,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immunoglobulin A deficiency,2510,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immunoglobulin G deficiency,2511,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Common variable immunodeficiency,2640,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Brutons disease,2401,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immunoglobulin A deficiency,2510,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immunoglobulin G deficiency,2511,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Common variable immunodeficiency,2640,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Karolinska Institutet,21110,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Yale University,20703,WO-2009094273,PA5330064,First Publication,2009-07-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Yale University,20703,WO-2009094273,PA5330064,First Publication,2009-07-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Yale University,20703,WO-2009094273,PA5330064,First Publication,2009-07-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Yale University,20703,WO-2009094273,PA5330064,First Publication,2009-07-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Yale University,20703,WO-2009094273,PA5330064,First Publication,2009-07-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Yale University,20703,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Yale University,20703,WO-2009094273,PA5330064,First Publication,2009-07-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Yale University,20703,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Yale University,20703,WO-2009094273,PA5330064,First Priority,2008-01-15 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Yale University,20703,WO-2009094273,PA5330064,First Priority,2008-01-15 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Yale University,20703,WO-2009094273,PA5330064,First Priority,2008-01-15 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Yale University,20703,WO-2009094273,PA5330064,First Priority,2008-01-15 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Yale University,20703,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Yale University,20703,WO-2009094273,PA5330064,First Priority,2008-01-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Yale University,20703,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Yale University,20703,WO-2009094273,PA5330064,First Priority,2008-01-15 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Vision 7 GmbH,1003156,Owner,World,WO,maC46/M87o,62695,Product,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Vision 7 GmbH,1003156,WO-2009087110,PA5320390,First Publication,2009-07-16 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Vision 7 GmbH,1003156,Owner,European Patent,EP,maC46/M87o,62695,Product,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Vision 7 GmbH,1003156,WO-2009087110,PA5320390,First Priority,2008-01-09 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Life Sciences Research Partners VZW,1038169,WO-2009100505,PA5348247,First Publication,2009-08-20 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Life Sciences Research Partners VZW,1038169,WO-2009100505,PA5348247,First Priority,2008-02-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Life Sciences Research Partners VZW,1038169,WO-2009101205,PA5348286,First Publication,2009-08-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Life Sciences Research Partners VZW,1038169,WO-2009101205,PA5348286,First Priority,2008-02-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Life Sciences Research Partners VZW,1038169,WO-2009101204,PA5348390,First Publication,2009-08-20 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Life Sciences Research Partners VZW,1038169,WO-2009101204,PA5348390,First Priority,2008-02-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium infection,218,null,Life Sciences Research Partners VZW,1038169,WO-2009101208,PA5348410,First Publication,2009-08-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Parasitic infection,252,null,Life Sciences Research Partners VZW,1038169,WO-2009101208,PA5348410,First Publication,2009-08-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Life Sciences Research Partners VZW,1038169,WO-2009101208,PA5348410,First Publication,2009-08-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bacterial infection,40,null,Life Sciences Research Partners VZW,1038169,WO-2009101208,PA5348410,First Publication,2009-08-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Mycobacterium infection,218,null,Life Sciences Research Partners VZW,1038169,WO-2009101208,PA5348410,First Priority,2008-02-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Parasitic infection,252,null,Life Sciences Research Partners VZW,1038169,WO-2009101208,PA5348410,First Priority,2008-02-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Life Sciences Research Partners VZW,1038169,WO-2009101208,PA5348410,First Priority,2008-02-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Bacterial infection,40,null,Life Sciences Research Partners VZW,1038169,WO-2009101208,PA5348410,First Priority,2008-02-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Life Sciences Research Partners VZW,1038169,WO-2009101207,PA5348493,First Publication,2009-08-20 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Life Sciences Research Partners VZW,1038169,WO-2009101207,PA5348493,First Priority,2008-02-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Publication,2007-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Transition Therapeutics Inc,28548,Third Party,US,US,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,OPKO Health Inc,21759,US-20070098685,PA3494597,First Priority,2005-01-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Life Sciences Research Partners VZW,1038169,WO-2009101206,PA5348084,First Publication,2009-08-20 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Life Sciences Research Partners VZW,1038169,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,Life Sciences Research Partners VZW,1038169,WO-2009101206,PA5348084,First Priority,2008-02-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergy,12,null,Duke University,20567,US-08802076,PA6844550,Granted,2014-08-12 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Duke University,20567,US-08802076,PA6844550,Granted,2014-08-12 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Viral infection,344,null,Duke University,20567,US-08802076,PA6844550,Granted,2014-08-12 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Autoimmune disease,36,null,Duke University,20567,US-08802076,PA6844550,Granted,2014-08-12 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergy,12,null,Duke University,20567,US-08802076,PA6844550,First Publication,2012-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Duke University,20567,US-08802076,PA6844550,First Publication,2012-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Viral infection,344,null,Duke University,20567,US-08802076,PA6844550,First Publication,2012-05-03 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Autoimmune disease,36,null,Duke University,20567,US-08802076,PA6844550,First Publication,2012-05-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergy,12,null,Duke University,20567,US-08802076,PA6844550,First Priority,2010-10-04 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Duke University,20567,US-08802076,PA6844550,First Priority,2010-10-04 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Viral infection,344,null,Duke University,20567,US-08802076,PA6844550,First Priority,2010-10-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Autoimmune disease,36,null,Duke University,20567,US-08802076,PA6844550,First Priority,2010-10-04 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Reperfusion injury,1024,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hypoxia,1053,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Gastrointestinal disease,129,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Wound healing,347,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain disease,556,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cystic fibrosis,88,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Publication,2011-01-13 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Reperfusion injury,1024,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hypoxia,1053,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Gastrointestinal disease,129,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Wound healing,347,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain disease,556,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cystic fibrosis,88,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Sabanci Universitesi,1010072,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Sabanci Universitesi,1010072,WO-2011004328,PA6314456,First Priority,2009-07-07 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Center of Molecular Immunology,29496,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastatic lung cancer,3668,null,The Center of Molecular Immunology,29496,WO-2012062228,PA6855551,First Publication,2012-05-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,The Center of Molecular Immunology,29496,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,The Center of Molecular Immunology,29496,WO-2012062228,PA6855551,First Publication,2012-05-18 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,The Center of Molecular Immunology,29496,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,The Center of Molecular Immunology,29496,WO-2012062228,PA6855551,First Publication,2012-05-18 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,The Center of Molecular Immunology,29496,Owner,Cuba,CU,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastatic lung cancer,3668,null,The Center of Molecular Immunology,29496,WO-2012062228,PA6855551,First Priority,2010-11-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,The Center of Molecular Immunology,29496,Owner,Cuba,CU,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,The Center of Molecular Immunology,29496,WO-2012062228,PA6855551,First Priority,2010-11-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,The Center of Molecular Immunology,29496,Owner,Cuba,CU,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,The Center of Molecular Immunology,29496,WO-2012062228,PA6855551,First Priority,2010-11-12 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteosarcoma,1772,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Adenocarcinoma,2399,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteosarcoma,1772,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Adenocarcinoma,2399,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Botanic Oil Innovations Inc,1017656,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Botanic Oil Innovations Inc,1017656,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Southern California,20673,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute lymphoblastic leukemia,1728,null,University of Southern California,20673,US-20120141505,PA6880196,First Publication,2012-06-07 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Southern California,20673,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Southern California,20673,US-20120141505,PA6880196,First Publication,2012-06-07 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Southern California,20673,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute lymphoblastic leukemia,1728,null,University of Southern California,20673,US-20120141505,PA6880196,First Priority,2010-11-01 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Southern California,20673,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Southern California,20673,US-20120141505,PA6880196,First Priority,2010-11-01 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Hospital of Los Angeles,21050,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute lymphoblastic leukemia,1728,null,Children's Hospital of Los Angeles,21050,US-20120141505,PA6880196,First Publication,2012-06-07 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Children's Hospital of Los Angeles,21050,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Children's Hospital of Los Angeles,21050,US-20120141505,PA6880196,First Publication,2012-06-07 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Hospital of Los Angeles,21050,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute lymphoblastic leukemia,1728,null,Children's Hospital of Los Angeles,21050,US-20120141505,PA6880196,First Priority,2010-11-01 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Children's Hospital of Los Angeles,21050,Third Party,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Children's Hospital of Los Angeles,21050,US-20120141505,PA6880196,First Priority,2010-11-01 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Uppsala University,22324,Third Party,World,WO,JNJ-64457107,67007,Tentative,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Uppsala University,22324,WO-2011061487,PA6452916,First Publication,2011-05-26 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Uppsala University,22324,Third Party,World,WO,JNJ-64457107,67007,Tentative,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,Uppsala University,22324,WO-2011061487,PA6452916,First Publication,2011-05-26 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Uppsala University,22324,Third Party,World,WO,JNJ-64457107,67007,Tentative,null,First Publication,First Publication,PUB,PUB,Skin tumor,722,null,Uppsala University,22324,WO-2011061487,PA6452916,First Publication,2011-05-26 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Uppsala University,22324,Third Party,World,WO,JNJ-64457107,67007,Tentative,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Uppsala University,22324,WO-2011061487,PA6452916,First Publication,2011-05-26 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Uppsala University,22324,Third Party,UK,GB,JNJ-64457107,67007,Tentative,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Uppsala University,22324,WO-2011061487,PA6452916,First Priority,2009-11-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Uppsala University,22324,Third Party,UK,GB,JNJ-64457107,67007,Tentative,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,Uppsala University,22324,WO-2011061487,PA6452916,First Priority,2009-11-19 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Uppsala University,22324,Third Party,UK,GB,JNJ-64457107,67007,Tentative,null,First Publication,First Priority,PUB,PRI,Skin tumor,722,null,Uppsala University,22324,WO-2011061487,PA6452916,First Priority,2009-11-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Uppsala University,22324,Third Party,UK,GB,JNJ-64457107,67007,Tentative,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Uppsala University,22324,WO-2011061487,PA6452916,First Priority,2009-11-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,JNJ-64457107,67007,Tentative,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Alligator Bioscience AB,31344,WO-2011061487,PA6452916,First Publication,2011-05-26 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,JNJ-64457107,67007,Tentative,null,First Publication,First Publication,PUB,PUB,Bladder tumor,42,null,Alligator Bioscience AB,31344,WO-2011061487,PA6452916,First Publication,2011-05-26 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,JNJ-64457107,67007,Tentative,null,First Publication,First Publication,PUB,PUB,Skin tumor,722,null,Alligator Bioscience AB,31344,WO-2011061487,PA6452916,First Publication,2011-05-26 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,JNJ-64457107,67007,Tentative,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Alligator Bioscience AB,31344,WO-2011061487,PA6452916,First Publication,2011-05-26 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,JNJ-64457107,67007,Tentative,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Alligator Bioscience AB,31344,WO-2011061487,PA6452916,First Priority,2009-11-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,JNJ-64457107,67007,Tentative,null,First Publication,First Priority,PUB,PRI,Bladder tumor,42,null,Alligator Bioscience AB,31344,WO-2011061487,PA6452916,First Priority,2009-11-19 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,JNJ-64457107,67007,Tentative,null,First Publication,First Priority,PUB,PRI,Skin tumor,722,null,Alligator Bioscience AB,31344,WO-2011061487,PA6452916,First Priority,2009-11-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,JNJ-64457107,67007,Tentative,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Alligator Bioscience AB,31344,WO-2011061487,PA6452916,First Priority,2009-11-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,US Government,20516,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Cancer Institute,20519,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,US Government,20516,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infertility,1079,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Factor VIII deficiency,121,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Growth disorder,140,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Growth disorder,140
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Organ transplantation,3004,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hypoglycemia,445,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Skin burns,52,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pulmonary fibrosis,708,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Publication,2007-09-13 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infertility,1079,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Factor VIII deficiency,121,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Growth disorder,140,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Growth disorder,140
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Organ transplantation,3004,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hypoglycemia,445,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Skin burns,52,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pulmonary fibrosis,708,null,Regenetech Inc,1013549,WO-2007102814,PA3544553,First Priority,2006-03-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Regenetech Inc,1013549,WO-2007102812,PA3544800,First Publication,2007-09-13 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Regenetech Inc,1013549,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Regenetech Inc,1013549,WO-2007102812,PA3544800,First Priority,2006-03-07 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone injury,1091,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Publication,2013-07-04 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone metastases,1829,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Publication,2013-07-04 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Tooth injury,3885,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Publication,2013-07-04 00:00:00,PUB,2,Mouth disease,663
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone disease,45,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Publication,2013-07-04 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Scar tissue,461,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Publication,2013-07-04 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone injury,1091,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone metastases,1829,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Tooth injury,3885,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Mouth disease,663
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone disease,45,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Scar tissue,461,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone injury,1091,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone metastases,1829,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Tooth injury,3885,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Mouth disease,663
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone disease,45,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Scar tissue,461,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone injury,1091,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone metastases,1829,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Tooth injury,3885,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Mouth disease,663
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone disease,45,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Scar tissue,461,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone injury,1091,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone metastases,1829,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Tooth injury,3885,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Mouth disease,663
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone disease,45,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Scar tissue,461,null,Bionest Ltd,1020282,WO-2013098331,PA7428922,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Hemolytic anemia,143,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Meningitis,206,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Atherosclerosis,33,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Bone disease,45,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Hypersensitivity,505,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Metabolic disorder,655,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,World,WO,COVA-322,67297,Product,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Publication,2011-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Hemolytic anemia,143,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Meningitis,206,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Atherosclerosis,33,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Bone disease,45,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Hypersensitivity,505,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Metabolic disorder,655,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,Covagen AG,1041383,Owner,European Patent,EP,COVA-322,67297,Product,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,Johnson & Johnson,17332,WO-2011023685,PA6364731,First Priority,2009-08-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Appendicitis,26,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Bronchitis,50,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Ischemia,637,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Toxicity,735,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,World,WO,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Publication,PUB,PUB,Injury,748,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Publication,2009-07-30 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Appendicitis,26,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Bronchitis,50,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Toxicity,735,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Injury,748,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Appendicitis,26,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Bronchitis,50,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Toxicity,735,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Injury,748,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Appendicitis,26,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Bronchitis,50,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Toxicity,735,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Warren Pharmaceuticals Inc,29904,Third Party,US,US,"cibinetide (sc, CLI/RA/diabetic retinopathy), Araim",71237,Product,null,First Publication,First Priority,PUB,PRI,Injury,748,null,Warren Pharmaceuticals Inc,29904,WO-2009094172,PA5330037,First Priority,2008-01-22 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,University of California,20547,WO-2010042765,PA5562122,First Publication,2010-04-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,University of California,20547,WO-2010042765,PA5562122,First Publication,2010-04-15 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,University of California,20547,WO-2010042765,PA5562122,First Priority,2008-10-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of California,20547,WO-2010042765,PA5562122,First Priority,2008-10-08 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,ramucirumab,45902,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,US Government,20516,WO-2011041093,PA6403831,First Publication,2011-04-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,DC-101,14919-X1,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,US Government,20516,WO-2011041093,PA6403831,First Publication,2011-04-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,IMC-1C11,14919,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,US Government,20516,WO-2011041093,PA6403831,First Publication,2011-04-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,ramucirumab,45902,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,US Government,20516,WO-2011041093,PA6403831,First Priority,2009-10-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,DC-101,14919-X1,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,US Government,20516,WO-2011041093,PA6403831,First Priority,2009-10-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,IMC-1C11,14919,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,US Government,20516,WO-2011041093,PA6403831,First Priority,2009-10-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Measles virus infection,1,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatitis A virus infection,151,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV-1 infection,159,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Plasmodium falciparum infection,267,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Streptococcus pneumoniae infection,313,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vibrio cholerae infection,343,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bacillus anthracis infection,39,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Duke University,20567,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Clostridium tetani infection,72,null,Duke University,20567,WO-2010053987,PA5591464,First Publication,2010-05-14 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Measles virus infection,1,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatitis A virus infection,151,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV-1 infection,159,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Plasmodium falciparum infection,267,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Streptococcus pneumoniae infection,313,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Vibrio cholerae infection,343,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bacillus anthracis infection,39,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Duke University,20567,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Clostridium tetani infection,72,null,Duke University,20567,WO-2010053987,PA5591464,First Priority,2008-11-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Sepsis,114,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Hypercholesterolemia,174,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Neurological disease,677,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Sepsis,114,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Hypercholesterolemia,174,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Neurological disease,677,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Axcella Health Inc,1070009,Third Party,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Axcella Health Inc,1070009,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Azurebio Slu,1046767,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Azurebio Slu,1046767,WO-2011054996,PA6439312,First Publication,2011-05-12 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Azurebio Slu,1046767,Third Party,Spain,ES,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Azurebio Slu,1046767,WO-2011054996,PA6439312,First Priority,2009-11-06 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Farmacore Biotecnologia Limitada,1060836,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Farmacore Biotecnologia Limitada,1060836,WO-2011026206,PA6375188,First Publication,2011-03-10 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Farmacore Biotecnologia Limitada,1060836,Owner,Brazil,BR,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Farmacore Biotecnologia Limitada,1060836,WO-2011026206,PA6375188,First Priority,2009-09-04 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,University of Utah,20690,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Carcinoma,54,null,University of Utah,20690,WO-2004080404,PA2910647,First Publication,2004-09-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Utah,20690,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Carcinoma,54,null,University of Utah,20690,WO-2004080404,PA2910647,First Priority,2003-03-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteosarcoma,1772,null,Individual,21144,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Individual,21144,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Individual,21144,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Individual,21144,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Individual,21144,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteosarcoma,1772,null,Individual,21144,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Individual,21144,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Individual,21144,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Individual,21144,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Individual,21144,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Individual,21144,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brutons disease,2401,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immunoglobulin A deficiency,2510,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immunoglobulin G deficiency,2511,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Common variable immunodeficiency,2640,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Publication,2010-07-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Brutons disease,2401,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immunoglobulin A deficiency,2510,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immunoglobulin G deficiency,2511,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Common variable immunodeficiency,2640,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fraunhofer-Gesellschaft,16217,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Fraunhofer-Gesellschaft,16217,WO-2010076339,PA5641264,First Priority,2009-01-05 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,French National Agency for Research on AIDS and Viral Hepatitis,1038437,Owner,World,WO,LIPO-5,59244,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,French National Agency for Research on AIDS and Viral Hepatitis,1038437,WO-2011091319,PA6522377,First Publication,2011-07-28 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,French National Agency for Research on AIDS and Viral Hepatitis,1038437,Owner,US,US,LIPO-5,59244,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,French National Agency for Research on AIDS and Viral Hepatitis,1038437,WO-2011091319,PA6522377,First Priority,2010-01-22 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Biotest AG,13737,Owner,World,WO,tregalizumab,53506,Formulation,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Biotest AG,13737,WO-2009121690,PA5399195,First Publication,2009-10-08 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Biotest AG,13737,Owner,World,WO,tregalizumab,53506,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Biotest AG,13737,WO-2009121690,PA5399195,First Publication,2009-10-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Biotest AG,13737,Owner,World,WO,tregalizumab,53506,Formulation,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Biotest AG,13737,WO-2009121690,PA5399195,First Publication,2009-10-08 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Biotest AG,13737,Owner,UK,GB,tregalizumab,53506,Formulation,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Biotest AG,13737,WO-2009121690,PA5399195,First Priority,2008-03-13 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Biotest AG,13737,Owner,UK,GB,tregalizumab,53506,Formulation,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Biotest AG,13737,WO-2009121690,PA5399195,First Priority,2008-03-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Biotest AG,13737,Owner,UK,GB,tregalizumab,53506,Formulation,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Biotest AG,13737,WO-2009121690,PA5399195,First Priority,2008-03-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Nimgenetics,1062372,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Nimgenetics,1062372,WO-2011054996,PA6439312,First Publication,2011-05-12 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Nimgenetics,1062372,Third Party,Spain,ES,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Nimgenetics,1062372,WO-2011054996,PA6439312,First Priority,2009-11-06 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Neo Virnatech,1062373,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Neo Virnatech,1062373,WO-2011054996,PA6439312,First Publication,2011-05-12 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Neo Virnatech,1062373,Third Party,Spain,ES,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Neo Virnatech,1062373,WO-2011054996,PA6439312,First Priority,2009-11-06 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,NSC-87877,CP207949,Component of Combination,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,US Government,20516,WO-2011060218,PA6446537,First Publication,2011-05-19 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,NSC-87877,CP207949,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,US Government,20516,WO-2011060218,PA6446537,First Publication,2011-05-19 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,World,WO,NSC-87877,CP207949,Component of Combination,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,US Government,20516,WO-2011060218,PA6446537,First Publication,2011-05-19 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,NSC-87877,CP207949,Component of Combination,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,US Government,20516,WO-2011060218,PA6446537,First Priority,2009-11-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,NSC-87877,CP207949,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,US Government,20516,WO-2011060218,PA6446537,First Priority,2009-11-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Institutes of Health,20518,Owner,US,US,NSC-87877,CP207949,Component of Combination,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,US Government,20516,WO-2011060218,PA6446537,First Priority,2009-11-13 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Adaptimmune Therapeutics plc,1047486,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,Adaptimmune Therapeutics plc,1047486,WO-2010099205,PA5697737,First Publication,2010-09-02 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Adaptimmune Therapeutics plc,1047486,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Progressive multifocal leukoencephalopathy,1997,null,Adaptimmune Therapeutics plc,1047486,WO-2010099205,PA5697737,First Publication,2010-09-02 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Adaptimmune Therapeutics plc,1047486,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,Adaptimmune Therapeutics plc,1047486,WO-2010099205,PA5697737,First Priority,2009-02-24 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adaptimmune Therapeutics plc,1047486,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Progressive multifocal leukoencephalopathy,1997,null,Adaptimmune Therapeutics plc,1047486,WO-2010099205,PA5697737,First Priority,2009-02-24 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leishmania infection,1136,null,University of Oxford,22182,WO-2010073043,PA5633023,First Publication,2010-07-01 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Oxford,22182,WO-2010073043,PA5633023,First Publication,2010-07-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,University of Oxford,22182,WO-2010073043,PA5633023,First Publication,2010-07-01 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Leishmania infection,1136,null,University of Oxford,22182,WO-2010073043,PA5633023,First Priority,2008-12-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Oxford,22182,WO-2010073043,PA5633023,First Priority,2008-12-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,University of Oxford,22182,WO-2010073043,PA5633023,First Priority,2008-12-24 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Publication,2013-07-04 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Irritable bowel syndrome,192,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Enterocolitis,2088,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoporosis,246,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Hernia,2754,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin burns,52,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin ulcer,723,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bionest Ltd,1020282,Owner,Italy,IT,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bionest Ltd,1020282,WO-2013098333,PA7429167,First Priority,2011-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Worcester Polytechnic Institute,20949,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Scar tissue,461,null,Worcester Polytechnic Institute,20949,WO-2011112601,PA6572644,First Publication,2011-09-15 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Worcester Polytechnic Institute,20949,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Injury,748,null,Worcester Polytechnic Institute,20949,WO-2011112601,PA6572644,First Publication,2011-09-15 00:00:00,PUB,2,Injury,748
IL-2 receptor agonist,221,null,Worcester Polytechnic Institute,20949,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Scar tissue,461,null,Worcester Polytechnic Institute,20949,WO-2011112601,PA6572644,First Priority,2010-03-08 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Worcester Polytechnic Institute,20949,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Injury,748,null,Worcester Polytechnic Institute,20949,WO-2011112601,PA6572644,First Priority,2010-03-08 00:00:00,PRI,1,Injury,748
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Georgia College and State University,1061539,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Georgia College and State University,1061539,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,University of Pennsylvania,20658,WO-2010099205,PA5697737,First Publication,2010-09-02 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Progressive multifocal leukoencephalopathy,1997,null,University of Pennsylvania,20658,WO-2010099205,PA5697737,First Publication,2010-09-02 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,University of Pennsylvania,20658,WO-2010099205,PA5697737,First Priority,2009-02-24 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Progressive multifocal leukoencephalopathy,1997,null,University of Pennsylvania,20658,WO-2010099205,PA5697737,First Priority,2009-02-24 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diarrhea,102,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Headache,148,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Fever,1833,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Temperature disorder,1023
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pain,20,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Nausea,226,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Skin rash,3020,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diarrhea,102,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Headache,148,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Fever,1833,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Temperature disorder,1023
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Nausea,226,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin rash,3020,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,La Jolla Institute of Allergy & Immunology,17747,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,La Jolla Institute of Allergy & Immunology,17747,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diarrhea,102,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Headache,148,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Fever,1833,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Temperature disorder,1023
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pain,20,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Nausea,226,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Skin rash,3020,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Virginia,20695,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diarrhea,102,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Headache,148,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Fever,1833,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Temperature disorder,1023
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Nausea,226,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin rash,3020,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Virginia,20695,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Virginia,20695,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diarrhea,102,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Headache,148,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Fever,1833,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Temperature disorder,1023
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pain,20,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Nausea,226,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Skin rash,3020,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Publication,2011-09-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diarrhea,102,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Headache,148,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Fever,1833,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Temperature disorder,1023
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pain,20,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Nausea,226,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Skin rash,3020,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Targeson Inc,1061322,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Targeson Inc,1061322,WO-2011119185,PA6580625,First Priority,2010-03-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Bonn,26805,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Bonn,26805,WO-2011103882,PA6555344,First Publication,2011-09-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Bonn,26805,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Bonn,26805,WO-2011103882,PA6555344,First Priority,2010-02-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Promedior Inc,1022762,Owner,World,WO,PRM-151,62221,General interest,null,First Publication,First Publication,PUB,PUB,Organ transplantation,3004,null,Promedior Inc,1022762,WO-2010104961,PA5717602,First Publication,2010-09-16 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,Promedior Inc,1022762,Owner,World,WO,PRM-151,62221,General interest,null,First Publication,First Publication,PUB,PUB,Tissue transplantation,3021,null,Promedior Inc,1022762,WO-2010104961,PA5717602,First Publication,2010-09-16 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,Promedior Inc,1022762,Owner,World,WO,PRM-151,62221,General interest,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Promedior Inc,1022762,WO-2010104961,PA5717602,First Publication,2010-09-16 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Promedior Inc,1022762,Owner,World,WO,PRM-151,62221,General interest,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Promedior Inc,1022762,WO-2010104961,PA5717602,First Publication,2010-09-16 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Promedior Inc,1022762,Owner,US,US,PRM-151,62221,General interest,null,First Publication,First Priority,PUB,PRI,Organ transplantation,3004,null,Promedior Inc,1022762,WO-2010104961,PA5717602,First Priority,2009-03-11 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,Promedior Inc,1022762,Owner,US,US,PRM-151,62221,General interest,null,First Publication,First Priority,PUB,PRI,Tissue transplantation,3021,null,Promedior Inc,1022762,WO-2010104961,PA5717602,First Priority,2009-03-11 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,Promedior Inc,1022762,Owner,US,US,PRM-151,62221,General interest,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Promedior Inc,1022762,WO-2010104961,PA5717602,First Priority,2009-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Promedior Inc,1022762,Owner,US,US,PRM-151,62221,General interest,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Promedior Inc,1022762,WO-2010104961,PA5717602,First Priority,2009-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Entamoeba histolytica infection,115,null,University of Louisville,21246,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Haemophilus influenzae infection,145,null,University of Louisville,21246,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,University of Louisville,21246,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neisseria gonorrhoeae infection,227,null,University of Louisville,21246,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Streptococcus pneumoniae infection,313,null,University of Louisville,21246,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Streptococcus mutans infection,3227,null,University of Louisville,21246,WO-2010090873,PA5678207,First Publication,2010-08-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Entamoeba histolytica infection,115,null,University of Louisville,21246,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Haemophilus influenzae infection,145,null,University of Louisville,21246,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,University of Louisville,21246,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neisseria gonorrhoeae infection,227,null,University of Louisville,21246,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Streptococcus pneumoniae infection,313,null,University of Louisville,21246,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Streptococcus mutans infection,3227,null,University of Louisville,21246,WO-2010090873,PA5678207,First Priority,2009-01-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Sepsis,114,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteoarthritis,245,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Publication,2011-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Sepsis,114,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoarthritis,245,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Makoto Life Sciences Inc,1031361,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Makoto Life Sciences Inc,1031361,WO-2011160042,PA6692365,First Priority,2010-06-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Zoticon Bioventures,1038614,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Zoticon Bioventures,1038614,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thrombosis,1076,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hormone deficiency,364,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Thrombosis,1076,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal disease,286,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Hormone deficiency,364,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,XL-Protein GmbH,1050061,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,XL-Protein GmbH,1050061,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Psoriatic arthritis,1781,null,Individual,21144,WO-2013179302,PA7593409,First Publication,2013-12-05 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Individual,21144,WO-2013179302,PA7593409,First Publication,2013-12-05 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,India,IN,null,null,null,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Individual,21144,WO-2013179302,PA7593409,First Priority,2012-05-15 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,India,IN,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Individual,21144,WO-2013179302,PA7593409,First Priority,2012-05-15 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,University of Minnesota,20626,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteosarcoma,1772,null,University of Minnesota,20626,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,University of Minnesota,20626,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Adenocarcinoma,2399,null,University of Minnesota,20626,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,University of Minnesota,20626,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Minnesota,20626,EP-02241324,PA6209955,First Publication,2010-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,University of Minnesota,20626,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteosarcoma,1772,null,University of Minnesota,20626,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,University of Minnesota,20626,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Adenocarcinoma,2399,null,University of Minnesota,20626,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,University of Minnesota,20626,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Minnesota,20626,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Minnesota,20626,EP-02241324,PA6209955,First Priority,2009-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Consorzio Per Il Centro Di Biomedicina Molecolare Scrl,1050542,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Consorzio Per Il Centro Di Biomedicina Molecolare Scrl,1050542,WO-2012013704,PA6745947,First Publication,2012-02-02 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Consorzio Per Il Centro Di Biomedicina Molecolare Scrl,1050542,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Consorzio Per Il Centro Di Biomedicina Molecolare Scrl,1050542,WO-2012013704,PA6745947,First Publication,2012-02-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Consorzio Per Il Centro Di Biomedicina Molecolare Scrl,1050542,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Consorzio Per Il Centro Di Biomedicina Molecolare Scrl,1050542,WO-2012013704,PA6745947,First Priority,2010-07-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Consorzio Per Il Centro Di Biomedicina Molecolare Scrl,1050542,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Consorzio Per Il Centro Di Biomedicina Molecolare Scrl,1050542,WO-2012013704,PA6745947,First Priority,2010-07-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,ImmunoCellular Therapeutics Ltd,1025216,Owner,World,WO,ICT-121,60746,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ImmunoCellular Therapeutics Ltd,1025216,WO-2010129895,PA6248487,First Publication,2010-11-11 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,ImmunoCellular Therapeutics Ltd,1025216,Owner,US,US,ICT-121,60746,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ImmunoCellular Therapeutics Ltd,1025216,WO-2010129895,PA6248487,First Priority,2009-05-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,InCube Laboratories LLC,1052196,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,InCube Laboratories LLC,1052196,WO-2010138171,PA6267928,First Publication,2010-12-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,InCube Laboratories LLC,1052196,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,InCube Laboratories LLC,1052196,WO-2010138171,PA6267928,First Priority,2009-05-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Innate Pharma SA,28788,WO-2008146167,PA3717601,First Publication,2008-12-04 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Innate Pharma SA,28788,WO-2008146167,PA3717601,First Publication,2008-12-04 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,Innate Pharma SA,28788,WO-2008146167,PA3717601,First Publication,2008-12-04 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Innate Pharma SA,28788,WO-2008146167,PA3717601,First Publication,2008-12-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Innate Pharma SA,28788,WO-2008146167,PA3717601,First Priority,2007-06-01 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Innate Pharma SA,28788,WO-2008146167,PA3717601,First Priority,2007-06-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,Innate Pharma SA,28788,WO-2008146167,PA3717601,First Priority,2007-06-01 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Innate Pharma SA,28788,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Innate Pharma SA,28788,WO-2008146167,PA3717601,First Priority,2007-06-01 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Breast tumor,49,null,Cleveland Clinic Foundation,22123,US-09327026,PA7535026,Granted,2016-05-03 00:00:00,GRT,3,Endocrine disease,112
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Breast tumor,49,null,Cleveland Clinic Foundation,22123,US-09327026,PA7535026,First Publication,2013-10-17 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Cleveland Clinic Foundation,22123,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Breast tumor,49,null,Cleveland Clinic Foundation,22123,US-09327026,PA7535026,First Priority,2012-04-16 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Norris Comprehensive Cancer Center,1041584,Third Party,World,WO,IRX-2,44521,New use,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,Norris Comprehensive Cancer Center,1041584,WO-2011072006,PA6478277,First Publication,2011-06-16 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Norris Comprehensive Cancer Center,1041584,Third Party,US,US,IRX-2,44521,New use,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,Norris Comprehensive Cancer Center,1041584,WO-2011072006,PA6478277,First Priority,2009-12-08 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Cellular Dynamics International Inc,1035898,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,FUJIFILM Holdings Corp,1037804,WO-2010141801,PA6277159,First Publication,2010-12-09 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,Cellular Dynamics International Inc,1035898,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Stem cell transplantation,2990,null,FUJIFILM Holdings Corp,1037804,WO-2010141801,PA6277159,First Priority,2009-06-05 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,Catholic University Industry Academy Cooperation Foundation,1032546,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Catholic University of Korea,DOL1000277,US-20120087900,PA6825366,First Publication,2012-04-12 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Catholic University Industry Academy Cooperation Foundation,1032546,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Catholic University of Korea,DOL1000277,US-20120087900,PA6825366,First Publication,2012-04-12 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Catholic University Industry Academy Cooperation Foundation,1032546,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Catholic University of Korea,DOL1000277,US-20120087900,PA6825366,First Priority,2010-10-07 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Catholic University Industry Academy Cooperation Foundation,1032546,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Catholic University of Korea,DOL1000277,US-20120087900,PA6825366,First Priority,2010-10-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Publication,2011-04-28 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Publication,2011-04-28 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Celiac disease,2539,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Publication,2011-04-28 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Publication,2011-04-28 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Publication,2011-04-28 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Priority,2009-10-23 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Priority,2009-10-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Celiac disease,2539,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Priority,2009-10-23 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Priority,2009-10-23 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Cellerix SA,1015116,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Takeda Pharmaceutical Co Ltd,20300,WO-2011048222,PA6424534,First Priority,2009-10-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Hybrid BioSystems Ltd,1054907,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Influenza virus infection,191,null,PsiOxus Therapeutics Ltd,1058712,WO-2010128303,PA6248037,First Publication,2010-11-11 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Hybrid BioSystems Ltd,1054907,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Influenza virus infection,191,null,PsiOxus Therapeutics Ltd,1058712,WO-2010128303,PA6248037,First Priority,2009-05-08 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Harvard Medical School,24839,WO-2011049603,PA6424840,First Publication,2011-04-28 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Brigham & Women's Hospital,21048,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Harvard Medical School,24839,WO-2011049603,PA6424840,First Priority,2009-10-22 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Sao Paulo,29294,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,University of Sao Paulo,29294,WO-2011026206,PA6375188,First Publication,2011-03-10 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,University of Sao Paulo,29294,Third Party,Brazil,BR,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,University of Sao Paulo,29294,WO-2011026206,PA6375188,First Priority,2009-09-04 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,ImmunoGen Inc,17202,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ImmunoGen Inc,17202,WO-2010141566,PA6277080,First Publication,2010-12-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,ImmunoGen Inc,17202,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ImmunoGen Inc,17202,WO-2010141566,PA6277080,First Priority,2009-06-03 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,University of Oxford,22182,WO-2011045612,PA6416337,First Publication,2011-04-21 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Oxford University Innovation,23104,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Mycobacterium tuberculosis infection,221,null,University of Oxford,22182,WO-2011045612,PA6416337,First Priority,2009-10-16 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Imaxio,1007058,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Imaxio,1007058,WO-2011045612,PA6416337,First Publication,2011-04-21 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Imaxio,1007058,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Mycobacterium tuberculosis infection,221,null,Imaxio,1007058,WO-2011045612,PA6416337,First Priority,2009-10-16 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,University of California,20547,WO-2011053991,PA6431926,First Publication,2011-05-05 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of California,20547,WO-2011053991,PA6431926,First Priority,2009-11-02 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,The University Health Network,28443,Owner,World,WO,NSC-87877,CP207949,Component of Combination,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,The University Health Network,28443,WO-2011060218,PA6446537,First Publication,2011-05-19 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,The University Health Network,28443,Owner,World,WO,NSC-87877,CP207949,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,The University Health Network,28443,WO-2011060218,PA6446537,First Publication,2011-05-19 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,The University Health Network,28443,Owner,World,WO,NSC-87877,CP207949,Component of Combination,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,The University Health Network,28443,WO-2011060218,PA6446537,First Publication,2011-05-19 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,The University Health Network,28443,Owner,US,US,NSC-87877,CP207949,Component of Combination,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,The University Health Network,28443,WO-2011060218,PA6446537,First Priority,2009-11-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,The University Health Network,28443,Owner,US,US,NSC-87877,CP207949,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,The University Health Network,28443,WO-2011060218,PA6446537,First Priority,2009-11-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,The University Health Network,28443,Owner,US,US,NSC-87877,CP207949,Component of Combination,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,The University Health Network,28443,WO-2011060218,PA6446537,First Priority,2009-11-13 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Glaxo Group Ltd,16453,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,GlaxoSmithKline plc,28355,WO-2011092253,PA6528767,First Publication,2011-08-04 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Glaxo Group Ltd,16453,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Mycobacterium tuberculosis infection,221,null,GlaxoSmithKline plc,28355,WO-2011092253,PA6528767,First Priority,2010-01-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,GlaxoSmithKline plc,28355,WO-2011092253,PA6528767,First Publication,2011-08-04 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Mycobacterium tuberculosis infection,221,null,GlaxoSmithKline plc,28355,WO-2011092253,PA6528767,First Priority,2010-01-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Janssen Pharmaceutica NV,17421,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Multiple myeloma,1828,null,Johnson & Johnson,17332,US-08075895,PA6388782,Extension,2029-12-30 00:00:00,EXT,4,Hematological disease,142
IL-2 receptor agonist,221,null,Janssen Pharmaceutica NV,17421,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Multiple myeloma,1828,null,Johnson & Johnson,17332,US-08075895,PA6388782,Granted,2011-12-13 00:00:00,GRT,3,Hematological disease,142
IL-2 receptor agonist,221,null,Janssen Pharmaceutica NV,17421,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Multiple myeloma,1828,null,Johnson & Johnson,17332,US-08075895,PA6388782,First Publication,2011-03-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Janssen Pharmaceutica NV,17421,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Multiple myeloma,1828,null,Johnson & Johnson,17332,US-08075895,PA6388782,First Priority,2009-09-22 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,APN-411,74172,New use,null,First Publication,First Publication,PUB,PUB,Fungal infection,124,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,APN-411,74172,New use,null,First Publication,First Publication,PUB,PUB,Parasitic infection,252,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,APN-411,74172,New use,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,APN-411,74172,New use,null,First Publication,First Publication,PUB,PUB,Bacterial infection,40,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,APN-411,74172,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,loxoribine,3521,New use,null,First Publication,First Publication,PUB,PUB,Fungal infection,124,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,loxoribine,3521,New use,null,First Publication,First Publication,PUB,PUB,Parasitic infection,252,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,loxoribine,3521,New use,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,loxoribine,3521,New use,null,First Publication,First Publication,PUB,PUB,Bacterial infection,40,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,World,WO,loxoribine,3521,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Publication,2012-07-05 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,APN-411,74172,New use,null,First Publication,First Priority,PUB,PRI,Fungal infection,124,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,APN-411,74172,New use,null,First Publication,First Priority,PUB,PRI,Parasitic infection,252,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,APN-411,74172,New use,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,APN-411,74172,New use,null,First Publication,First Priority,PUB,PRI,Bacterial infection,40,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,APN-411,74172,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,loxoribine,3521,New use,null,First Publication,First Priority,PUB,PRI,Fungal infection,124,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,loxoribine,3521,New use,null,First Publication,First Priority,PUB,PRI,Parasitic infection,252,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,loxoribine,3521,New use,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,loxoribine,3521,New use,null,First Publication,First Priority,PUB,PRI,Bacterial infection,40,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Apeiron Biologics GmbH,1019284,Owner,European Patent,EP,loxoribine,3521,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Apeiron Biologics GmbH,1019284,WO-2012089736,PA6963376,First Priority,2010-12-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Anza Therapeutics Inc,1039732,Owner,World,WO,ANZ-521,57286,Product,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Anza Therapeutics Inc,1039732,WO-2010011870,PA5495394,First Publication,2010-01-28 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Anza Therapeutics Inc,1039732,Owner,World,WO,ANZ-100,54704,General interest,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Anza Therapeutics Inc,1039732,WO-2010011870,PA5495394,First Publication,2010-01-28 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Anza Therapeutics Inc,1039732,Owner,World,WO,CRS-207,51139,General interest,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Anza Therapeutics Inc,1039732,WO-2010011870,PA5495394,First Publication,2010-01-28 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Anza Therapeutics Inc,1039732,Owner,US,US,ANZ-521,57286,Product,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Anza Therapeutics Inc,1039732,WO-2010011870,PA5495394,First Priority,2008-07-24 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Anza Therapeutics Inc,1039732,Owner,US,US,ANZ-100,54704,General interest,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Anza Therapeutics Inc,1039732,WO-2010011870,PA5495394,First Priority,2008-07-24 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Anza Therapeutics Inc,1039732,Owner,US,US,CRS-207,51139,General interest,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Anza Therapeutics Inc,1039732,WO-2010011870,PA5495394,First Priority,2008-07-24 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,ID Biomedical Corp,17084,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,GlaxoSmithKline plc,28355,WO-2011092253,PA6528767,First Publication,2011-08-04 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,ID Biomedical Corp,17084,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Mycobacterium tuberculosis infection,221,null,GlaxoSmithKline plc,28355,WO-2011092253,PA6528767,First Priority,2010-01-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Publication,2017-04-06 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hodgkins disease,161,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Publication,2017-04-06 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Publication,2017-04-06 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Squamous cell carcinoma,307,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Publication,2017-04-06 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Publication,2017-04-06 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Publication,2017-04-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Priority,2015-10-02 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hodgkins disease,161,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Priority,2015-10-02 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Priority,2015-10-02 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Squamous cell carcinoma,307,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Priority,2015-10-02 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Priority,2015-10-02 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Symphogen A/S,28600,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Symphogen A/S,28600,WO-2017055547,PA9302111,First Priority,2015-10-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Sopherion Therapeutics LLC,30666,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Sopherion Therapeutics LLC,30666,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,TenX Biopharma Inc,1052332,Owner,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,TenX Biopharma Inc,1052332,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,zanolimumab,19463,New use,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,World,WO,zanolimumab,19463,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stage IV melanoma,3257,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Publication,2011-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,zanolimumab,19463,New use,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Genmab A/S,26469,Third Party,US,US,zanolimumab,19463,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stage IV melanoma,3257,null,Genmab A/S,26469,WO-2011139738,PA6640602,First Priority,2010-04-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,World,WO,"F4co vaccine (AIDS/HIV infection), GlaxoSmithKline",59740,Formulation,null,First Publication,First Publication,PUB,PUB,HIV-1 infection,159,null,GlaxoSmithKline plc,28355,WO-2011117408,PA6580277,First Publication,2011-09-29 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,GlaxoSmithKline Biologicals,24166,Owner,US,US,"F4co vaccine (AIDS/HIV infection), GlaxoSmithKline",59740,Formulation,null,First Publication,First Priority,PUB,PRI,HIV-1 infection,159,null,GlaxoSmithKline plc,28355,WO-2011117408,PA6580277,First Priority,2010-03-26 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone tumor,1012,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological disease,142,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone metastases,1829,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neutropenia,1991,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ostealgia,2854,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thrombocytopenia,324,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Toxicity,735,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Publication,2010-01-21 00:00:00,PUB,2,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone tumor,1012,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological disease,142,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone metastases,1829,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neutropenia,1991,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ostealgia,2854,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Thrombocytopenia,324,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Novus Therapeutics Inc,1031349,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Toxicity,735,null,Novus Therapeutics Inc,1031349,WO-2010008561,PA5487324,First Priority,2008-07-16 00:00:00,PRI,1,Toxicity and intoxication,753
IL-2 receptor agonist,221,null,Admark Healthcare Llc,1100683,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Admark Healthcare Llc,1100683,WO-2014139468,PA7906223,First Publication,2014-09-18 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Admark Healthcare Llc,1100683,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Admark Healthcare Llc,1100683,WO-2014139468,PA7906223,First Publication,2014-09-18 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Admark Healthcare Llc,1100683,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Admark Healthcare Llc,1100683,WO-2014139468,PA7906223,First Priority,2013-03-15 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Admark Healthcare Llc,1100683,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Admark Healthcare Llc,1100683,WO-2014139468,PA7906223,First Priority,2013-03-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Cambium Medical Technologies LLC,1110284,Third Party,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Cambium Medical Technologies LLC,1110284,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,University of California,20547,WO-2011150281,PA6668225,First Publication,2011-12-01 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Motor neurone disease,212,null,University of California,20547,WO-2011150281,PA6668225,First Publication,2011-12-01 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Parkinsons disease,255,null,University of California,20547,WO-2011150281,PA6668225,First Publication,2011-12-01 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,University of California,20547,WO-2011150281,PA6668225,First Publication,2011-12-01 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of California,20547,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,University of California,20547,WO-2011150281,PA6668225,First Publication,2011-12-01 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,University of California,20547,WO-2011150281,PA6668225,First Priority,2010-05-26 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Motor neurone disease,212,null,University of California,20547,WO-2011150281,PA6668225,First Priority,2010-05-26 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Parkinsons disease,255,null,University of California,20547,WO-2011150281,PA6668225,First Priority,2010-05-26 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,University of California,20547,WO-2011150281,PA6668225,First Priority,2010-05-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,University of California,20547,WO-2011150281,PA6668225,First Priority,2010-05-26 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Merck KGaA,18101,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteosarcoma,1772,null,Merck KGaA,18101,WO-2010117448,PA5986385,First Publication,2010-10-14 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Merck KGaA,18101,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Merck KGaA,18101,WO-2010117448,PA5986385,First Publication,2010-10-14 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Merck KGaA,18101,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck KGaA,18101,WO-2010117448,PA5986385,First Publication,2010-10-14 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Merck KGaA,18101,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteosarcoma,1772,null,Merck KGaA,18101,WO-2010117448,PA5986385,First Priority,2009-04-05 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Merck KGaA,18101,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Merck KGaA,18101,WO-2010117448,PA5986385,First Priority,2009-04-05 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Merck KGaA,18101,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck KGaA,18101,WO-2010117448,PA5986385,First Priority,2009-04-05 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thrombosis,1076,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hormone deficiency,364,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Thrombosis,1076,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal disease,286,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Hormone deficiency,364,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Easton Pharmaceuticals Inc,1062762,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Easton Pharmaceuticals Inc,1062762,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Hannover Medical School,28959,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Hannover Medical School,28959,EP-02388338,PA6660311,First Publication,2011-11-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Hannover Medical School,28959,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Hannover Medical School,28959,EP-02388338,PA6660311,First Priority,2010-04-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,INSERM,17229,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Sjoegrens syndrome,1148,null,INSERM,17229,WO-2009050267,PA4627714,First Publication,2009-04-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,INSERM,17229,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,INSERM,17229,WO-2009050267,PA4627714,First Publication,2009-04-23 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,INSERM,17229,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,INSERM,17229,WO-2009050267,PA4627714,First Publication,2009-04-23 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,INSERM,17229,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,INSERM,17229,WO-2009050267,PA4627714,First Publication,2009-04-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,INSERM,17229,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,INSERM,17229,WO-2009050267,PA4627714,First Publication,2009-04-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,INSERM,17229,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,INSERM,17229,WO-2009050267,PA4627714,First Publication,2009-04-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,INSERM,17229,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Sjoegrens syndrome,1148,null,INSERM,17229,WO-2009050267,PA4627714,First Priority,2007-10-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,INSERM,17229,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,INSERM,17229,WO-2009050267,PA4627714,First Priority,2007-10-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,INSERM,17229,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,INSERM,17229,WO-2009050267,PA4627714,First Priority,2007-10-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,INSERM,17229,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,INSERM,17229,WO-2009050267,PA4627714,First Priority,2007-10-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,INSERM,17229,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,INSERM,17229,WO-2009050267,PA4627714,First Priority,2007-10-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,INSERM,17229,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,INSERM,17229,WO-2009050267,PA4627714,First Priority,2007-10-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Chimera Pharma,1043928,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Bionostra SL,1010306,WO-2011054996,PA6439312,First Publication,2011-05-12 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Chimera Pharma,1043928,Owner,Spain,ES,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Bionostra SL,1010306,WO-2011054996,PA6439312,First Priority,2009-11-06 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Oncotyrol - Center For Personalized Cancer Medicine GmbH,1076813,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Oncotyrol - Center For Personalized Cancer Medicine GmbH,1076813,WO-2012175598,PA7224552,First Publication,2012-12-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Oncotyrol - Center For Personalized Cancer Medicine GmbH,1076813,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Oncotyrol - Center For Personalized Cancer Medicine GmbH,1076813,WO-2012175598,PA7224552,First Publication,2012-12-27 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Oncotyrol - Center For Personalized Cancer Medicine GmbH,1076813,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Oncotyrol - Center For Personalized Cancer Medicine GmbH,1076813,WO-2012175598,PA7224552,First Priority,2011-06-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Oncotyrol - Center For Personalized Cancer Medicine GmbH,1076813,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Oncotyrol - Center For Personalized Cancer Medicine GmbH,1076813,WO-2012175598,PA7224552,First Priority,2011-06-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteoarthritis,245,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Organ transplantation,3004,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Tissue transplantation,3021,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal injury,3108,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Heart injury,3111,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Scar tissue,461,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ischemia,637,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal failure,69,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Publication,2012-02-16 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteoarthritis,245,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal disease,286,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Organ transplantation,3004,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Tissue transplantation,3021,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal injury,3108,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Heart injury,3111,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Scar tissue,461,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal failure,69,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Glasgow,20580,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,University of Glasgow,20580,WO-2012020308,PA6762723,First Priority,2010-08-13 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteosarcoma,1772,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Publication,2012-12-27 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteosarcoma,1772,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Provenance Biopharmaceuticals Corp,1046272,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Provenance Biopharmaceuticals Corp,1046272,WO-2012178137,PA7225180,First Priority,2011-06-24 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Sanofi Pasteur,22127,Owner,World,WO,"PlyD1 pneumococcal vaccine, Netherlands Vaccine Institute/Sanofi Pasteur",71106,General interest,null,First Publication,First Publication,PUB,PUB,Streptococcus pneumoniae infection,313,null,Sanofi SA,1009547,WO-2012075428,PA6879064,First Publication,2012-06-07 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Sanofi Pasteur,22127,Owner,World,WO,"PlyD1 pneumococcal vaccine, Netherlands Vaccine Institute/Sanofi Pasteur",71106,General interest,null,First Publication,First Publication,PUB,PUB,Otitis media,394,null,Sanofi SA,1009547,WO-2012075428,PA6879064,First Publication,2012-06-07 00:00:00,PUB,2,Otorhinolaryngological disease,592
IL-2 receptor agonist,221,null,Sanofi Pasteur,22127,Owner,World,WO,"Streptococcus pneumoniae vaccine (meningitis/ pneumonia), Sanofi Pasteur",65211,New use,null,First Publication,First Publication,PUB,PUB,Streptococcus pneumoniae infection,313,null,Sanofi SA,1009547,WO-2012075428,PA6879064,First Publication,2012-06-07 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Sanofi Pasteur,22127,Owner,World,WO,"Streptococcus pneumoniae vaccine (meningitis/ pneumonia), Sanofi Pasteur",65211,New use,null,First Publication,First Publication,PUB,PUB,Otitis media,394,null,Sanofi SA,1009547,WO-2012075428,PA6879064,First Publication,2012-06-07 00:00:00,PUB,2,Otorhinolaryngological disease,592
IL-2 receptor agonist,221,null,Sanofi Pasteur,22127,Owner,US,US,"PlyD1 pneumococcal vaccine, Netherlands Vaccine Institute/Sanofi Pasteur",71106,General interest,null,First Publication,First Priority,PUB,PRI,Streptococcus pneumoniae infection,313,null,Sanofi SA,1009547,WO-2012075428,PA6879064,First Priority,2010-12-03 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Sanofi Pasteur,22127,Owner,US,US,"PlyD1 pneumococcal vaccine, Netherlands Vaccine Institute/Sanofi Pasteur",71106,General interest,null,First Publication,First Priority,PUB,PRI,Otitis media,394,null,Sanofi SA,1009547,WO-2012075428,PA6879064,First Priority,2010-12-03 00:00:00,PRI,1,Otorhinolaryngological disease,592
IL-2 receptor agonist,221,null,Sanofi Pasteur,22127,Owner,US,US,"Streptococcus pneumoniae vaccine (meningitis/ pneumonia), Sanofi Pasteur",65211,New use,null,First Publication,First Priority,PUB,PRI,Streptococcus pneumoniae infection,313,null,Sanofi SA,1009547,WO-2012075428,PA6879064,First Priority,2010-12-03 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Sanofi Pasteur,22127,Owner,US,US,"Streptococcus pneumoniae vaccine (meningitis/ pneumonia), Sanofi Pasteur",65211,New use,null,First Publication,First Priority,PUB,PRI,Otitis media,394,null,Sanofi SA,1009547,WO-2012075428,PA6879064,First Priority,2010-12-03 00:00:00,PRI,1,Otorhinolaryngological disease,592
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Universite Pierre et Marie Curie,20660,WO-2014206899,PA8016897,First Publication,2014-12-31 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Universite Pierre et Marie Curie,20660,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Universite Pierre et Marie Curie,20660,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Individual,21144,WO-2014172805,PA7951960,First Publication,2014-10-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Individual,21144,WO-2014172805,PA7951960,First Publication,2014-10-30 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Individual,21144,WO-2014172805,PA7951960,First Publication,2014-10-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Individual,21144,WO-2014172805,PA7951960,First Priority,2013-04-26 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Individual,21144,WO-2014172805,PA7951960,First Priority,2013-04-26 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Individual,21144,WO-2014172805,PA7951960,First Priority,2013-04-26 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Esophagus tumor,1011,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Endometrioid carcinoma,1705,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Squamous cell carcinoma,307,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Publication,2009-12-10 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Esophagus tumor,1011,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Endometrioid carcinoma,1705,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Squamous cell carcinoma,307,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Pittsburgh,20659,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,University of Pittsburgh,20659,WO-2009149094,PA5454071,First Priority,2008-06-02 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Howard Hughes Medical Institute,21084,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,cisplatin,2821,Formulation,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,University of California,20547,US-20150094518,PA8123251,First Publication,2015-04-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,cisplatin,2821,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,University of California,20547,US-20150094518,PA8123251,First Publication,2015-04-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,cisplatin,2821,Formulation,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,University of California,20547,US-20150094518,PA8123251,First Priority,2013-09-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of California,20547,Owner,US,US,cisplatin,2821,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,University of California,20547,US-20150094518,PA8123251,First Priority,2013-09-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CT Atlantic AG,1051924,Third Party,World,WO,12D7,67714,Product,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,CT Atlantic AG,1051924,WO-2010003529,PA5479665,First Publication,2010-01-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,CT Atlantic AG,1051924,Third Party,World,WO,12D7,67714,Product,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,CT Atlantic AG,1051924,WO-2010003529,PA5479665,First Publication,2010-01-14 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,CT Atlantic AG,1051924,Third Party,World,WO,12D7,67714,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,CT Atlantic AG,1051924,WO-2010003529,PA5479665,First Publication,2010-01-14 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,CT Atlantic AG,1051924,Third Party,World,WO,12D7,67714,Product,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,CT Atlantic AG,1051924,WO-2010003529,PA5479665,First Publication,2010-01-14 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,CT Atlantic AG,1051924,Third Party,European Patent,EP,12D7,67714,Product,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,CT Atlantic AG,1051924,WO-2010003529,PA5479665,First Priority,2008-06-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,CT Atlantic AG,1051924,Third Party,European Patent,EP,12D7,67714,Product,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,CT Atlantic AG,1051924,WO-2010003529,PA5479665,First Priority,2008-06-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,CT Atlantic AG,1051924,Third Party,European Patent,EP,12D7,67714,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,CT Atlantic AG,1051924,WO-2010003529,PA5479665,First Priority,2008-06-16 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CT Atlantic AG,1051924,Third Party,European Patent,EP,12D7,67714,Product,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,CT Atlantic AG,1051924,WO-2010003529,PA5479665,First Priority,2008-06-16 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City of Hope,20558,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,City of Hope,20558,US-20160298193,PA8995820,First Publication,2016-10-13 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,City of Hope,20558,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,City of Hope,20558,US-20160298193,PA8995820,First Publication,2016-10-13 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,City of Hope,20558,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,City of Hope,20558,US-20160298193,PA8995820,First Priority,2015-04-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,City of Hope,20558,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,City of Hope,20558,US-20160298193,PA8995820,First Priority,2015-04-08 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Feinstein Institute for Medical Research,29117,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,North Shore Long Island Jewish Health System,27678,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Children's Healthcare of Atlanta,1043838,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Children's Healthcare of Atlanta,1043838,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Medical University of Gdansk,1039650,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Helicobacter pylori infection,149,null,Medical University of Gdansk,1039650,WO-2013147628,PA7511299,First Publication,2013-10-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Medical University of Gdansk,1039650,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Stomach ulcer,805,null,Medical University of Gdansk,1039650,WO-2013147628,PA7511299,First Publication,2013-10-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Medical University of Gdansk,1039650,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Duodenal ulcer,808,null,Medical University of Gdansk,1039650,WO-2013147628,PA7511299,First Publication,2013-10-03 00:00:00,PUB,2,Ulcer,372
IL-2 receptor agonist,221,null,Medical University of Gdansk,1039650,Owner,Poland,PL,null,null,null,null,First Publication,First Priority,PUB,PRI,Helicobacter pylori infection,149,null,Medical University of Gdansk,1039650,WO-2013147628,PA7511299,First Priority,2012-03-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Medical University of Gdansk,1039650,Owner,Poland,PL,null,null,null,null,First Publication,First Priority,PUB,PRI,Stomach ulcer,805,null,Medical University of Gdansk,1039650,WO-2013147628,PA7511299,First Priority,2012-03-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Medical University of Gdansk,1039650,Owner,Poland,PL,null,null,null,null,First Publication,First Priority,PUB,PRI,Duodenal ulcer,808,null,Medical University of Gdansk,1039650,WO-2013147628,PA7511299,First Priority,2012-03-29 00:00:00,PRI,1,Ulcer,372
IL-2 receptor agonist,221,null,Isarna Therapeutics GmbH,28736,Third Party,World,WO,SD-208,39180-X1,Component of Combination,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Isarna Therapeutics GmbH,28736,WO-2015140150,PA8349414,First Publication,2015-09-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Isarna Therapeutics GmbH,28736,Third Party,European Patent,EP,SD-208,39180-X1,Component of Combination,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Isarna Therapeutics GmbH,28736,WO-2015140150,PA8349414,First Priority,2014-03-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,pomalidomide,27696,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,pomalidomide,27696,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,thalidomide,8050,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,thalidomide,8050,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,doxorubicin,4563,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,doxorubicin,4563,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,lenalidomide,27572,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,lenalidomide,27572,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,dexamethasone,12735,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,dexamethasone,12735,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,pomalidomide,27696,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,pomalidomide,27696,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,thalidomide,8050,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,thalidomide,8050,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,doxorubicin,4563,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,doxorubicin,4563,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,lenalidomide,27572,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,lenalidomide,27572,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,dexamethasone,12735,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,dexamethasone,12735,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053321,PA6431663,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,pomalidomide,27696,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,pomalidomide,27696,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,elotuzumab,56518,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,elotuzumab,56518,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,thalidomide,8050,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,thalidomide,8050,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,doxorubicin,4563,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,doxorubicin,4563,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,lenalidomide,27572,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,lenalidomide,27572,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,dexamethasone,12735,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,dexamethasone,12735,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Publication,2011-05-05 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,pomalidomide,27696,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,pomalidomide,27696,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,elotuzumab,56518,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,elotuzumab,56518,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,thalidomide,8050,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,thalidomide,8050,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,doxorubicin,4563,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,doxorubicin,4563,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,lenalidomide,27572,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,lenalidomide,27572,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,bortezomib,15954,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,dexamethasone,12735,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas for Medical Sciences,1013492,Owner,World,WO,dexamethasone,12735,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stem cell transplantation,2990,null,The University of Arkansas System,1018113,WO-2011053322,PA6431664,First Priority,2009-10-30 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Okayama University,1002254,WO-2013122178,PA7474401,First Publication,2013-08-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung disease,283,null,Okayama University,1002254,WO-2013122178,PA7474401,First Publication,2013-08-22 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,Okayama University,1002254,WO-2013122178,PA7474401,First Publication,2013-08-22 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Okayama University,1002254,WO-2013122178,PA7474401,First Publication,2013-08-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neurological disease,677,null,Okayama University,1002254,WO-2013122178,PA7474401,First Publication,2013-08-22 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Okayama University,1002254,WO-2013122178,PA7474401,First Publication,2013-08-22 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,Japan,JP,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Okayama University,1002254,WO-2013122178,PA7474401,First Priority,2012-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,Japan,JP,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung disease,283,null,Okayama University,1002254,WO-2013122178,PA7474401,First Priority,2012-02-16 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,Japan,JP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,Okayama University,1002254,WO-2013122178,PA7474401,First Priority,2012-02-16 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,Japan,JP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Okayama University,1002254,WO-2013122178,PA7474401,First Priority,2012-02-16 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,Japan,JP,null,null,null,null,First Publication,First Priority,PUB,PRI,Neurological disease,677,null,Okayama University,1002254,WO-2013122178,PA7474401,First Priority,2012-02-16 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Okayama University,1002254,Owner,Japan,JP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Okayama University,1002254,WO-2013122178,PA7474401,First Priority,2012-02-16 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Aplastic anemia,1006,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Atopic dermatitis,1102,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Addisons disease,6,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,World,WO,ciprofloxacin,15429,Formulation,null,First Publication,First Publication,PUB,PUB,Dermatological disease,95,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Publication,2011-06-30 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Aplastic anemia,1006,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Atopic dermatitis,1102,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Addisons disease,6,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Deutsches Krebsforschungszentrum,23844,Owner,European Patent,EP,ciprofloxacin,15429,Formulation,null,First Publication,First Priority,PUB,PRI,Dermatological disease,95,null,Deutsches Krebsforschungszentrum,23844,WO-2011076721,PA6496412,First Priority,2009-12-22 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Food hypersensitivity,3612,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Wheat hypersensitivity,3613,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Milk hypersensitivity,3614,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Peanut hypersensitivity,3615,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Egg hypersensitivity,3616,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Food hypersensitivity,3612,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Wheat hypersensitivity,3613,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Milk hypersensitivity,3614,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Peanut hypersensitivity,3615,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Egg hypersensitivity,3616,null,Universite Pierre et Marie Curie,20660,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Life Force Homeopathy,1090757,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Psoriatic arthritis,1781,null,Life Force Homeopathy,1090757,WO-2013179302,PA7593409,First Publication,2013-12-05 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Life Force Homeopathy,1090757,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Life Force Homeopathy,1090757,WO-2013179302,PA7593409,First Publication,2013-12-05 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Life Force Homeopathy,1090757,Third Party,India,IN,null,null,null,null,First Publication,First Priority,PUB,PRI,Psoriatic arthritis,1781,null,Life Force Homeopathy,1090757,WO-2013179302,PA7593409,First Priority,2012-05-15 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Life Force Homeopathy,1090757,Third Party,India,IN,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Life Force Homeopathy,1090757,WO-2013179302,PA7593409,First Priority,2012-05-15 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatocellular carcinoma,1767,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,aldesleukin,6306,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Publication,PUB,PUB,Hepatocellular carcinoma,1767,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,World,WO,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Publication,2016-01-07 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatocellular carcinoma,1767,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,aldesleukin,6306,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Priority,PUB,PRI,Hepatocellular carcinoma,1767,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Vicus Therapeutics LLC,1023205,Owner,US,US,"propranolol + etodolac (cachexia/cancer), Vicus Therapeutics",56642,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Vicus Therapeutics LLC,1023205,WO-2016004213,PA8497298,First Priority,2014-07-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2015063085,PA8154221,First Publication,2015-05-07 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2015063085,PA8154221,First Publication,2015-05-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Individual,21144,WO-2015063085,PA8154221,First Priority,2013-10-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2015063085,PA8154221,First Priority,2013-10-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SolaranRx Inc,1100190,Third Party,World,WO,SRX-1177,95417,Product,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,SolaranRx Inc,1100190,WO-2011066521,PA6463373,First Publication,2011-06-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,SolaranRx Inc,1100190,Third Party,World,WO,SRX-1177,95417,Product,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,SolaranRx Inc,1100190,WO-2011066521,PA6463373,First Publication,2011-06-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,SolaranRx Inc,1100190,Third Party,US,US,SRX-1177,95417,Product,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,SolaranRx Inc,1100190,WO-2011066521,PA6463373,First Priority,2009-11-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,SolaranRx Inc,1100190,Third Party,US,US,SRX-1177,95417,Product,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,SolaranRx Inc,1100190,WO-2011066521,PA6463373,First Priority,2009-11-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thrombosis,1076,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hormone deficiency,364,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vascular disease,742,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Publication,2008-12-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Thrombosis,1076,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal disease,286,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Hormone deficiency,364,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Vascular disease,742,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Technical University of Munich,25011,WO-2008155134,PA3725940,First Priority,2007-06-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Baylor Research Institute,28731,Owner,World,WO,LIPO-5,59244,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Baylor University,15500,WO-2011091319,PA6522377,First Publication,2011-07-28 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Baylor Research Institute,28731,Owner,US,US,LIPO-5,59244,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Baylor University,15500,WO-2011091319,PA6522377,First Priority,2010-01-22 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,interferon gamma,7461,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Emory University,20573,US-20140147411,PA7798470,First Publication,2014-05-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,vemurafenib,54469,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Emory University,20573,US-20140147411,PA7798470,First Publication,2014-05-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,interferon alfa,14232,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Emory University,20573,US-20140147411,PA7798470,First Publication,2014-05-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,interferon gamma,7461,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Emory University,20573,US-20140147411,PA7798470,First Priority,2012-11-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,vemurafenib,54469,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Emory University,20573,US-20140147411,PA7798470,First Priority,2012-11-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,interferon alfa,14232,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Emory University,20573,US-20140147411,PA7798470,First Priority,2012-11-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Enumeral Biomedical Holdings Inc,1099166,Owner,World,WO,ENUM-244C8,93669,Product,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,Enumeral Biomedical Holdings Inc,1099166,WO-2016106160,PA8715595,First Publication,2016-06-30 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Enumeral Biomedical Holdings Inc,1099166,Owner,World,WO,ENUM-244C8,93669,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Enumeral Biomedical Holdings Inc,1099166,WO-2016106160,PA8715595,First Publication,2016-06-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Enumeral Biomedical Holdings Inc,1099166,Owner,US,US,ENUM-244C8,93669,Product,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,Enumeral Biomedical Holdings Inc,1099166,WO-2016106160,PA8715595,First Priority,2014-12-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Enumeral Biomedical Holdings Inc,1099166,Owner,US,US,ENUM-244C8,93669,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Enumeral Biomedical Holdings Inc,1099166,WO-2016106160,PA8715595,First Priority,2014-12-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Publication,2014-05-08 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Publication,2014-05-08 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Publication,2014-05-08 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Publication,2014-05-08 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Corynebacterium diphtheriae infection,81,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Publication,2014-05-08 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Priority,2012-11-02 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Priority,2012-11-02 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Priority,2012-11-02 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Priority,2012-11-02 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,CyTuVax RP,1063213,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Corynebacterium diphtheriae infection,81,null,CyTuVax RP,1063213,WO-2014068085,PA7766726,First Priority,2012-11-02 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,AltraVax Inc,1052591,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,AltraVax Inc,1052591,WO-2014159714,PA7921009,First Publication,2014-10-02 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,AltraVax Inc,1052591,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,AltraVax Inc,1052591,WO-2014159714,PA7921009,First Priority,2013-03-14 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioma,1108,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Publication,2014-09-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Publication,2014-09-25 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Astrocytoma,2453,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Publication,2014-09-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Publication,2014-09-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Medulloblastoma,2533,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Publication,2014-09-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Publication,2014-09-25 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Publication,2014-09-25 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioma,1108,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Priority,2013-03-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Astrocytoma,2453,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Medulloblastoma,2533,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Priority,2013-03-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Texas A&M University System,23290,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Texas A&M University System,23290,WO-2014152932,PA7916553,First Priority,2013-03-14 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,OncBioMune Pharmaceuticals Inc,1064053,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,OncBioMune Pharmaceuticals Inc,1064053,WO-2012096862,PA7012167,First Publication,2012-07-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,OncBioMune Pharmaceuticals Inc,1064053,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,OncBioMune Pharmaceuticals Inc,1064053,WO-2012096862,PA7012167,First Publication,2012-07-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,OncBioMune Pharmaceuticals Inc,1064053,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,OncBioMune Pharmaceuticals Inc,1064053,WO-2012096862,PA7012167,First Publication,2012-07-19 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,OncBioMune Pharmaceuticals Inc,1064053,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,OncBioMune Pharmaceuticals Inc,1064053,WO-2012096862,PA7012167,First Priority,2011-01-13 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,OncBioMune Pharmaceuticals Inc,1064053,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,OncBioMune Pharmaceuticals Inc,1064053,WO-2012096862,PA7012167,First Priority,2011-01-13 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,OncBioMune Pharmaceuticals Inc,1064053,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,OncBioMune Pharmaceuticals Inc,1064053,WO-2012096862,PA7012167,First Priority,2011-01-13 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Chinese Academy of Medical Military Sciences,14168,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Chinese Academy of Medical Military Sciences,14168,WO-2012094905,PA7012609,First Publication,2012-07-19 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Chinese Academy of Medical Military Sciences,14168,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Chinese Academy of Medical Military Sciences,14168,WO-2012094905,PA7012609,First Publication,2012-07-19 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Chinese Academy of Medical Military Sciences,14168,Owner,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,Chinese Academy of Medical Military Sciences,14168,WO-2012094905,PA7012609,First Priority,2011-01-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Chinese Academy of Medical Military Sciences,14168,Owner,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Chinese Academy of Medical Military Sciences,14168,WO-2012094905,PA7012609,First Priority,2011-01-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,World,WO,ATOR-1015,86921,General interest,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Publication,2016-11-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Alligator Bioscience AB,31344,Owner,UK,GB,ATOR-1015,86921,General interest,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Alligator Bioscience AB,31344,WO-2016185016,PA9061431,First Priority,2015-05-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Roche Holding AG,19446,WO-2012107417,PA7057638,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Roche Holding AG,19446,WO-2012107417,PA7057638,First Priority,2011-02-10 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Roche Holding AG,19446,WO-2012107416,PA7057826,First Publication,2012-08-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Roche Holding AG,19446,WO-2012107416,PA7057826,First Priority,2011-02-10 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2014206899,PA8016897,First Publication,2014-12-31 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Institut du Cerveau et de la Moelle epiniere,1077917,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Institut du Cerveau et de la Moelle epiniere,1077917,WO-2014206899,PA8016897,First Publication,2014-12-31 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Institut du Cerveau et de la Moelle epiniere,1077917,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Institut du Cerveau et de la Moelle epiniere,1077917,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Institut du Cerveau et de la Moelle epiniere,1077917,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Institut du Cerveau et de la Moelle epiniere,1077917,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,MTRX-1011A,60865,New use,null,First Publication,First Publication,PUB,PUB,Von Willebrands disease,1229,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,MTRX-1011A,60865,New use,null,First Publication,First Publication,PUB,PUB,Hypothyroidism,182,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,MTRX-1011A,60865,New use,null,First Publication,First Publication,PUB,PUB,Growth hormone deficiency,2535,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,MTRX-1011A,60865,New use,null,First Publication,First Publication,PUB,PUB,Protein C deficiency,3469,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,MTRX-1011A,60865,New use,null,First Publication,First Publication,PUB,PUB,Turners syndrome,406,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,MTRX-1011A,60865,New use,null,First Publication,First Publication,PUB,PUB,Hemophilia,439,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,MTRX-1011A,60865,New use,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,"TRX-1, Tolerx",36540,New use,null,First Publication,First Publication,PUB,PUB,Von Willebrands disease,1229,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,"TRX-1, Tolerx",36540,New use,null,First Publication,First Publication,PUB,PUB,Hypothyroidism,182,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,"TRX-1, Tolerx",36540,New use,null,First Publication,First Publication,PUB,PUB,Growth hormone deficiency,2535,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,"TRX-1, Tolerx",36540,New use,null,First Publication,First Publication,PUB,PUB,Protein C deficiency,3469,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,"TRX-1, Tolerx",36540,New use,null,First Publication,First Publication,PUB,PUB,Turners syndrome,406,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,"TRX-1, Tolerx",36540,New use,null,First Publication,First Publication,PUB,PUB,Hemophilia,439,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,World,WO,"TRX-1, Tolerx",36540,New use,null,First Publication,First Publication,PUB,PUB,Lysosome storage disease,648,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Publication,2012-10-26 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,MTRX-1011A,60865,New use,null,First Publication,First Priority,PUB,PRI,Von Willebrands disease,1229,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,MTRX-1011A,60865,New use,null,First Publication,First Priority,PUB,PRI,Hypothyroidism,182,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,MTRX-1011A,60865,New use,null,First Publication,First Priority,PUB,PRI,Growth hormone deficiency,2535,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,MTRX-1011A,60865,New use,null,First Publication,First Priority,PUB,PRI,Protein C deficiency,3469,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,MTRX-1011A,60865,New use,null,First Publication,First Priority,PUB,PRI,Turners syndrome,406,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,MTRX-1011A,60865,New use,null,First Publication,First Priority,PUB,PRI,Hemophilia,439,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,MTRX-1011A,60865,New use,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,"TRX-1, Tolerx",36540,New use,null,First Publication,First Priority,PUB,PRI,Von Willebrands disease,1229,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,"TRX-1, Tolerx",36540,New use,null,First Publication,First Priority,PUB,PRI,Hypothyroidism,182,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,"TRX-1, Tolerx",36540,New use,null,First Publication,First Priority,PUB,PRI,Growth hormone deficiency,2535,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,"TRX-1, Tolerx",36540,New use,null,First Publication,First Priority,PUB,PRI,Protein C deficiency,3469,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,"TRX-1, Tolerx",36540,New use,null,First Publication,First Priority,PUB,PRI,Turners syndrome,406,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,"TRX-1, Tolerx",36540,New use,null,First Publication,First Priority,PUB,PRI,Hemophilia,439,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Tolerx Inc,29147,Owner,US,US,"TRX-1, Tolerx",36540,New use,null,First Publication,First Priority,PUB,PRI,Lysosome storage disease,648,null,Tolerx Inc,29147,WO-2012145238,PA7144943,First Priority,2011-04-20 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Atopic dermatitis,1102,null,National Yang Ming University,1002709,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergic rhinitis,1107,null,National Yang Ming University,1002709,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Asthma,31,null,National Yang Ming University,1002709,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Food hypersensitivity,3612,null,National Yang Ming University,1002709,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung inflammation,646,null,National Yang Ming University,1002709,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Inflammatory disease,188
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Respiratory tract inflammation,713,null,National Yang Ming University,1002709,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Inflammatory disease,188
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Atopic dermatitis,1102,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergic rhinitis,1107,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Asthma,31,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Food hypersensitivity,3612,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung inflammation,646,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Respiratory tract inflammation,713,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Atopic dermatitis,1102,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergic rhinitis,1107,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Asthma,31,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Food hypersensitivity,3612,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung inflammation,646,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,National Yang Ming University,1002709,Third Party,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Respiratory tract inflammation,713,null,National Yang Ming University,1002709,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Staten Island University Hospital,1051758,Third Party,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,Staten Island University Hospital,1051758,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Koch Institute for Integrative Cancer Research,1110278,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Koch Institute for Integrative Cancer Research,1110278,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Vivaldi Biosciences Inc,1044854,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Vivaldi Biosciences Inc,1044854,WO-2015063085,PA8154221,First Publication,2015-05-07 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Vivaldi Biosciences Inc,1044854,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Vivaldi Biosciences Inc,1044854,WO-2015063085,PA8154221,First Publication,2015-05-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Vivaldi Biosciences Inc,1044854,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Vivaldi Biosciences Inc,1044854,WO-2015063085,PA8154221,First Priority,2013-10-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Vivaldi Biosciences Inc,1044854,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Vivaldi Biosciences Inc,1044854,WO-2015063085,PA8154221,First Priority,2013-10-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Blue Sky Vaccines KG,1109007,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Blue Sky Vaccines KG,1109007,WO-2015063085,PA8154221,First Publication,2015-05-07 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Blue Sky Vaccines KG,1109007,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Blue Sky Vaccines KG,1109007,WO-2015063085,PA8154221,First Publication,2015-05-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Blue Sky Vaccines KG,1109007,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Blue Sky Vaccines KG,1109007,WO-2015063085,PA8154221,First Priority,2013-10-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Blue Sky Vaccines KG,1109007,Third Party,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Blue Sky Vaccines KG,1109007,WO-2015063085,PA8154221,First Priority,2013-10-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Vasculitis,1532,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Vasculitis,1532,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Ludwig Institute for Cancer Research,21091,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Indiana University,20593,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Indiana University,20593,WO-2012166875,PA7199238,First Publication,2012-12-06 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Indiana University,20593,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Indiana University,20593,WO-2012166875,PA7199238,First Publication,2012-12-06 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Indiana University,20593,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Indiana University,20593,WO-2012166875,PA7199238,First Publication,2012-12-06 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Indiana University,20593,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Indiana University,20593,WO-2012166875,PA7199238,First Publication,2012-12-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Indiana University,20593,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Indiana University,20593,WO-2012166875,PA7199238,First Priority,2011-05-31 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Indiana University,20593,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Indiana University,20593,WO-2012166875,PA7199238,First Priority,2011-05-31 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Indiana University,20593,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Indiana University,20593,WO-2012166875,PA7199238,First Priority,2011-05-31 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Indiana University,20593,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Indiana University,20593,WO-2012166875,PA7199238,First Priority,2011-05-31 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Publication,2012-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,"GLP-1 agonist (oral sublingual tablet, diabetes), BioLingus",92644,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,erythropoietin,7257,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,somatropin,4433,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,exenatide,13572,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioLingus AG,1100405,Owner,World,WO,granulocyte colony-stimulating factor,1002881-D,Formulation,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,BioLingus AG,1100405,WO-2012109694,PA7064187,First Priority,2011-02-18 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,C4 Therapeutics Inc,1118122,Third Party,World,WO,ENUM-244C8,93669,Product,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,C4 Therapeutics Inc,1118122,WO-2016106160,PA8715595,First Publication,2016-06-30 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,C4 Therapeutics Inc,1118122,Third Party,World,WO,ENUM-244C8,93669,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,C4 Therapeutics Inc,1118122,WO-2016106160,PA8715595,First Publication,2016-06-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,C4 Therapeutics Inc,1118122,Third Party,US,US,ENUM-244C8,93669,Product,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,C4 Therapeutics Inc,1118122,WO-2016106160,PA8715595,First Priority,2014-12-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,C4 Therapeutics Inc,1118122,Third Party,US,US,ENUM-244C8,93669,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,C4 Therapeutics Inc,1118122,WO-2016106160,PA8715595,First Priority,2014-12-22 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Baylor College of Medicine,20534,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Baylor College of Medicine,20534,US-20130071414,PA7315972,First Publication,2013-03-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Baylor College of Medicine,20534,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Baylor College of Medicine,20534,US-20130071414,PA7315972,First Priority,2011-04-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Food hypersensitivity,3612,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Wheat hypersensitivity,3613,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Milk hypersensitivity,3614,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Peanut hypersensitivity,3615,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Egg hypersensitivity,3616,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Food hypersensitivity,3612,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Wheat hypersensitivity,3613,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Milk hypersensitivity,3614,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Peanut hypersensitivity,3615,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Centre National de la Recherche Scientifique (CNRS),15511,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Egg hypersensitivity,3616,null,Centre National de la Recherche Scientifique (CNRS),15511,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Alcoholism,11,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Publication,2011-08-04 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Nicotine dependence,235,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Publication,2011-08-04 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,World,WO,aldesleukin,6306,Formulation,null,First Publication,First Publication,PUB,PUB,Alcoholism,11,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Publication,2011-08-04 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,World,WO,aldesleukin,6306,Formulation,null,First Publication,First Publication,PUB,PUB,Nicotine dependence,235,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Publication,2011-08-04 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,US,US,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Alcoholism,11,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Priority,2010-01-28 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,US,US,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Nicotine dependence,235,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Priority,2010-01-28 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,US,US,aldesleukin,6306,Formulation,null,First Publication,First Priority,PUB,PRI,Alcoholism,11,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Priority,2010-01-28 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,US,US,aldesleukin,6306,Formulation,null,First Publication,First Priority,PUB,PRI,Nicotine dependence,235,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Priority,2010-01-28 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Alcoholism,11,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Priority,2010-01-28 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Nicotine dependence,235,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Priority,2010-01-28 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,European Patent,EP,aldesleukin,6306,Formulation,null,First Publication,First Priority,PUB,PRI,Alcoholism,11,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Priority,2010-01-28 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Immunservice GmbH,1047834,Owner,European Patent,EP,aldesleukin,6306,Formulation,null,First Publication,First Priority,PUB,PRI,Nicotine dependence,235,null,Immunservice GmbH,1047834,WO-2011092231,PA6528763,First Priority,2010-01-28 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone tumor,1012,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioma,1108,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Candida infection,1308,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Influenza virus infection,191,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Plasmodium infection,268,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Individual,21144,WO-2016022630,PA8553138,First Publication,2016-02-11 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone tumor,1012,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioma,1108,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Candida infection,1308,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Influenza virus infection,191,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Plasmodium infection,268,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Individual,21144,WO-2016022630,PA8553138,First Priority,2014-08-05 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Atopic dermatitis,1102,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergic rhinitis,1107,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Asthma,31,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Food hypersensitivity,3612,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung inflammation,646,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Inflammatory disease,188
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Respiratory tract inflammation,713,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,Granted,2017-03-07 00:00:00,GRT,3,Inflammatory disease,188
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Atopic dermatitis,1102,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergic rhinitis,1107,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Asthma,31,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Food hypersensitivity,3612,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung inflammation,646,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Respiratory tract inflammation,713,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Publication,2015-08-27 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Atopic dermatitis,1102,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Allergic rhinitis,1107,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Asthma,31,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Food hypersensitivity,3612,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Lung inflammation,646,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Asian Probiotics & Prebiotics Ltd,1113223,Owner,US,US,null,null,null,null,Granted,Granted,GRT,GRT,Respiratory tract inflammation,713,null,Asian Probiotics & Prebiotics Ltd,1113223,US-09587284,PA8282418,First Priority,2014-02-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatocellular carcinoma,1767,null,University of Virginia,20695,WO-2015160928,PA8395662,First Publication,2015-10-22 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Virginia,20695,WO-2015160928,PA8395662,First Publication,2015-10-22 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,University of Virginia,20695,WO-2015160928,PA8395662,First Publication,2015-10-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,University of Virginia,20695,WO-2015160928,PA8395662,First Publication,2015-10-22 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,University of Virginia,20695,WO-2015160928,PA8395662,First Publication,2015-10-22 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,University of Virginia,20695,WO-2015160928,PA8395662,First Publication,2015-10-22 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Virginia,20695,WO-2015160928,PA8395662,First Publication,2015-10-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,University of Virginia,20695,WO-2015160928,PA8395662,First Publication,2015-10-22 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatocellular carcinoma,1767,null,University of Virginia,20695,WO-2015160928,PA8395662,First Priority,2014-04-15 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Virginia,20695,WO-2015160928,PA8395662,First Priority,2014-04-15 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,University of Virginia,20695,WO-2015160928,PA8395662,First Priority,2014-04-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,University of Virginia,20695,WO-2015160928,PA8395662,First Priority,2014-04-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,University of Virginia,20695,WO-2015160928,PA8395662,First Priority,2014-04-15 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Virginia,20695,WO-2015160928,PA8395662,First Priority,2014-04-15 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Virginia,20695,WO-2015160928,PA8395662,First Priority,2014-04-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Virginia,20695,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,University of Virginia,20695,WO-2015160928,PA8395662,First Priority,2014-04-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Emory University,20573,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Emory University,20573,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Emory University,20573,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Emory University,20573,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Emory University,20573,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Emory University,20573,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Owner,World,WO,GIFT-4,88866,General interest,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Emory University,20573,WO-2015164107,PA8402864,First Publication,2015-10-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Emory University,20573,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Emory University,20573,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Emory University,20573,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Emory University,20573,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Emory University,20573,Owner,US,US,GIFT-4,88866,General interest,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Emory University,20573,WO-2015164107,PA8402864,First Priority,2014-04-23 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Institute for Medical and Biological Engineering,1119864,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Institute for Medical and Biological Engineering,1119864,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thrombosis,1076,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Anemia,17,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal disease,286,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hormone deficiency,364,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Publication,2011-11-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Thrombosis,1076,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Anemia,17,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal disease,286,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Hormone deficiency,364,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Technical University of Munich,25011,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Technical University of Munich,25011,WO-2011144756,PA6659474,First Priority,2010-05-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Chengdu Yongan Pharmaceutical Co Ltd,1094682,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Chengdu Yongan Pharmaceutical Co Ltd,1094682,WO-2017028040,PA9224283,First Publication,2017-02-23 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Chengdu Yongan Pharmaceutical Co Ltd,1094682,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Chengdu Yongan Pharmaceutical Co Ltd,1094682,WO-2017028040,PA9224283,First Priority,2015-08-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Boehringer Ingelheim International GmbH,14881,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cell transplantation,2981,null,Boehringer Ingelheim International GmbH,14881,EP-01361268,PA2879265,First Publication,2003-11-12 00:00:00,PUB,2,Surgical procedure,2979
IL-2 receptor agonist,221,null,Boehringer Ingelheim International GmbH,14881,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Boehringer Ingelheim International GmbH,14881,EP-01361268,PA2879265,First Publication,2003-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Boehringer Ingelheim International GmbH,14881,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Boehringer Ingelheim International GmbH,14881,EP-01361268,PA2879265,First Publication,2003-11-12 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Boehringer Ingelheim International GmbH,14881,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Boehringer Ingelheim International GmbH,14881,EP-01361268,PA2879265,First Publication,2003-11-12 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Boehringer Ingelheim International GmbH,14881,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cell transplantation,2981,null,Boehringer Ingelheim International GmbH,14881,EP-01361268,PA2879265,First Priority,2002-05-08 00:00:00,PRI,1,Surgical procedure,2979
IL-2 receptor agonist,221,null,Boehringer Ingelheim International GmbH,14881,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,Boehringer Ingelheim International GmbH,14881,EP-01361268,PA2879265,First Priority,2002-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Boehringer Ingelheim International GmbH,14881,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Boehringer Ingelheim International GmbH,14881,EP-01361268,PA2879265,First Priority,2002-05-08 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Boehringer Ingelheim International GmbH,14881,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Boehringer Ingelheim International GmbH,14881,EP-01361268,PA2879265,First Priority,2002-05-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Academy of Engineering,1119865,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,National Academy of Engineering,1119865,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Delinia Inc,1119004,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Delinia Inc,1119004,WO-2016025385,PA8557381,First Publication,2016-02-18 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Delinia Inc,1119004,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Delinia Inc,1119004,WO-2016025385,PA8557381,First Priority,2014-08-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Universita degli Studi di Napoli Federico II,1012341,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Helicobacter pylori infection,149,null,Universita degli Studi di Napoli Federico II,1012341,WO-2013147628,PA7511299,First Publication,2013-10-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Universita degli Studi di Napoli Federico II,1012341,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Stomach ulcer,805,null,Universita degli Studi di Napoli Federico II,1012341,WO-2013147628,PA7511299,First Publication,2013-10-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Universita degli Studi di Napoli Federico II,1012341,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Duodenal ulcer,808,null,Universita degli Studi di Napoli Federico II,1012341,WO-2013147628,PA7511299,First Publication,2013-10-03 00:00:00,PUB,2,Ulcer,372
IL-2 receptor agonist,221,null,Universita degli Studi di Napoli Federico II,1012341,Third Party,Poland,PL,null,null,null,null,First Publication,First Priority,PUB,PRI,Helicobacter pylori infection,149,null,Universita degli Studi di Napoli Federico II,1012341,WO-2013147628,PA7511299,First Priority,2012-03-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Universita degli Studi di Napoli Federico II,1012341,Third Party,Poland,PL,null,null,null,null,First Publication,First Priority,PUB,PRI,Stomach ulcer,805,null,Universita degli Studi di Napoli Federico II,1012341,WO-2013147628,PA7511299,First Priority,2012-03-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Universita degli Studi di Napoli Federico II,1012341,Third Party,Poland,PL,null,null,null,null,First Publication,First Priority,PUB,PRI,Duodenal ulcer,808,null,Universita degli Studi di Napoli Federico II,1012341,WO-2013147628,PA7511299,First Priority,2012-03-29 00:00:00,PRI,1,Ulcer,372
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,American Association for the Advancement of Science,1119863,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,American Association for the Advancement of Science,1119863,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Polybiocept Ab,1117429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Polybiocept Ab,1117429,WO-2015189356,PA8469785,First Publication,2015-12-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Polybiocept Ab,1117429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Polybiocept Ab,1117429,WO-2015189356,PA8469785,First Publication,2015-12-17 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Polybiocept Ab,1117429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Polybiocept Ab,1117429,WO-2015189356,PA8469785,First Publication,2015-12-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Polybiocept Ab,1117429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Polybiocept Ab,1117429,WO-2015189356,PA8469785,First Publication,2015-12-17 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Polybiocept Ab,1117429,Owner,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Polybiocept Ab,1117429,WO-2015189356,PA8469785,First Priority,2014-06-11 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Polybiocept Ab,1117429,Owner,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Polybiocept Ab,1117429,WO-2015189356,PA8469785,First Priority,2014-06-11 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Polybiocept Ab,1117429,Owner,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Polybiocept Ab,1117429,WO-2015189356,PA8469785,First Priority,2014-06-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Polybiocept Ab,1117429,Owner,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Polybiocept Ab,1117429,WO-2015189356,PA8469785,First Priority,2014-06-11 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Delinia Inc,1119004,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Delinia Inc,1119004,WO-2016014428,PA8534142,First Publication,2016-01-28 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Delinia Inc,1119004,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Delinia Inc,1119004,WO-2016014428,PA8534142,First Priority,2014-07-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Scleroderma,1105,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vasculitis,1532,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Celiac disease,2539,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alopecia areata,2564,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Arthritis,28,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,University of Miami,20622,WO-2016022671,PA8553474,First Publication,2016-02-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Scleroderma,1105,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Vasculitis,1532,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Celiac disease,2539,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Alopecia areata,2564,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Arthritis,28,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Miami,20622,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,University of Miami,20622,WO-2016022671,PA8553474,First Priority,2014-08-06 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Soonchunhyang University Industry Academy Cooperation Foundation,1047985,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Soonchunhyang University,1048029,WO-2016068428,PA8652356,First Publication,2016-05-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Soonchunhyang University Industry Academy Cooperation Foundation,1047985,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Soonchunhyang University,1048029,WO-2016068428,PA8652356,First Priority,2014-10-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Soonchunhyang University Industry Academy Cooperation Foundation,1047985,Owner,South Korea,KR,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Soonchunhyang University,1048029,WO-2016068428,PA8652356,First Priority,2014-10-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Publication,2014-02-13 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Publication,2014-02-13 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Publication,2014-02-13 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Publication,2014-02-13 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Publication,2014-02-13 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Publication,2014-02-13 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Priority,2012-08-10 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Priority,2012-08-10 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Priority,2012-08-10 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Priority,2012-08-10 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Priority,2012-08-10 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Roche Holding AG,19446,WO-2014023752,PA7662094,First Priority,2012-08-10 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Roche Holding AG,19446,WO-2014023679,PA7662495,First Publication,2014-02-13 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Roche GlycArt Ag,30654,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Roche Holding AG,19446,WO-2014023679,PA7662495,First Priority,2012-08-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ludwig Institute for Cancer Research,21091,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Ludwig Institute for Cancer Research,21091,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone tumor,1012,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thyroid tumor,1134,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Publication,2016-11-10 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bone tumor,1012,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Musculoskeletal disease,216
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Thyroid tumor,1134,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Rubicon Biotechnology Inc,1104750,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Rubicon Biotechnology Inc,1104750,WO-2016179430,PA9044748,First Priority,2015-05-05 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Osteosarcoma,1772,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mouth tumor,793,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Mouth disease,663
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Publication,2014-06-26 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Osteosarcoma,1772,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Mouth tumor,793,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Mouth disease,663
IL-2 receptor agonist,221,null,Ottawa Hospital Research Institute,1051479,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Ottawa Hospital Research Institute,1051479,WO-2014094182,PA7822524,First Priority,2012-12-21 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Navigo Proteins GmbH,29816,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,UV-Cap GmbH & Co KG,1143306,WO-2014094799,PA7822985,First Publication,2014-06-26 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Navigo Proteins GmbH,29816,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,UV-Cap GmbH & Co KG,1143306,WO-2014094799,PA7822985,First Priority,2012-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Open Monoclonal Technologies Inc,1038611,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Ligand Pharmaceuticals Inc,17808,WO-2017020291,PA9201445,First Publication,2017-02-09 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Open Monoclonal Technologies Inc,1038611,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Ligand Pharmaceuticals Inc,17808,WO-2017020291,PA9201445,First Publication,2017-02-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Open Monoclonal Technologies Inc,1038611,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Ligand Pharmaceuticals Inc,17808,WO-2017020291,PA9201445,First Priority,2015-08-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Open Monoclonal Technologies Inc,1038611,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Ligand Pharmaceuticals Inc,17808,WO-2017020291,PA9201445,First Priority,2015-08-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Individual,21144,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Individual,21144,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Individual,21144,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Utah,20690,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Utah,20690,WO-2010129770,PA6248443,First Publication,2010-11-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Utah,20690,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,University of Utah,20690,WO-2010129770,PA6248443,First Publication,2010-11-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Utah,20690,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,University of Utah,20690,WO-2010129770,PA6248443,First Publication,2010-11-11 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Utah,20690,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Utah,20690,WO-2010129770,PA6248443,First Priority,2009-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Utah,20690,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,University of Utah,20690,WO-2010129770,PA6248443,First Priority,2009-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Utah,20690,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,University of Utah,20690,WO-2010129770,PA6248443,First Priority,2009-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Schering-Plough Biopharma,19723,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Toronto,20688,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,University of Toronto,20688,WO-2017028040,PA9224283,First Publication,2017-02-23 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Toronto,20688,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,University of Toronto,20688,WO-2017028040,PA9224283,First Priority,2015-08-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,ACCRA,1020515,WO-2010081766,PA5653566,First Publication,2010-07-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,ACCRA,1020515,WO-2010081766,PA5653566,First Publication,2010-07-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,ACCRA,1020515,WO-2010081766,PA5653566,First Publication,2010-07-22 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ACCRA,1020515,WO-2010081766,PA5653566,First Publication,2010-07-22 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,ACCRA,1020515,WO-2010081766,PA5653566,First Publication,2010-07-22 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,ACCRA,1020515,WO-2010081766,PA5653566,First Priority,2009-01-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,ACCRA,1020515,WO-2010081766,PA5653566,First Priority,2009-01-13 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,ACCRA,1020515,WO-2010081766,PA5653566,First Priority,2009-01-13 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ACCRA,1020515,WO-2010081766,PA5653566,First Priority,2009-01-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,ACCRA,1020515,WO-2010081766,PA5653566,First Priority,2009-01-13 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4010,33476,General interest,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,ACCRA,1020515,WO-2010084100,PA5660605,First Publication,2010-07-29 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4010,33476,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ACCRA,1020515,WO-2010084100,PA5660605,First Publication,2010-07-29 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,gemcitabine,3199,General interest,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,ACCRA,1020515,WO-2010084100,PA5660605,First Publication,2010-07-29 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,gemcitabine,3199,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ACCRA,1020515,WO-2010084100,PA5660605,First Publication,2010-07-29 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,cisplatin,2821,General interest,null,First Publication,First Publication,PUB,PUB,Non-small-cell lung cancer,1262,null,ACCRA,1020515,WO-2010084100,PA5660605,First Publication,2010-07-29 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,cisplatin,2821,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ACCRA,1020515,WO-2010084100,PA5660605,First Publication,2010-07-29 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4010,33476,General interest,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,ACCRA,1020515,WO-2010084100,PA5660605,First Priority,2009-01-20 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4010,33476,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ACCRA,1020515,WO-2010084100,PA5660605,First Priority,2009-01-20 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,gemcitabine,3199,General interest,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,ACCRA,1020515,WO-2010084100,PA5660605,First Priority,2009-01-20 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,gemcitabine,3199,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ACCRA,1020515,WO-2010084100,PA5660605,First Priority,2009-01-20 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,cisplatin,2821,General interest,null,First Publication,First Priority,PUB,PRI,Non-small-cell lung cancer,1262,null,ACCRA,1020515,WO-2010084100,PA5660605,First Priority,2009-01-20 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,cisplatin,2821,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ACCRA,1020515,WO-2010084100,PA5660605,First Priority,2009-01-20 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Myocardial infarction,224,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Retrovirus infection,290,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Atherosclerosis,33,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Acquired immune deficiency syndrome,4,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Arteriosclerosis,540,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,World,WO,ALG-889,17887,Tentative,null,First Publication,First Publication,PUB,PUB,Septic shock,816,null,University of Arizona,20527,WO-00195785,PA147272,First Publication,2001-12-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Myocardial infarction,224,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Retrovirus infection,290,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Atherosclerosis,33,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Acquired immune deficiency syndrome,4,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Arteriosclerosis,540,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Arizona,20527,Owner,US,US,ALG-889,17887,Tentative,null,First Publication,First Priority,PUB,PRI,Septic shock,816,null,University of Arizona,20527,WO-00195785,PA147272,First Priority,2000-06-12 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Fibrosis,1127,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bleeding,552,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Depression,93,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hearing disorder,997,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Otorhinolaryngological disease,592
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Fibrosis,1127,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bleeding,552,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Depression,93,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Alkermes plc,14005,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hearing disorder,997,null,Alkermes plc,14005,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Otorhinolaryngological disease,592
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Pennsylvania,20658,WO-2014011984,PA7635338,First Publication,2014-01-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Pennsylvania,20658,WO-2014011984,PA7635338,First Priority,2012-07-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Howard Hughes Medical Institute,21084,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,The Innovation Institute Ti2,1119866,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Howard Hughes Medical Institute,21084,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Howard Hughes Medical Institute,21084,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Adimab LLC,1043519,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Adimab LLC,1043519,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The Innovation Institute Ti2,1119866,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,The Innovation Institute Ti2,1119866,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Merck Sharp & Dohme Corp,1059823,Owner,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Merck & Co Inc,18077,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Miltenyi Biotec GmbH,28791,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Miltenyi Biotec GmbH,28791,WO-2016026742,PA8565239,First Publication,2016-02-25 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Miltenyi Biotec GmbH,28791,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Miltenyi Biotec GmbH,28791,WO-2016026742,PA8565239,First Publication,2016-02-25 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Miltenyi Biotec GmbH,28791,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Miltenyi Biotec GmbH,28791,WO-2016026742,PA8565239,First Publication,2016-02-25 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Miltenyi Biotec GmbH,28791,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Miltenyi Biotec GmbH,28791,WO-2016026742,PA8565239,First Priority,2014-08-19 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Miltenyi Biotec GmbH,28791,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Miltenyi Biotec GmbH,28791,WO-2016026742,PA8565239,First Priority,2014-08-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Miltenyi Biotec GmbH,28791,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Miltenyi Biotec GmbH,28791,WO-2016026742,PA8565239,First Priority,2014-08-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Rochester,20669,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,University of Rochester,20669,WO-2011123683,PA6590213,First Publication,2011-10-06 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,University of Rochester,20669,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Rochester,20669,WO-2011123683,PA6590213,First Priority,2010-04-02 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,Extension,Extension,EXT,EXT,Melanoma,205,null,US Government,20516,US-08383099,PA6367356,Extension,2030-12-22 00:00:00,EXT,4,Dermatological disease,95
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,Extension,Extension,EXT,EXT,Cancer,651,null,US Government,20516,US-08383099,PA6367356,Extension,2030-12-22 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,fludarabine,6156,Component of Combination,null,Extension,Extension,EXT,EXT,Melanoma,205,null,US Government,20516,US-08383099,PA6367356,Extension,2030-12-22 00:00:00,EXT,4,Dermatological disease,95
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,fludarabine,6156,Component of Combination,null,Extension,Extension,EXT,EXT,Cancer,651,null,US Government,20516,US-08383099,PA6367356,Extension,2030-12-22 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,Extension,Extension,EXT,EXT,Melanoma,205,null,US Government,20516,US-08383099,PA6367356,Granted,2013-02-26 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,Extension,Extension,EXT,EXT,Cancer,651,null,US Government,20516,US-08383099,PA6367356,Granted,2013-02-26 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,fludarabine,6156,Component of Combination,null,Extension,Extension,EXT,EXT,Melanoma,205,null,US Government,20516,US-08383099,PA6367356,Granted,2013-02-26 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,fludarabine,6156,Component of Combination,null,Extension,Extension,EXT,EXT,Cancer,651,null,US Government,20516,US-08383099,PA6367356,Granted,2013-02-26 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,Extension,Extension,EXT,EXT,Melanoma,205,null,US Government,20516,US-08383099,PA6367356,First Publication,2011-03-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,Extension,Extension,EXT,EXT,Cancer,651,null,US Government,20516,US-08383099,PA6367356,First Publication,2011-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,fludarabine,6156,Component of Combination,null,Extension,Extension,EXT,EXT,Melanoma,205,null,US Government,20516,US-08383099,PA6367356,First Publication,2011-03-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,fludarabine,6156,Component of Combination,null,Extension,Extension,EXT,EXT,Cancer,651,null,US Government,20516,US-08383099,PA6367356,First Publication,2011-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,Extension,Extension,EXT,EXT,Melanoma,205,null,US Government,20516,US-08383099,PA6367356,First Priority,2009-08-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,Extension,Extension,EXT,EXT,Cancer,651,null,US Government,20516,US-08383099,PA6367356,First Priority,2009-08-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,fludarabine,6156,Component of Combination,null,Extension,Extension,EXT,EXT,Melanoma,205,null,US Government,20516,US-08383099,PA6367356,First Priority,2009-08-28 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,US Government,20516,Owner,US,US,fludarabine,6156,Component of Combination,null,Extension,Extension,EXT,EXT,Cancer,651,null,US Government,20516,US-08383099,PA6367356,First Priority,2009-08-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Konkuk University,1008802,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Konkuk University,1008802,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Diabetes mellitus,97,null,Konkuk University,1008802,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Endocrine disease,112
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Konkuk University,1008802,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Konkuk University,1008802,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Diabetes mellitus,97,null,Konkuk University,1008802,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Immune disorder,185,null,Konkuk University,1008802,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Infectious disease,746,null,Konkuk University,1008802,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Konkuk University,1008802,Owner,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Diabetes mellitus,97,null,Konkuk University,1008802,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Inje University,1014150,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Inje University,1014150,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Diabetes mellitus,97,null,Inje University,1014150,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Endocrine disease,112
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Inje University,1014150,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Inje University,1014150,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Diabetes mellitus,97,null,Inje University,1014150,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Immune disorder,185,null,Inje University,1014150,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Infectious disease,746,null,Inje University,1014150,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Inje University,1014150,Third Party,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Diabetes mellitus,97,null,Inje University,1014150,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Jeju National University,1091172,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Immune disorder,185
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Jeju National University,1091172,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Diabetes mellitus,97,null,Jeju National University,1091172,US-09669073,PA8716371,Granted,2017-06-06 00:00:00,GRT,3,Endocrine disease,112
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Immune disorder,185,null,Jeju National University,1091172,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Jeju National University,1091172,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,US,US,proinsulin,DOC1000754,New use,null,Granted,Granted,GRT,GRT,Diabetes mellitus,97,null,Jeju National University,1091172,US-09669073,PA8716371,First Publication,2016-06-30 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Immune disorder,185,null,Jeju National University,1091172,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Infectious disease,746,null,Jeju National University,1091172,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Jeju National University,1091172,Third Party,South Korea,KR,proinsulin,DOC1000754,New use,null,Granted,First Priority,GRT,PRI,Diabetes mellitus,97,null,Jeju National University,1091172,US-09669073,PA8716371,First Priority,2014-12-30 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Tsing Hua University,29247,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,National Tsing Hua University,29247,US-20130315828,PA7586414,First Publication,2013-11-28 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Tsing Hua University,29247,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Squamous cell carcinoma,307,null,National Tsing Hua University,29247,US-20130315828,PA7586414,First Publication,2013-11-28 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,National Tsing Hua University,29247,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,National Tsing Hua University,29247,US-20130315828,PA7586414,First Publication,2013-11-28 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,National Tsing Hua University,29247,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,National Tsing Hua University,29247,US-20130315828,PA7586414,First Publication,2013-11-28 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,National Tsing Hua University,29247,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,National Tsing Hua University,29247,US-20130315828,PA7586414,First Priority,2012-05-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,National Tsing Hua University,29247,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Squamous cell carcinoma,307,null,National Tsing Hua University,29247,US-20130315828,PA7586414,First Priority,2012-05-23 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,National Tsing Hua University,29247,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,National Tsing Hua University,29247,US-20130315828,PA7586414,First Priority,2012-05-23 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,National Tsing Hua University,29247,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,National Tsing Hua University,29247,US-20130315828,PA7586414,First Priority,2012-05-23 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Sarcoma,194,null,Philogen SpA,29032,WO-2016180715,PA9052588,First Publication,2016-11-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Philogen SpA,29032,WO-2016180715,PA9052588,First Publication,2016-11-17 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Philogen SpA,29032,WO-2016180715,PA9052588,First Publication,2016-11-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Philogen SpA,29032,WO-2016180715,PA9052588,First Publication,2016-11-17 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Sarcoma,194,null,Philogen SpA,29032,WO-2016180715,PA9052588,First Priority,2015-05-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Philogen SpA,29032,WO-2016180715,PA9052588,First Priority,2015-05-08 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Philogen SpA,29032,WO-2016180715,PA9052588,First Priority,2015-05-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Philogen SpA,29032,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Philogen SpA,29032,WO-2016180715,PA9052588,First Priority,2015-05-08 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Pasteur Merieux,23407,Owner,European Patent,EP,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Sanofi SA,1009547,EP-00421876,IN1572794,First Publication,1991-04-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Pasteur Merieux,23407,Owner,France,FR,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Sanofi SA,1009547,EP-00421876,IN1572794,First Priority,1989-10-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Harbour BioMed,1141056,Owner,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Harbour BioMed,1141056,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,31432,Owner,World,WO,Ontak,7237-X1,New use,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,31432,WO-2012110596,PA7064272,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,31432,Owner,World,WO,Ontak,7237-X1,New use,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,31432,WO-2012110596,PA7064272,First Publication,2012-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,31432,Owner,European Patent,EP,Ontak,7237-X1,New use,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,31432,WO-2012110596,PA7064272,First Priority,2011-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,31432,Owner,European Patent,EP,Ontak,7237-X1,New use,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,31432,WO-2012110596,PA7064272,First Priority,2011-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Testis tumor,1054,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Rectal tumor,1055,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Uterus tumor,740,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Testis tumor,1054,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Rectal tumor,1055,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Uterus tumor,740,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,University of Pennsylvania,20658,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Pennsylvania,20658,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Roger Williams Medical Center,28132,Owner,World,WO,"anti-CEA CAR-T cell therapy (CEA-positive cancers), Sorrento/TNK therapeutics/Roger Williams Medical Center",27611,New use,null,First Publication,First Publication,PUB,PUB,Liver disease,201,null,Roger Williams Medical Center,28132,WO-2016168493,PA9008737,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Roger Williams Medical Center,28132,Owner,World,WO,"anti-CEA CAR-T cell therapy (CEA-positive cancers), Sorrento/TNK therapeutics/Roger Williams Medical Center",27611,New use,null,First Publication,First Publication,PUB,PUB,Metastatic liver cancer,3462,null,Roger Williams Medical Center,28132,WO-2016168493,PA9008737,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Roger Williams Medical Center,28132,Owner,US,US,"anti-CEA CAR-T cell therapy (CEA-positive cancers), Sorrento/TNK therapeutics/Roger Williams Medical Center",27611,New use,null,First Publication,First Priority,PUB,PRI,Liver disease,201,null,Roger Williams Medical Center,28132,WO-2016168493,PA9008737,First Priority,2015-04-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Roger Williams Medical Center,28132,Owner,US,US,"anti-CEA CAR-T cell therapy (CEA-positive cancers), Sorrento/TNK therapeutics/Roger Williams Medical Center",27611,New use,null,First Publication,First Priority,PUB,PRI,Metastatic liver cancer,3462,null,Roger Williams Medical Center,28132,WO-2016168493,PA9008737,First Priority,2015-04-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Formulation,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Formulation,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Publication,2016-10-20 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Formulation,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Formulation,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,BioXcel Therapeutics Inc,1102582,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,BioXcel Therapeutics Inc,1102582,WO-2016168809,PA9008885,First Priority,2015-04-17 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Pieris Pharmaceuticals Inc,28892,WO-2016177762,PA9044296,First Publication,2016-11-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Pieris Pharmaceuticals Inc,28892,WO-2016177762,PA9044296,First Publication,2016-11-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Pieris Pharmaceuticals Inc,28892,WO-2016177762,PA9044296,First Publication,2016-11-10 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Pieris Pharmaceuticals Inc,28892,WO-2016177762,PA9044296,First Priority,2015-05-04 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Pieris Pharmaceuticals Inc,28892,WO-2016177762,PA9044296,First Priority,2015-05-04 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Pieris Pharmaceuticals Inc,28892,WO-2016177762,PA9044296,First Priority,2015-05-04 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Testis tumor,1054,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Rectal tumor,1055,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Uterus tumor,740,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,World,WO,CTL-119,88688,New use,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Novartis AG,23137,WO-2015142675,PA8349674,First Publication,2015-09-24 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Testis tumor,1054,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Rectal tumor,1055,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Uterus tumor,740,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Novartis AG,23137,Owner,US,US,CTL-119,88688,New use,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Novartis AG,23137,WO-2015142675,PA8349674,First Priority,2014-03-15 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,INSERM,17229,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,INSERM,17229,WO-2014206899,PA8016897,First Publication,2014-12-31 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,INSERM,17229,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,INSERM,17229,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,INSERM,17229,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,INSERM,17229,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,University of Illinois,20592,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,University of Illinois,20592,WO-2009114816,PA5378523,First Publication,2009-09-17 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Illinois,20592,WO-2009114816,PA5378523,First Publication,2009-09-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Illinois,20592,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Illinois,20592,WO-2009114816,PA5378523,First Priority,2008-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Illinois,20592,WO-2009114816,PA5378523,First Priority,2008-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CARNK-92 cells,102132,New use,null,First Publication,First Publication,PUB,PUB,B-cell acute lymphoblastic leukemia,1729,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CARNK-92 cells,102132,New use,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CARNK-92 cells,102132,New use,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CARNK-92 cells,102132,New use,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CARNK-92 cells,102132,New use,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CARNK-92 cells,102132,New use,null,First Publication,First Publication,PUB,PUB,T-cell lymphoma,311,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CARNK-92 cells,102132,New use,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CAR,103024,New use,null,First Publication,First Publication,PUB,PUB,B-cell acute lymphoblastic leukemia,1729,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CAR,103024,New use,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CAR,103024,New use,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CAR,103024,New use,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CAR,103024,New use,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CAR,103024,New use,null,First Publication,First Publication,PUB,PUB,T-cell lymphoma,311,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,World,WO,CD4CAR,103024,New use,null,First Publication,First Publication,PUB,PUB,B-cell lymphoma,316,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Publication,2016-12-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CARNK-92 cells,102132,New use,null,First Publication,First Priority,PUB,PRI,B-cell acute lymphoblastic leukemia,1729,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CARNK-92 cells,102132,New use,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CARNK-92 cells,102132,New use,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CARNK-92 cells,102132,New use,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CARNK-92 cells,102132,New use,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CARNK-92 cells,102132,New use,null,First Publication,First Priority,PUB,PRI,T-cell lymphoma,311,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CARNK-92 cells,102132,New use,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CAR,103024,New use,null,First Publication,First Priority,PUB,PRI,B-cell acute lymphoblastic leukemia,1729,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CAR,103024,New use,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CAR,103024,New use,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CAR,103024,New use,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CAR,103024,New use,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CAR,103024,New use,null,First Publication,First Priority,PUB,PRI,T-cell lymphoma,311,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,iCell Gene Therapeutics,1124295,Owner,US,US,CD4CAR,103024,New use,null,First Publication,First Priority,PUB,PRI,B-cell lymphoma,316,null,iCell Gene Therapeutics,1124295,WO-2016210293,PA9124713,First Priority,2015-06-25 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Aging,1042,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute lymphoblastic leukemia,1728,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic leukemia,1733,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Chronic myelocytic leukemia,1735,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Eosinophilia,1983,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bacterial infection,40,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Publication,2016-05-06 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Aging,1042,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Acute lymphoblastic leukemia,1728,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic leukemia,1733,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Chronic myelocytic leukemia,1735,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Eosinophilia,1983,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bacterial infection,40,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Fred Hutchinson Cancer Research Center,16218,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Fred Hutchinson Cancer Research Center,16218,WO-2016069647,PA8651659,First Priority,2014-10-27 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,streptavidin,CP387897,New use,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,University of Louisville,21246,WO-2016205714,PA9112006,First Publication,2016-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,streptavidin,CP387897,New use,null,First Publication,First Publication,PUB,PUB,Heart transplant rejection,2987,null,University of Louisville,21246,WO-2016205714,PA9112006,First Publication,2016-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,streptavidin,CP387897,New use,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Louisville,21246,WO-2016205714,PA9112006,First Publication,2016-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,streptavidin,CP387897,New use,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,University of Louisville,21246,WO-2016205714,PA9112006,First Publication,2016-12-22 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,World,WO,streptavidin,CP387897,New use,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,University of Louisville,21246,WO-2016205714,PA9112006,First Publication,2016-12-22 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,streptavidin,CP387897,New use,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,University of Louisville,21246,WO-2016205714,PA9112006,First Priority,2015-06-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,streptavidin,CP387897,New use,null,First Publication,First Priority,PUB,PRI,Heart transplant rejection,2987,null,University of Louisville,21246,WO-2016205714,PA9112006,First Priority,2015-06-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,streptavidin,CP387897,New use,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Louisville,21246,WO-2016205714,PA9112006,First Priority,2015-06-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,streptavidin,CP387897,New use,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,University of Louisville,21246,WO-2016205714,PA9112006,First Priority,2015-06-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Louisville,21246,Owner,US,US,streptavidin,CP387897,New use,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,University of Louisville,21246,WO-2016205714,PA9112006,First Priority,2015-06-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Fudan University,DOL1000375,WO-2017028040,PA9224283,First Publication,2017-02-23 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Fudan University,DOL1000375,WO-2017028040,PA9224283,First Priority,2015-08-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University College London,23505,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of London,20607,WO-2017029511,PA9224509,First Publication,2017-02-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University College London,23505,Third Party,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of London,20607,WO-2017029511,PA9224509,First Priority,2015-08-20 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,University of Illinois,20592,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Illinois,20592,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,University of Illinois,20592,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Illinois,20592,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Imperial College London,23577,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Imperial College London,23577,WO-2017029511,PA9224509,First Publication,2017-02-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial College London,23577,Third Party,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Imperial College London,23577,WO-2017029511,PA9224509,First Priority,2015-08-20 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,University of Illinois,20592,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Illinois,20592,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,University of Illinois,20592,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Publication,2017-02-02 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Fudan University,DOL1000375,Third Party,China,CN,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Fudan University,DOL1000375,WO-2017016497,PA9194446,First Priority,2015-07-28 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-388D4,CP379041,New use,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-388D4,CP379041,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-388D4,CP379041,New use,null,First Publication,First Publication,PUB,PUB,Autoinflammatory disease,3600,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-388D4,CP379041,New use,null,First Publication,First Publication,PUB,PUB,Organ transplant rejection,3878,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-388D4,CP379041,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-244C8,93669,New use,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-244C8,93669,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-244C8,93669,New use,null,First Publication,First Publication,PUB,PUB,Autoinflammatory disease,3600,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-244C8,93669,New use,null,First Publication,First Publication,PUB,PUB,Organ transplant rejection,3878,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,ENUM-244C8,93669,New use,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,PRS-332,103097,Product,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,PRS-332,103097,Product,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,PRS-332,103097,Product,null,First Publication,First Publication,PUB,PUB,Autoinflammatory disease,3600,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,PRS-332,103097,Product,null,First Publication,First Publication,PUB,PUB,Organ transplant rejection,3878,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,World,WO,PRS-332,103097,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-388D4,CP379041,New use,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-388D4,CP379041,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-388D4,CP379041,New use,null,First Publication,First Priority,PUB,PRI,Autoinflammatory disease,3600,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-388D4,CP379041,New use,null,First Publication,First Priority,PUB,PRI,Organ transplant rejection,3878,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-388D4,CP379041,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-244C8,93669,New use,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-244C8,93669,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-244C8,93669,New use,null,First Publication,First Priority,PUB,PRI,Autoinflammatory disease,3600,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-244C8,93669,New use,null,First Publication,First Priority,PUB,PRI,Organ transplant rejection,3878,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,ENUM-244C8,93669,New use,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,PRS-332,103097,Product,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,PRS-332,103097,Product,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,PRS-332,103097,Product,null,First Publication,First Priority,PUB,PRI,Autoinflammatory disease,3600,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,PRS-332,103097,Product,null,First Publication,First Priority,PUB,PRI,Organ transplant rejection,3878,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Pieris Pharmaceuticals Inc,28892,Owner,European Patent,EP,PRS-332,103097,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Pieris Pharmaceuticals Inc,28892,WO-2017025498,PA9211659,First Priority,2015-08-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Publication,2017-03-02 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Primary biliary cholangitis,1995,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Publication,2017-03-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Primary sclerosing cholangitis,2477,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Publication,2017-03-02 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune hepatitis,3065,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Publication,2017-03-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatobiliary disease,628,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Publication,2017-03-02 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Priority,2015-08-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Primary biliary cholangitis,1995,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Priority,2015-08-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Primary sclerosing cholangitis,2477,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Priority,2015-08-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune hepatitis,3065,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Priority,2015-08-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,The University of Birmingham,20537,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatobiliary disease,628,null,The University of Birmingham,20537,WO-2017033025,PA9241749,First Priority,2015-08-27 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Fibrosis,1127,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Psoriasis,281,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Bleeding,552,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Depression,93,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hearing disorder,997,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Publication,2016-06-23 00:00:00,PUB,2,Otorhinolaryngological disease,592
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Fibrosis,1127,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Psoriasis,281,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Bleeding,552,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Depression,93,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Potenza Therapeutics,1102074,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hearing disorder,997,null,Astellas Pharma Inc,1013295,WO-2016100788,PA8708477,First Priority,2014-12-19 00:00:00,PRI,1,Otorhinolaryngological disease,592
IL-2 receptor agonist,221,null,Mayo Clinic Foundation,21111,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Mayo Clinic Foundation,21111,WO-2017053671,PA9291279,First Publication,2017-03-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Mayo Clinic Foundation,21111,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Mayo Clinic Foundation,21111,WO-2017053671,PA9291279,First Priority,2015-09-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Commissariat a l`Energie Atomique,15529,Owner,World,WO,BV-CYP01,78225,Product,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Commissariat a l`Energie Atomique,15529,WO-2017060510,PA9312289,First Publication,2017-04-13 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Commissariat a l`Energie Atomique,15529,Owner,European Patent,EP,BV-CYP01,78225,Product,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Commissariat a l`Energie Atomique,15529,WO-2017060510,PA9312289,First Priority,2015-10-09 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,World,WO,BV-CYP01,78225,Product,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Universite Pierre et Marie Curie,20660,WO-2017060510,PA9312289,First Publication,2017-04-13 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Universite Pierre et Marie Curie,20660,Owner,European Patent,EP,BV-CYP01,78225,Product,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Universite Pierre et Marie Curie,20660,WO-2017060510,PA9312289,First Priority,2015-10-09 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Hopital Universitaire de la Pitie Salpetriere,1034974,Third Party,World,WO,BV-CYP01,78225,Product,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Hopital Universitaire de la Pitie Salpetriere,1034974,WO-2017060510,PA9312289,First Publication,2017-04-13 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Hopital Universitaire de la Pitie Salpetriere,1034974,Third Party,European Patent,EP,BV-CYP01,78225,Product,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Hopital Universitaire de la Pitie Salpetriere,1034974,WO-2017060510,PA9312289,First Priority,2015-10-09 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Publication,2017-04-13 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Virginia Commonwealth University,20696,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Virginia Commonwealth University,20696,WO-2017062708,PA9312832,First Priority,2015-10-09 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Imperial College London,23577,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Imperial College London,23577,WO-2017068360,PA9331288,First Publication,2017-04-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Imperial College London,23577,Third Party,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Imperial College London,23577,WO-2017068360,PA9331288,First Priority,2015-10-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Streptococcus pneumoniae infection,313,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Toxoplasma infection,329,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Trypanosomiasis,336,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Burkitts lymphoma,791,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,World,WO,TAS-121,81771,New use,null,First Publication,First Publication,PUB,PUB,Kaposis sarcoma,936,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Publication,2017-04-20 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Mycobacterium tuberculosis infection,221,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Streptococcus pneumoniae infection,313,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Toxoplasma infection,329,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Trypanosomiasis,336,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Burkitts lymphoma,791,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Taiho Pharmaceutical Co Ltd,18720,Owner,Japan,JP,TAS-121,81771,New use,null,First Publication,First Priority,PUB,PRI,Kaposis sarcoma,936,null,Otsuka Holdings Co Ltd,1040632,WO-2017064558,PA9320788,First Priority,2015-10-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,obinutuzumab,53227,Component of Combination,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Publication,2017-06-15 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,obinutuzumab,53227,Component of Combination,null,First Publication,First Publication,PUB,PUB,Diffuse large B-cell lymphoma,1749,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Publication,2017-06-15 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,World,WO,obinutuzumab,53227,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Publication,2017-06-15 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,obinutuzumab,53227,Component of Combination,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Priority,2015-12-09 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,obinutuzumab,53227,Component of Combination,null,First Publication,First Priority,PUB,PRI,Diffuse large B-cell lymphoma,1749,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Priority,2015-12-09 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,F Hoffmann-La Roche AG,26178,Owner,European Patent,EP,obinutuzumab,53227,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Priority,2015-12-09 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,obinutuzumab,53227,Component of Combination,null,First Publication,First Publication,PUB,PUB,Chronic lymphocytic leukemia,1734,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Publication,2017-06-15 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,obinutuzumab,53227,Component of Combination,null,First Publication,First Publication,PUB,PUB,Diffuse large B-cell lymphoma,1749,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Publication,2017-06-15 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,obinutuzumab,53227,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Publication,2017-06-15 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,obinutuzumab,53227,Component of Combination,null,First Publication,First Priority,PUB,PRI,Chronic lymphocytic leukemia,1734,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Priority,2015-12-09 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,obinutuzumab,53227,Component of Combination,null,First Publication,First Priority,PUB,PRI,Diffuse large B-cell lymphoma,1749,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Priority,2015-12-09 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,obinutuzumab,53227,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,Roche Holding AG,19446,WO-2017097723,PA9442885,First Priority,2015-12-09 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,atezolizumab,72699,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,World,WO,RG-7461,90987,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Publication,2016-03-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,cergutuzumab amunaleukin,84691,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,atezolizumab,72699,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Hoffmann-La Roche Inc,19461,Owner,European Patent,EP,RG-7461,90987,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Roche Holding AG,19446,WO-2016030350,PA8572821,First Priority,2014-08-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,Third Party,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,"The Ragon Institute of MGH, MIT and Harvard",1099414,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,National Cheng Kung University,1010719,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,National Cheng Kung University,1010719,US-07132407,PA2942153,Extension,2024-04-16 00:00:00,EXT,4,Neoplasm,230
IL-2 receptor agonist,221,null,National Cheng Kung University,1010719,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,National Cheng Kung University,1010719,US-07132407,PA2942153,Granted,2006-11-07 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,National Cheng Kung University,1010719,Owner,US,US,null,null,null,null,Extension,Extension,EXT,EXT,Cancer,651,null,National Cheng Kung University,1010719,US-07132407,PA2942153,First Publication,2005-01-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,National Cheng Kung University,1010719,Owner,Taiwan,TW,null,null,null,null,Extension,First Priority,EXT,PRI,Cancer,651,null,National Cheng Kung University,1010719,US-07132407,PA2942153,First Priority,2002-09-24 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bayer Pharmaceuticals Corp,30751,Owner,World,WO,AIC-284,28450,Process,null,First Publication,First Publication,PUB,PUB,Factor VIII deficiency,121,null,Bayer AG,14455,WO-2005010046,PA2942865,First Publication,2005-02-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Bayer Pharmaceuticals Corp,30751,Owner,World,WO,"octocog alfa (plasma-free, sucrose-formulated), Bayer",94438,Process,null,First Publication,First Publication,PUB,PUB,Factor VIII deficiency,121,null,Bayer AG,14455,WO-2005010046,PA2942865,First Publication,2005-02-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Bayer Pharmaceuticals Corp,30751,Owner,World,WO,"octocog alfa, Genentech/Bayer",3091,Process,null,First Publication,First Publication,PUB,PUB,Factor VIII deficiency,121,null,Bayer AG,14455,WO-2005010046,PA2942865,First Publication,2005-02-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Bayer Pharmaceuticals Corp,30751,Owner,World,WO,"ulinastatin (inhaled, cystic fibrosis/COPD), Aerovance",16366,Process,null,First Publication,First Publication,PUB,PUB,Factor VIII deficiency,121,null,Bayer AG,14455,WO-2005010046,PA2942865,First Publication,2005-02-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Bayer Pharmaceuticals Corp,30751,Owner,US,US,AIC-284,28450,Process,null,First Publication,First Priority,PUB,PRI,Factor VIII deficiency,121,null,Bayer AG,14455,WO-2005010046,PA2942865,First Priority,2003-06-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Bayer Pharmaceuticals Corp,30751,Owner,US,US,"octocog alfa (plasma-free, sucrose-formulated), Bayer",94438,Process,null,First Publication,First Priority,PUB,PRI,Factor VIII deficiency,121,null,Bayer AG,14455,WO-2005010046,PA2942865,First Priority,2003-06-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Bayer Pharmaceuticals Corp,30751,Owner,US,US,"octocog alfa, Genentech/Bayer",3091,Process,null,First Publication,First Priority,PUB,PRI,Factor VIII deficiency,121,null,Bayer AG,14455,WO-2005010046,PA2942865,First Priority,2003-06-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Bayer Pharmaceuticals Corp,30751,Owner,US,US,"ulinastatin (inhaled, cystic fibrosis/COPD), Aerovance",16366,Process,null,First Publication,First Priority,PUB,PRI,Factor VIII deficiency,121,null,Bayer AG,14455,WO-2005010046,PA2942865,First Priority,2003-06-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,World,WO,GX-188E,73714,Product,null,First Publication,First Publication,PUB,PUB,Neuroendocrine tumor,1128,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,World,WO,GX-188E,73714,Product,null,First Publication,First Publication,PUB,PUB,Cervical dysplasia,1235,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Publication,2016-02-18 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,World,WO,GX-188E,73714,Product,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,World,WO,GX-188E,73714,Product,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,World,WO,GX-188E,73714,Product,null,First Publication,First Publication,PUB,PUB,Adenocarcinoma,2399,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Publication,2016-02-18 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,World,WO,GX-188E,73714,Product,null,First Publication,First Publication,PUB,PUB,Squamous cell carcinoma,307,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,World,WO,GX-188E,73714,Product,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Publication,2016-02-18 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,US,US,GX-188E,73714,Product,null,First Publication,First Priority,PUB,PRI,Neuroendocrine tumor,1128,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Priority,2014-08-15 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,US,US,GX-188E,73714,Product,null,First Publication,First Priority,PUB,PRI,Cervical dysplasia,1235,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Priority,2014-08-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,US,US,GX-188E,73714,Product,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Priority,2014-08-15 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,US,US,GX-188E,73714,Product,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Priority,2014-08-15 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,US,US,GX-188E,73714,Product,null,First Publication,First Priority,PUB,PRI,Adenocarcinoma,2399,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Priority,2014-08-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,US,US,GX-188E,73714,Product,null,First Publication,First Priority,PUB,PRI,Squamous cell carcinoma,307,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Priority,2014-08-15 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Genexine Co Ltd,29830,Owner,US,US,GX-188E,73714,Product,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Genexine Co Ltd,29830,WO-2016024255,PA8557817,First Priority,2014-08-15 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Vasculitis,1532,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Vasculitis,1532,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Agenus Inc,23221,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Harvard Medical School,24839,WO-2011049603,PA6424840,First Publication,2011-04-28 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Harvard Medical School,24839,WO-2011049603,PA6424840,First Priority,2009-10-22 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Publication,2010-07-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Publication,2010-07-29 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Arthritis,28,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Publication,2010-07-29 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Publication,2010-07-29 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Transplant rejection,515,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Publication,2010-07-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Publication,2010-07-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Publication,2010-07-29 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Priority,2009-01-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Priority,2009-01-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Arthritis,28,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Priority,2009-01-21 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Priority,2009-01-21 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Transplant rejection,515,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Priority,2009-01-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Priority,2009-01-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Amgen Inc,14109,WO-2010085495,PA5660948,First Priority,2009-01-21 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Agenus Inc,23221,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Agenus Inc,23221,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,T-cell lymphoma,311,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,T-cell lymphoma,311,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts General Hospital,21569,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,WuXi Biologics,1122083,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,WuXi PharmaTech (Cayman) Inc,1014227,WO-2017020291,PA9201445,First Publication,2017-02-09 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,WuXi Biologics,1122083,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,WuXi PharmaTech (Cayman) Inc,1014227,WO-2017020291,PA9201445,First Publication,2017-02-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,WuXi Biologics,1122083,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,WuXi PharmaTech (Cayman) Inc,1014227,WO-2017020291,PA9201445,First Priority,2015-08-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,WuXi Biologics,1122083,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,WuXi PharmaTech (Cayman) Inc,1014227,WO-2017020291,PA9201445,First Priority,2015-08-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,curcumin,DOC1002071,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,cianidanol,DOC1000191,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis B virus infection,152,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Herpes simplex virus infection,157,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Epstein Barr virus infection,3299,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,World,WO,resveratrol,16523,Formulation,null,First Publication,First Publication,PUB,PUB,Cytomegalovirus infection,89,null,City University of New York,20557,WO-2015081319,PA8188826,First Publication,2015-06-04 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,curcumin,DOC1002071,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,cianidanol,DOC1000191,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis B virus infection,152,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Herpes simplex virus infection,157,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Epstein Barr virus infection,3299,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,City University of New York,20557,Owner,US,US,resveratrol,16523,Formulation,null,First Publication,First Priority,PUB,PRI,Cytomegalovirus infection,89,null,City University of New York,20557,WO-2015081319,PA8188826,First Priority,2013-11-27 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,US Department of Veterans Affairs,26104,Owner,US,US,interferon gamma,7461,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,US-20140147411,PA7798470,First Publication,2014-05-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,US Department of Veterans Affairs,26104,Owner,US,US,vemurafenib,54469,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,US-20140147411,PA7798470,First Publication,2014-05-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,US Department of Veterans Affairs,26104,Owner,US,US,interferon alfa,14232,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,US-20140147411,PA7798470,First Publication,2014-05-29 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,US Department of Veterans Affairs,26104,Owner,US,US,interferon gamma,7461,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,US-20140147411,PA7798470,First Priority,2012-11-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,US Department of Veterans Affairs,26104,Owner,US,US,vemurafenib,54469,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,US-20140147411,PA7798470,First Priority,2012-11-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,US Department of Veterans Affairs,26104,Owner,US,US,interferon alfa,14232,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,US Government,20516,US-20140147411,PA7798470,First Priority,2012-11-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Michigan,20623,Owner,World,WO,sirolimus,4200,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Michigan,20623,WO-2010151517,PA6295859,First Publication,2010-12-29 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Michigan,20623,Owner,US,US,sirolimus,4200,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Michigan,20623,WO-2010151517,PA6295859,First Priority,2009-06-25 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Science & Technology Corporation @ UNM,28506,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of New Mexico,20639,WO-2011005380,PA6314669,First Publication,2011-01-13 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Science & Technology Corporation @ UNM,28506,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of New Mexico,20639,WO-2011005380,PA6314669,First Priority,2009-06-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,US Department of Veterans Affairs,26104,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,US Government,20516,WO-2011053991,PA6431926,First Publication,2011-05-05 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,US Department of Veterans Affairs,26104,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,US Government,20516,WO-2011053991,PA6431926,First Priority,2009-11-02 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Science & Technology Corporation @ UNM,28506,Owner,World,WO,SRX-1177,95417,Product,null,First Publication,First Publication,PUB,PUB,Metastasis,1069,null,University of New Mexico,20639,WO-2011066521,PA6463373,First Publication,2011-06-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Science & Technology Corporation @ UNM,28506,Owner,World,WO,SRX-1177,95417,Product,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of New Mexico,20639,WO-2011066521,PA6463373,First Publication,2011-06-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Science & Technology Corporation @ UNM,28506,Owner,US,US,SRX-1177,95417,Product,null,First Publication,First Priority,PUB,PRI,Metastasis,1069,null,University of New Mexico,20639,WO-2011066521,PA6463373,First Priority,2009-11-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Science & Technology Corporation @ UNM,28506,Owner,US,US,SRX-1177,95417,Product,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of New Mexico,20639,WO-2011066521,PA6463373,First Priority,2009-11-30 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioma,1108,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thyroid tumor,1134,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioma,1108,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Thyroid tumor,1134,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Torque Therapeutics Inc,1140684,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Torque Therapeutics Inc,1140684,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Torque Therapeutics Inc,1140684,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Torque Therapeutics Inc,1140684,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Torque Therapeutics Inc,1140684,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Torque Therapeutics Inc,1140684,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Torque Therapeutics Inc,1140684,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Torque Therapeutics Inc,1140684,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Torque Therapeutics Inc,1140684,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Torque Therapeutics Inc,1140684,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Torque Therapeutics Inc,1140684,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Torque Therapeutics Inc,1140684,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,World,WO,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Publication,PUB,PUB,Gastrointestinal tumor,131,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Publication,2016-02-04 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,World,WO,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Publication,PUB,PUB,Liver tumor,202,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Publication,2016-02-04 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,World,WO,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Publication,2016-02-04 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,World,WO,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Publication,2016-02-04 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,World,WO,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Publication,2016-02-04 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,World,WO,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Publication,2016-02-04 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,World,WO,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Publication,2016-02-04 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,China,CN,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Priority,PUB,PRI,Gastrointestinal tumor,131,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Priority,2014-08-01 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,China,CN,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Priority,PUB,PRI,Liver tumor,202,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Priority,2014-08-01 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,China,CN,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Priority,2014-08-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,China,CN,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Priority,2014-08-01 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,China,CN,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Priority,2014-08-01 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,China,CN,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Priority,2014-08-01 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Akeso Biopharma Inc,1075032,Owner,China,CN,"anti-CTLA-4/anti-PD-1 bispecific humanized antibody (cancer), Akeso Biopharma",93622,General interest,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Akeso Biopharma Inc,1075032,WO-2016015675,PA8541305,First Priority,2014-08-01 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Karolinska Institutet,21110,WO-2015189356,PA8469785,First Publication,2015-12-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Karolinska Institutet,21110,WO-2015189356,PA8469785,First Publication,2015-12-17 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Karolinska Institutet,21110,WO-2015189356,PA8469785,First Publication,2015-12-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Karolinska Institutet,21110,WO-2015189356,PA8469785,First Publication,2015-12-17 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Karolinska Institutet,21110,WO-2015189356,PA8469785,First Priority,2014-06-11 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Karolinska Institutet,21110,WO-2015189356,PA8469785,First Priority,2014-06-11 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Karolinska Institutet,21110,WO-2015189356,PA8469785,First Priority,2014-06-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Karolinska Institutet,21110,Third Party,Germany,DE,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Karolinska Institutet,21110,WO-2015189356,PA8469785,First Priority,2014-06-11 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Myelodysplastic syndrome,1272,null,Stanford University,20679,US-20090208918,PA5349183,First Publication,2009-08-20 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological disease,142,null,Stanford University,20679,US-20090208918,PA5349183,First Publication,2009-08-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,Stanford University,20679,US-20090208918,PA5349183,First Publication,2009-08-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Stanford University,20679,US-20090208918,PA5349183,First Publication,2009-08-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Stanford University,20679,US-20090208918,PA5349183,First Publication,2009-08-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Thalassemia,322,null,Stanford University,20679,US-20090208918,PA5349183,First Publication,2009-08-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone marrow disease,555,null,Stanford University,20679,US-20090208918,PA5349183,First Publication,2009-08-20 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Myelodysplastic syndrome,1272,null,Stanford University,20679,US-20090208918,PA5349183,First Priority,2008-02-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological disease,142,null,Stanford University,20679,US-20090208918,PA5349183,First Priority,2008-02-13 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,Stanford University,20679,US-20090208918,PA5349183,First Priority,2008-02-13 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Stanford University,20679,US-20090208918,PA5349183,First Priority,2008-02-13 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,Stanford University,20679,US-20090208918,PA5349183,First Priority,2008-02-13 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Thalassemia,322,null,Stanford University,20679,US-20090208918,PA5349183,First Priority,2008-02-13 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Publication,PUB,PUB,Bone marrow disease,555,null,Stanford University,20679,US-20090208918,PA5349183,First Priority,2008-02-13 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Gaucher disease,132,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hypercholesterolemia,174,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ataxia telangiectasia,1840,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Tay Sachs disease,2000,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Retinitis pigmentosa,2004,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Ocular disease,239
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Blooms syndrome,2016,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Duchenne dystrophy,2020,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Growth disorder,140
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Retinoblastoma,289,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Sickle cell anemia,303,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Genetic disorder,609
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thalassemia,322,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hemophilia,439,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ischemia,637,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cystic fibrosis,88,null,Stanford University,20679,WO-2005107790,PA3060237,First Publication,2005-11-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Gaucher disease,132,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hypercholesterolemia,174,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ataxia telangiectasia,1840,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Tay Sachs disease,2000,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Retinitis pigmentosa,2004,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Ocular disease,239
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Blooms syndrome,2016,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Duchenne dystrophy,2020,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Growth disorder,140
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Retinoblastoma,289,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Sickle cell anemia,303,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Genetic disorder,609
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Thalassemia,322,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hemophilia,439,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ischemia,637,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Stanford University,20679,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cystic fibrosis,88,null,Stanford University,20679,WO-2005107790,PA3060237,First Priority,2004-04-30 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Vedantra Pharmaceuticals Inc,1096435,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Vedantra Pharmaceuticals Inc,1096435,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Vedantra Pharmaceuticals Inc,1096435,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Vedantra Pharmaceuticals Inc,1096435,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Vedantra Pharmaceuticals Inc,1096435,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Vedantra Pharmaceuticals Inc,1096435,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Vedantra Pharmaceuticals Inc,1096435,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Vedantra Pharmaceuticals Inc,1096435,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Vedantra Pharmaceuticals Inc,1096435,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Vedantra Pharmaceuticals Inc,1096435,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Vedantra Pharmaceuticals Inc,1096435,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Vedantra Pharmaceuticals Inc,1096435,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Vasculitis,1532,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,INCAGN-1949,89666,General interest,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Publication,2016-11-10 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Vasculitis,1532,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,INCAGN-1949,89666,General interest,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2016179517,PA9044779,First Priority,2015-05-07 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Memorial Sloan-Kettering Cancer Center,22122,Owner,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Memorial Sloan-Kettering Cancer Center,22122,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Allergy,12,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neoplasm,230,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Asthma,31,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Publication,2007-08-23 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Allergy,12,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neoplasm,230,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Asthma,31,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Lausanne,25174,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,University of Lausanne,25174,WO-2007095643,PA3536685,First Priority,2006-02-16 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Harvard Medical School,24839,WO-2011049603,PA6424840,First Publication,2011-04-28 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Harvard Medical School,24839,WO-2011049603,PA6424840,First Priority,2009-10-22 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Stanford University,20679,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Stanford University,20679,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Stanford University,20679,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,T-cell lymphoma,311,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,T-cell lymphoma,311,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Dana-Farber Cancer Institute Inc,15615,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,West Nile virus infection,1281,null,University of Washington,20701,WO-2016100375,PA8708319,First Publication,2016-06-23 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,University of Washington,20701,WO-2016100375,PA8708319,First Publication,2016-06-23 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,University of Washington,20701,WO-2016100375,PA8708319,First Publication,2016-06-23 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hematological neoplasm,2054,null,University of Washington,20701,WO-2016100375,PA8708319,First Publication,2016-06-23 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,University of Washington,20701,WO-2016100375,PA8708319,First Publication,2016-06-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,University of Washington,20701,WO-2016100375,PA8708319,First Publication,2016-06-23 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,West Nile virus infection,1281,null,University of Washington,20701,WO-2016100375,PA8708319,First Priority,2014-12-15 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,University of Washington,20701,WO-2016100375,PA8708319,First Priority,2014-12-15 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,University of Washington,20701,WO-2016100375,PA8708319,First Priority,2014-12-15 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hematological neoplasm,2054,null,University of Washington,20701,WO-2016100375,PA8708319,First Priority,2014-12-15 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,University of Washington,20701,WO-2016100375,PA8708319,First Priority,2014-12-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Washington,20701,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,University of Washington,20701,WO-2016100375,PA8708319,First Priority,2014-12-15 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Harvard Medical School,24839,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Harvard Medical School,24839,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Neuroblastoma,2726,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Harvard Medical School,24839,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,T-cell lymphoma,311,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Harvard Medical School,24839,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Publication,2014-06-19 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Harvard Medical School,24839,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Harvard Medical School,24839,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Neuroblastoma,2726,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Harvard Medical School,24839,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,T-cell lymphoma,311,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Harvard Medical School,24839,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Harvard Medical School,24839,WO-2014093240,PA7817607,First Priority,2012-12-10 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,World,WO,LU-103793,10327-X1,Formulation,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,ETH Zurich,23144,WO-2014174105,PA7952033,First Publication,2014-10-30 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,World,WO,LU-103793,10327-X1,Formulation,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,ETH Zurich,23144,WO-2014174105,PA7952033,First Publication,2014-10-30 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,World,WO,LU-103793,10327-X1,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ETH Zurich,23144,WO-2014174105,PA7952033,First Publication,2014-10-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,European Patent,EP,LU-103793,10327-X1,Formulation,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,ETH Zurich,23144,WO-2014174105,PA7952033,First Priority,2013-04-25 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,European Patent,EP,LU-103793,10327-X1,Formulation,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,ETH Zurich,23144,WO-2014174105,PA7952033,First Priority,2013-04-25 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,European Patent,EP,LU-103793,10327-X1,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ETH Zurich,23144,WO-2014174105,PA7952033,First Priority,2013-04-25 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,gemcitabine,3199,Component of Combination,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Bayer AG,14455,EP-01842553,PA3557272,First Publication,2007-10-10 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,gemcitabine,3199,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Bayer AG,14455,EP-01842553,PA3557272,First Publication,2007-10-10 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,gemcitabine,3199,Component of Combination,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Bayer AG,14455,EP-01842553,PA3557272,First Priority,2006-04-07 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,gemcitabine,3199,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Bayer AG,14455,EP-01842553,PA3557272,First Priority,2006-04-07 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,World,WO,indometacin,DOC1000482,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphocytopenia,1992,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Publication,2007-11-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,World,WO,indometacin,DOC1000482,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Publication,2007-11-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,World,WO,indometacin,DOC1000482,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Publication,2007-11-29 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,World,WO,cyclophosphamide,DOC1000274,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphocytopenia,1992,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Publication,2007-11-29 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,World,WO,cyclophosphamide,DOC1000274,Component of Combination,null,First Publication,First Publication,PUB,PUB,Immune deficiency,504,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Publication,2007-11-29 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,World,WO,cyclophosphamide,DOC1000274,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Publication,2007-11-29 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,US,US,indometacin,DOC1000482,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphocytopenia,1992,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Priority,2006-03-14 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,US,US,indometacin,DOC1000482,Component of Combination,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Priority,2006-03-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,US,US,indometacin,DOC1000482,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Priority,2006-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphocytopenia,1992,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Priority,2006-03-14 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,First Publication,First Priority,PUB,PRI,Immune deficiency,504,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Priority,2006-03-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,US,US,cyclophosphamide,DOC1000274,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2007136910,PA3574380,First Priority,2006-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,"HIV-specific STAR fusions, Altor Bioscience",61288,General interest,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,NantWorks LLC,1103920,WO-2010111467,PA5790863,First Publication,2010-09-30 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,"HIV-specific STAR fusions, Altor Bioscience",61288,General interest,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,NantWorks LLC,1103920,WO-2010111467,PA5790863,First Priority,2009-03-25 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Autoimmune hemolytic anemia,2643,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Publication,PUB,PUB,Autoimmune hemolytic anemia,2643,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Publication,PUB,PUB,Rheumatoid arthritis,291,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ulcerative colitis,337,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,World,WO,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Bayer AG,14455,WO-2009089858,PA5324610,First Publication,2009-07-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Autoimmune hemolytic anemia,2643,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Priority,PUB,PRI,Autoimmune hemolytic anemia,2643,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Priority,PUB,PRI,Rheumatoid arthritis,291,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ulcerative colitis,337,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Bayer Schering Pharma AG,19687,Owner,European Patent,EP,"L19-IL-2 fusion protein, Philogen",45599,Component of Combination,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Bayer AG,14455,WO-2009089858,PA5324610,First Priority,2008-01-17 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Colby Pharmaceutical Co,1031137,Owner,World,WO,MKC-1106-PP,41921,General interest,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Colby Pharmaceutical Co,1031137,WO-2008100598,PA3674486,First Publication,2008-08-21 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Colby Pharmaceutical Co,1031137,Owner,World,WO,MKC-1106-PP,41921,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Colby Pharmaceutical Co,1031137,WO-2008100598,PA3674486,First Publication,2008-08-21 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Colby Pharmaceutical Co,1031137,Owner,World,WO,MKC-1106-PP,41921,General interest,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Colby Pharmaceutical Co,1031137,WO-2008100598,PA3674486,First Publication,2008-08-21 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Colby Pharmaceutical Co,1031137,Owner,US,US,MKC-1106-PP,41921,General interest,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Colby Pharmaceutical Co,1031137,WO-2008100598,PA3674486,First Priority,2007-02-15 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Colby Pharmaceutical Co,1031137,Owner,US,US,MKC-1106-PP,41921,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Colby Pharmaceutical Co,1031137,WO-2008100598,PA3674486,First Priority,2007-02-15 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Colby Pharmaceutical Co,1031137,Owner,US,US,MKC-1106-PP,41921,General interest,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Colby Pharmaceutical Co,1031137,WO-2008100598,PA3674486,First Priority,2007-02-15 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Centre for Addiction and Mental Health,1005429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Nicotine dependence,235,null,Centre for Addiction and Mental Health,1005429,WO-2009149562,PA5459660,First Publication,2009-12-17 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Centre for Addiction and Mental Health,1005429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Drug dependence,588,null,Centre for Addiction and Mental Health,1005429,WO-2009149562,PA5459660,First Publication,2009-12-17 00:00:00,PUB,2,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Centre for Addiction and Mental Health,1005429,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Nicotine dependence,235,null,Centre for Addiction and Mental Health,1005429,WO-2009149562,PA5459660,First Priority,2008-06-13 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Centre for Addiction and Mental Health,1005429,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Drug dependence,588,null,Centre for Addiction and Mental Health,1005429,WO-2009149562,PA5459660,First Priority,2008-06-13 00:00:00,PRI,1,Psychiatric disorder,207
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Publication,2009-09-24 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Publication,2009-09-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Publication,2009-09-24 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Publication,2009-09-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Publication,2009-09-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Priority,2008-03-19 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Priority,2008-03-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Priority,2008-03-19 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Priority,2008-03-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,"ALT-801 (bolus injection, cancer), Altor",57607,Formulation,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,NantWorks LLC,1103920,WO-2009117117,PA5386714,First Priority,2008-03-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Third Party,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Cancer,651,null,Brooklyn ImmunoTherapeutics LLC,30720,US-08470562,PA5404180,Granted,2013-06-25 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Third Party,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Brooklyn ImmunoTherapeutics LLC,30720,US-08470562,PA5404180,Granted,2013-06-25 00:00:00,GRT,3,Infectious disease,746
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Third Party,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Cancer,651,null,Brooklyn ImmunoTherapeutics LLC,30720,US-08470562,PA5404180,First Publication,2009-10-15 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Third Party,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Brooklyn ImmunoTherapeutics LLC,30720,US-08470562,PA5404180,First Publication,2009-10-15 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Third Party,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Cancer,651,null,Brooklyn ImmunoTherapeutics LLC,30720,US-08470562,PA5404180,First Priority,2008-04-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Third Party,US,US,IRX-2,44521,Process,null,Granted,Granted,GRT,GRT,Infectious disease,746,null,Brooklyn ImmunoTherapeutics LLC,30720,US-08470562,PA5404180,First Priority,2008-04-14 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,ETH Zurich,23144,WO-2016026742,PA8565239,First Publication,2016-02-25 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,ETH Zurich,23144,WO-2016026742,PA8565239,First Publication,2016-02-25 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,ETH Zurich,23144,WO-2016026742,PA8565239,First Publication,2016-02-25 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,ETH Zurich,23144,WO-2016026742,PA8565239,First Priority,2014-08-19 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,ETH Zurich,23144,WO-2016026742,PA8565239,First Priority,2014-08-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,ETH Zurich,23144,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,ETH Zurich,23144,WO-2016026742,PA8565239,First Priority,2014-08-19 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatocellular carcinoma,1767,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Carcinoma,54,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatocellular carcinoma,1767,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Carcinoma,54,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Academia Sinica,28429,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Academia Sinica,28429,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,"ALT-801 (bolus injection, cancer), Altor",57607,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Publication,2013-10-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,"ALT-801 (bolus injection, cancer), Altor",57607,Component of Combination,null,First Publication,First Publication,PUB,PUB,Urinary tract tumor,738,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Publication,2013-10-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,gemcitabine,3199,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Publication,2013-10-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,gemcitabine,3199,Component of Combination,null,First Publication,First Publication,PUB,PUB,Urinary tract tumor,738,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Publication,2013-10-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,cisplatin,2821,Component of Combination,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Publication,2013-10-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,World,WO,cisplatin,2821,Component of Combination,null,First Publication,First Publication,PUB,PUB,Urinary tract tumor,738,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Publication,2013-10-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,"ALT-801 (bolus injection, cancer), Altor",57607,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Priority,2012-03-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,"ALT-801 (bolus injection, cancer), Altor",57607,Component of Combination,null,First Publication,First Priority,PUB,PRI,Urinary tract tumor,738,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Priority,2012-03-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,gemcitabine,3199,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Priority,2012-03-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,gemcitabine,3199,Component of Combination,null,First Publication,First Priority,PUB,PRI,Urinary tract tumor,738,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Priority,2012-03-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,cisplatin,2821,Component of Combination,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Priority,2012-03-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Altor BioScience Corp,1007204,Owner,US,US,cisplatin,2821,Component of Combination,null,First Publication,First Priority,PUB,PRI,Urinary tract tumor,738,null,NantWorks LLC,1103920,WO-2013148337,PA7511517,First Priority,2012-03-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4040,54741,Process,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4040,54741,Process,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4040,54741,Process,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4023,46818,Process,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4023,46818,Process,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4023,46818,Process,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4010,33476,Process,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4010,33476,Process,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,TG-4010,33476,Process,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,tipapkinogene sovacivec,20368,Process,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,tipapkinogene sovacivec,20368,Process,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,World,WO,tipapkinogene sovacivec,20368,Process,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,ACCRA,1020515,WO-2011009613,PA6326421,First Publication,2011-01-27 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4040,54741,Process,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4040,54741,Process,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4040,54741,Process,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4023,46818,Process,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4023,46818,Process,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4023,46818,Process,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4010,33476,Process,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4010,33476,Process,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,TG-4010,33476,Process,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,tipapkinogene sovacivec,20368,Process,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,tipapkinogene sovacivec,20368,Process,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Transgene SA,23924,Owner,European Patent,EP,tipapkinogene sovacivec,20368,Process,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,ACCRA,1020515,WO-2011009613,PA6326421,First Priority,2009-07-21 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,World,WO,IRX-2,44521,New use,null,First Publication,First Publication,PUB,PUB,Papillomavirus infection,396,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2011072006,PA6478277,First Publication,2011-06-16 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Brooklyn ImmunoTherapeutics LLC,30720,Owner,US,US,IRX-2,44521,New use,null,First Publication,First Priority,PUB,PRI,Papillomavirus infection,396,null,Brooklyn ImmunoTherapeutics LLC,30720,WO-2011072006,PA6478277,First Priority,2009-12-08 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Childrens Hospital of Philadelphia,21052,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Childrens Hospital of Philadelphia,21052,WO-2014011984,PA7635338,First Publication,2014-01-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Childrens Hospital of Philadelphia,21052,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Childrens Hospital of Philadelphia,21052,WO-2014011984,PA7635338,First Priority,2012-07-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,interleukin-12,CP301535,Formulation,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,World,WO,chitosan,13311-1,Formulation,null,First Publication,First Publication,PUB,PUB,Renal tumor,999,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Publication,2015-12-03 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,interleukin-12,CP301535,Formulation,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,University of Arkansas,24207,Owner,US,US,chitosan,13311-1,Formulation,null,First Publication,First Priority,PUB,PRI,Renal tumor,999,null,The University of Arkansas System,1018113,WO-2015184445,PA8445889,First Priority,2014-05-31 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Wayne State University,20702,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Influenza virus infection,191,null,Wayne State University,20702,WO-2007008918,PA3455898,First Publication,2007-01-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Wayne State University,20702,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Wayne State University,20702,WO-2007008918,PA3455898,First Publication,2007-01-18 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Wayne State University,20702,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Influenza virus infection,191,null,Wayne State University,20702,WO-2007008918,PA3455898,First Priority,2005-07-08 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Wayne State University,20702,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Wayne State University,20702,WO-2007008918,PA3455898,First Priority,2005-07-08 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Atopic dermatitis,1102,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Hepatitis C virus infection,153,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Cutaneous T-cell lymphoma,1754,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Bladder cancer,2380,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Juvenile rheumatoid arthritis,3003,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,World,WO,NKTR-358,105507,Tentative,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Publication,2012-05-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Atopic dermatitis,1102,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Hepatitis C virus infection,153,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Cutaneous T-cell lymphoma,1754,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Bladder cancer,2380,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Juvenile rheumatoid arthritis,3003,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Nektar Therapeutics,17221,Owner,US,US,NKTR-358,105507,Tentative,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Nektar Therapeutics,17221,WO-2012065086,PA6855743,First Priority,2010-11-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2014201378,PA8002747,First Publication,2014-12-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Massachusetts Institute of Technology,18225,WO-2014201378,PA8002747,First Publication,2014-12-18 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2014201378,PA8002747,First Priority,2013-06-13 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Massachusetts Institute of Technology,18225,WO-2014201378,PA8002747,First Priority,2013-06-13 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Massachusetts Institute of Technology,18225,WO-2014204762,PA8010512,First Publication,2014-12-24 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Massachusetts Institute of Technology,18225,WO-2014204762,PA8010512,First Publication,2014-12-24 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Massachusetts Institute of Technology,18225,WO-2014204762,PA8010512,First Priority,2013-06-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Massachusetts Institute of Technology,18225,WO-2014204762,PA8010512,First Priority,2013-06-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cardiovascular disease,57,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Diabetes mellitus,97,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Publication,2015-04-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cardiovascular disease,57,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Diabetes mellitus,97,null,Massachusetts Institute of Technology,18225,WO-2015048498,PA8121105,First Priority,2013-09-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025647,PA8557297,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,TA-99,CP207546,Component of Combination,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,TA-99,CP207546,Component of Combination,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025645,PA8557359,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Publication,2016-02-18 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Brain tumor,760,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2016025642,PA8557516,First Priority,2014-08-12 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,World,WO,tumor necrosis factor,DOC1000919,Formulation,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Publication,2016-04-07 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,World,WO,tumor necrosis factor,DOC1000919,Formulation,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Publication,2016-04-07 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,World,WO,tumor necrosis factor,DOC1000919,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Publication,2016-04-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Autoimmune disease,36,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Publication,2016-04-07 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Publication,2016-04-07 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,World,WO,interleukin-2,DOC1000491,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Publication,2016-04-07 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,US,US,tumor necrosis factor,DOC1000919,Formulation,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Priority,2014-10-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,US,US,tumor necrosis factor,DOC1000919,Formulation,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Priority,2014-10-03 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,US,US,tumor necrosis factor,DOC1000919,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Priority,2014-10-03 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,US,US,interleukin-2,DOC1000491,Formulation,null,First Publication,First Priority,PUB,PRI,Autoimmune disease,36,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Priority,2014-10-03 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,US,US,interleukin-2,DOC1000491,Formulation,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Priority,2014-10-03 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Ntercept LLC,1112212,Owner,US,US,interleukin-2,DOC1000491,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Ntercept LLC,1112212,WO-2016054522,PA8613289,First Priority,2014-10-03 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioblastoma,2454,null,Massachusetts Institute of Technology,18225,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Massachusetts Institute of Technology,18225,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Massachusetts Institute of Technology,18225,WO-2017027843,PA9212253,First Publication,2017-02-16 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioblastoma,2454,null,Massachusetts Institute of Technology,18225,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Massachusetts Institute of Technology,18225,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Massachusetts Institute of Technology,18225,WO-2017027843,PA9212253,First Priority,2015-08-12 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Glioma,1108,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Thyroid tumor,1134,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mesothelioma,1240,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Renal cell carcinoma,1766,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Pancreas tumor,249,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colorectal tumor,989,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Publication,2014-10-02 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Glioma,1108,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Thyroid tumor,1134,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Mesothelioma,1240,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Renal cell carcinoma,1766,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Pancreas tumor,249,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Mount Sinai Medical Center,24815,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colorectal tumor,989,null,Mount Sinai School of Medicine,20631,WO-2014158811,PA7921560,First Priority,2013-03-14 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colitis,1072,null,Massachusetts Institute of Technology,18225,WO-2017087811,PA9398406,First Publication,2017-05-26 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Massachusetts Institute of Technology,18225,WO-2017087811,PA9398406,First Publication,2017-05-26 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Intestine disease,599,null,Massachusetts Institute of Technology,18225,WO-2017087811,PA9398406,First Publication,2017-05-26 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Crohns disease,84,null,Massachusetts Institute of Technology,18225,WO-2017087811,PA9398406,First Publication,2017-05-26 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colitis,1072,null,Massachusetts Institute of Technology,18225,WO-2017087811,PA9398406,First Priority,2015-11-20 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Massachusetts Institute of Technology,18225,WO-2017087811,PA9398406,First Priority,2015-11-20 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Intestine disease,599,null,Massachusetts Institute of Technology,18225,WO-2017087811,PA9398406,First Priority,2015-11-20 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Crohns disease,84,null,Massachusetts Institute of Technology,18225,WO-2017087811,PA9398406,First Priority,2015-11-20 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Uterine cervix tumor,427,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Intestine tumor,765,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Publication,2013-11-28 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Prostate tumor,276,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Andrology,1785
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Uterine cervix tumor,427,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Intestine tumor,765,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Massachusetts Institute of Technology,18225,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Ovary tumor,799,null,Massachusetts Institute of Technology,18225,WO-2013177187,PA7584008,First Priority,2012-05-22 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,MUSC Foundation for Research Development,25880,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Medical University of South Carolina,20675,WO-2016118857,PA8775981,First Publication,2016-07-28 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,MUSC Foundation for Research Development,25880,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Medical University of South Carolina,20675,WO-2016118857,PA8775981,First Priority,2015-01-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Spontaneous abortion,1525,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Publication,2014-09-25 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Vasculitis,1532,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Publication,2014-09-25 00:00:00,PUB,2,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Inflammatory bowel disease,189,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Publication,2014-09-25 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Multiple sclerosis,213,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Publication,2014-09-25 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Systemic lupus erythematosus,318,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Publication,2014-09-25 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Graft versus host disease,616,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Publication,2014-09-25 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Insulin dependent diabetes,836,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Publication,2014-09-25 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Spontaneous abortion,1525,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Priority,2013-03-14 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Vasculitis,1532,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Priority,2013-03-14 00:00:00,PRI,1,Cardiovascular disease,57
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Inflammatory bowel disease,189,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Priority,2013-03-14 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Multiple sclerosis,213,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Priority,2013-03-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Systemic lupus erythematosus,318,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Priority,2013-03-14 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Graft versus host disease,616,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Priority,2013-03-14 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Amgen Inc,14109,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Insulin dependent diabetes,836,null,Amgen Inc,14109,WO-2014153111,PA7916545,First Priority,2013-03-14 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Hepatocellular carcinoma,1767,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Carcinoma,54,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Solid tumor,725,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Publication,2016-03-17 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Hepatocellular carcinoma,1767,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Carcinoma,54,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Solid tumor,725,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Scripps Research Institute,21102,Third Party,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Scripps Research Institute,21102,WO-2016040369,PA8586738,First Priority,2014-09-08 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Sesen Bio Inc,1052472,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Gout,136,null,Sesen Bio Inc,1052472,WO-2013075066,PA7376063,First Publication,2013-05-23 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Sesen Bio Inc,1052472,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,Sesen Bio Inc,1052472,WO-2013075066,PA7376063,First Publication,2013-05-23 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Sesen Bio Inc,1052472,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Gout,136,null,Sesen Bio Inc,1052472,WO-2013075066,PA7376063,First Priority,2011-11-18 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Sesen Bio Inc,1052472,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,Sesen Bio Inc,1052472,WO-2013075066,PA7376063,First Priority,2011-11-18 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,MedImmune LLC,18008,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Sepsis,114,null,AstraZeneca plc,14190,WO-2015038538,PA8110925,First Publication,2015-03-19 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,MedImmune LLC,18008,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Immune disorder,185,null,AstraZeneca plc,14190,WO-2015038538,PA8110925,First Publication,2015-03-19 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,MedImmune LLC,18008,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Sepsis,114,null,AstraZeneca plc,14190,WO-2015038538,PA8110925,First Priority,2013-09-10 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,MedImmune LLC,18008,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Immune disorder,185,null,AstraZeneca plc,14190,WO-2015038538,PA8110925,First Priority,2013-09-10 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Sepsis,114,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,HIV infection,158,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Hypercholesterolemia,174,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Metabolic disorder,655
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Neurological disease,677,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Neurological disease,677
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,World,WO,mRNA-2416,104238,Tentative,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Publication,2015-06-11 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Sepsis,114,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,HIV infection,158,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Hypercholesterolemia,174,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Metabolic disorder,655
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Neurological disease,677,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Neurological disease,677
IL-2 receptor agonist,221,null,ModeRNA Therapeutics,1060964,Owner,US,US,mRNA-2416,104238,Tentative,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,ModeRNA Therapeutics,1060964,WO-2015085318,PA8194635,First Priority,2013-12-06 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Jiangnan University,1043874,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Jiangnan University,1043874,WO-2017028040,PA9224283,First Publication,2017-02-23 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Jiangnan University,1043874,Third Party,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Mycobacterium tuberculosis infection,221,null,Jiangnan University,1043874,WO-2017028040,PA9224283,First Priority,2015-08-14 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Universite Paris Sud XI,21281,Owner,World,WO,BV-CYP01,78225,Product,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Universite Paris Sud XI,21281,WO-2017060510,PA9312289,First Publication,2017-04-13 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Universite Paris Sud XI,21281,Owner,European Patent,EP,BV-CYP01,78225,Product,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Universite Paris Sud XI,21281,WO-2017060510,PA9312289,First Priority,2015-10-09 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,rituximab,6736,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Product,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Product,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Product,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Product,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Product,null,First Publication,First Publication,PUB,PUB,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,CST-103,53543,Product,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,alemtuzumab,2716,Component of Combination,null,First Publication,First Publication,PUB,PUB,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,alemtuzumab,2716,Component of Combination,null,First Publication,First Publication,PUB,PUB,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,alemtuzumab,2716,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,alemtuzumab,2716,Component of Combination,null,First Publication,First Publication,PUB,PUB,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,alemtuzumab,2716,Component of Combination,null,First Publication,First Publication,PUB,PUB,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,World,WO,alemtuzumab,2716,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Publication,2016-10-06 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,rituximab,6736,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Component of Combination,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Product,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Product,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Product,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Product,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Product,null,First Publication,First Priority,PUB,PRI,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,CST-103,53543,Product,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,gemtuzumab ozogamicin,5202,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,alemtuzumab,2716,Component of Combination,null,First Publication,First Priority,PUB,PRI,Stomach tumor,127,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,alemtuzumab,2716,Component of Combination,null,First Publication,First Priority,PUB,PRI,Multiple myeloma,1828,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,alemtuzumab,2716,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,alemtuzumab,2716,Component of Combination,null,First Publication,First Priority,PUB,PRI,Non-Hodgkin lymphoma,319,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,alemtuzumab,2716,Component of Combination,null,First Publication,First Priority,PUB,PRI,Metastatic breast cancer,3657,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,NantKwest Inc,1015036,Owner,US,US,alemtuzumab,2716,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,NantKwest Inc,1015036,WO-2016160602,PA8978417,First Priority,2015-03-27 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Assistance Publique Hopitaux de Paris,23948,WO-2014206899,PA8016897,First Publication,2014-12-31 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,European Patent,EP,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Assistance Publique Hopitaux de Paris,23948,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,US,US,null,null,null,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Assistance Publique Hopitaux de Paris,23948,WO-2014206899,PA8016897,First Priority,2013-06-25 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Philochem AG,1039289,Owner,World,WO,LU-103793,10327-X1,Formulation,null,First Publication,First Publication,PUB,PUB,Acute myelogenous leukemia,1731,null,Philogen SpA,29032,WO-2014174105,PA7952033,First Publication,2014-10-30 00:00:00,PUB,2,Rare disease,9099
IL-2 receptor agonist,221,null,Philochem AG,1039289,Owner,World,WO,LU-103793,10327-X1,Formulation,null,First Publication,First Publication,PUB,PUB,Inflammatory disease,188,null,Philogen SpA,29032,WO-2014174105,PA7952033,First Publication,2014-10-30 00:00:00,PUB,2,Inflammatory disease,188
IL-2 receptor agonist,221,null,Philochem AG,1039289,Owner,World,WO,LU-103793,10327-X1,Formulation,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Philogen SpA,29032,WO-2014174105,PA7952033,First Publication,2014-10-30 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Philochem AG,1039289,Owner,European Patent,EP,LU-103793,10327-X1,Formulation,null,First Publication,First Priority,PUB,PRI,Acute myelogenous leukemia,1731,null,Philogen SpA,29032,WO-2014174105,PA7952033,First Priority,2013-04-25 00:00:00,PRI,1,Rare disease,9099
IL-2 receptor agonist,221,null,Philochem AG,1039289,Owner,European Patent,EP,LU-103793,10327-X1,Formulation,null,First Publication,First Priority,PUB,PRI,Inflammatory disease,188,null,Philogen SpA,29032,WO-2014174105,PA7952033,First Priority,2013-04-25 00:00:00,PRI,1,Inflammatory disease,188
IL-2 receptor agonist,221,null,Philochem AG,1039289,Owner,European Patent,EP,LU-103793,10327-X1,Formulation,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Philogen SpA,29032,WO-2014174105,PA7952033,First Priority,2013-04-25 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,World,WO,BV-CYP01,78225,Product,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,Assistance Publique Hopitaux de Paris,23948,WO-2017060510,PA9312289,First Publication,2017-04-13 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,European Patent,EP,BV-CYP01,78225,Product,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,Assistance Publique Hopitaux de Paris,23948,WO-2017060510,PA9312289,First Priority,2015-10-09 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Food hypersensitivity,3612,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Wheat hypersensitivity,3613,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Milk hypersensitivity,3614,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Peanut hypersensitivity,3615,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,World,WO,aldesleukin,6306,New use,null,First Publication,First Publication,PUB,PUB,Egg hypersensitivity,3616,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Publication,2015-09-17 00:00:00,PUB,2,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Food hypersensitivity,3612,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Wheat hypersensitivity,3613,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Milk hypersensitivity,3614,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Peanut hypersensitivity,3615,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Assistance Publique Hopitaux de Paris,23948,Owner,European Patent,EP,aldesleukin,6306,New use,null,First Publication,First Priority,PUB,PRI,Egg hypersensitivity,3616,null,Assistance Publique Hopitaux de Paris,23948,WO-2015135956,PA8336667,First Priority,2014-03-11 00:00:00,PRI,1,Immune disorder,185
IL-2 receptor agonist,221,null,Autolus Therapeutics Limited,1105192,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Autolus Therapeutics Limited,1105192,WO-2017029511,PA9224509,First Publication,2017-02-23 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Autolus Therapeutics Limited,1105192,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Autolus Therapeutics Limited,1105192,WO-2017029511,PA9224509,First Priority,2015-08-20 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Autolus Therapeutics Limited,1105192,Owner,World,WO,null,null,null,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Autolus Therapeutics Limited,1105192,WO-2017068360,PA9331288,First Publication,2017-04-27 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Autolus Therapeutics Limited,1105192,Owner,UK,GB,null,null,null,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Autolus Therapeutics Limited,1105192,WO-2017068360,PA9331288,First Priority,2015-10-23 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,Granted,Granted,GRT,GRT,Chronic myelocytic leukemia,1735,null,Batu Biologics,1095918,US-09687472,PA8447385,Granted,2017-06-27 00:00:00,GRT,3,Hematological disease,142
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Batu Biologics,1095918,US-09687472,PA8447385,Granted,2017-06-27 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,ascorbic acid,DOC1000096,Component of Combination,null,Granted,Granted,GRT,GRT,Chronic myelocytic leukemia,1735,null,Batu Biologics,1095918,US-09687472,PA8447385,Granted,2017-06-27 00:00:00,GRT,3,Hematological disease,142
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,ascorbic acid,DOC1000096,Component of Combination,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Batu Biologics,1095918,US-09687472,PA8447385,Granted,2017-06-27 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,Granted,Granted,GRT,GRT,Chronic myelocytic leukemia,1735,null,Batu Biologics,1095918,US-09687472,PA8447385,First Publication,2015-12-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Batu Biologics,1095918,US-09687472,PA8447385,First Publication,2015-12-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,ascorbic acid,DOC1000096,Component of Combination,null,Granted,Granted,GRT,GRT,Chronic myelocytic leukemia,1735,null,Batu Biologics,1095918,US-09687472,PA8447385,First Publication,2015-12-03 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,ascorbic acid,DOC1000096,Component of Combination,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Batu Biologics,1095918,US-09687472,PA8447385,First Publication,2015-12-03 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,Granted,Granted,GRT,GRT,Chronic myelocytic leukemia,1735,null,Batu Biologics,1095918,US-09687472,PA8447385,First Priority,2014-05-08 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,interleukin-2,DOC1000491,Component of Combination,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Batu Biologics,1095918,US-09687472,PA8447385,First Priority,2014-05-08 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,ascorbic acid,DOC1000096,Component of Combination,null,Granted,Granted,GRT,GRT,Chronic myelocytic leukemia,1735,null,Batu Biologics,1095918,US-09687472,PA8447385,First Priority,2014-05-08 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Batu Biologics,1095918,Owner,US,US,ascorbic acid,DOC1000096,Component of Combination,null,Granted,Granted,GRT,GRT,Melanoma,205,null,Batu Biologics,1095918,US-09687472,PA8447385,First Priority,2014-05-08 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,INSERM,17229,Owner,World,WO,BV-CYP01,78225,Product,null,First Publication,First Publication,PUB,PUB,Alzheimers disease,14,null,INSERM,17229,WO-2017060510,PA9312289,First Publication,2017-04-13 00:00:00,PUB,2,Degeneration,817
IL-2 receptor agonist,221,null,INSERM,17229,Owner,European Patent,EP,BV-CYP01,78225,Product,null,First Publication,First Priority,PUB,PRI,Alzheimers disease,14,null,INSERM,17229,WO-2017060510,PA9312289,First Priority,2015-10-09 00:00:00,PRI,1,Degeneration,817
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,World,WO,relatlimab,75813,General interest,null,First Publication,First Publication,PUB,PUB,Viral infection,344,null,Bristol-Myers Squibb Co,15065,WO-2014008218,PA7629380,First Publication,2014-01-09 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,World,WO,relatlimab,75813,General interest,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Bristol-Myers Squibb Co,15065,WO-2014008218,PA7629380,First Publication,2014-01-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,relatlimab,75813,General interest,null,First Publication,First Priority,PUB,PRI,Viral infection,344,null,Bristol-Myers Squibb Co,15065,WO-2014008218,PA7629380,First Priority,2012-07-02 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,relatlimab,75813,General interest,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Bristol-Myers Squibb Co,15065,WO-2014008218,PA7629380,First Priority,2012-07-02 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,Granted,2017-05-09 00:00:00,GRT,3,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Publication,2016-12-01 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,nivolumab,54804,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,ipilimumab,36630,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,New use,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Non-small-cell lung cancer,1262,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Bladder cancer,2380,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Genitourinary disease,366
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Squamous cell carcinoma,307,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Uterine cervix tumor,427,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Gynecology and obstetrics,1521
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Head and neck tumor,623,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Ovary tumor,799,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Owner,US,US,BMS-986178,101638,Component of Combination,null,Granted,Granted,GRT,GRT,Colorectal tumor,989,null,Bristol-Myers Squibb Co,15065,US-09644032,PA9078220,First Priority,2015-05-29 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,World,WO,pembrolizumab,70667,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Cancer,651,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Infectious disease,746,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Infectious disease,746
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,World,WO,nivolumab,54804,Component of Combination,null,First Publication,First Publication,PUB,PUB,Colon tumor,767,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Publication,2016-02-25 00:00:00,PUB,2,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,US,US,pembrolizumab,70667,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Cancer,651,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Infectious disease,746,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Infectious disease,746
IL-2 receptor agonist,221,null,Bristol-Myers Squibb Co,15065,Third Party,US,US,nivolumab,54804,Component of Combination,null,First Publication,First Priority,PUB,PRI,Colon tumor,767,null,Bristol-Myers Squibb Co,15065,WO-2016028656,PA8564581,First Priority,2014-08-19 00:00:00,PRI,1,Gastrointestinal disease,129
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,New use,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,ipilimumab,36630,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Leukemia,199,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lymphoma,203,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Melanoma,205,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Dermatological disease,95
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Breast tumor,49,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Endocrine disease,112
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Head and neck tumor,623,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Neoplasm,230
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,World,WO,AGEN-2034,103946,Component of Combination,null,First Publication,First Publication,PUB,PUB,Lung tumor,755,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Publication,2017-03-09 00:00:00,PUB,2,Respiratory disease,711
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,New use,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,ipilimumab,36630,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Leukemia,199,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lymphoma,203,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Hematological disease,142
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Melanoma,205,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Dermatological disease,95
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Breast tumor,49,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Endocrine disease,112
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Head and neck tumor,623,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Neoplasm,230
IL-2 receptor agonist,221,null,Eli Lilly & Co,17810,Third Party,US,US,AGEN-2034,103946,Component of Combination,null,First Publication,First Priority,PUB,PRI,Lung tumor,755,null,Eli Lilly & Co,17810,WO-2017040790,PA9251844,First Priority,2015-09-01 00:00:00,PRI,1,Respiratory disease,711